WO2008093075A2 - 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors - Google Patents

5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors Download PDF

Info

Publication number
WO2008093075A2
WO2008093075A2 PCT/GB2008/000303 GB2008000303W WO2008093075A2 WO 2008093075 A2 WO2008093075 A2 WO 2008093075A2 GB 2008000303 W GB2008000303 W GB 2008000303W WO 2008093075 A2 WO2008093075 A2 WO 2008093075A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
methyl
carbamoyl
group
Prior art date
Application number
PCT/GB2008/000303
Other languages
French (fr)
Other versions
WO2008093075A3 (en
Inventor
Thorsten Nowak
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to JP2009547752A priority Critical patent/JP2010517989A/en
Priority to CN200880010915A priority patent/CN101652365A/en
Priority to DE602008003404T priority patent/DE602008003404D1/en
Priority to CA002675677A priority patent/CA2675677A1/en
Priority to EP08701973A priority patent/EP2109612B1/en
Priority to MX2009008084A priority patent/MX2009008084A/en
Priority to AT08701973T priority patent/ATE487720T1/en
Priority to BRPI0807868-8A priority patent/BRPI0807868A2/en
Priority to KR1020097018333A priority patent/KR20090104920A/en
Priority to AU2008211729A priority patent/AU2008211729A1/en
Publication of WO2008093075A2 publication Critical patent/WO2008093075A2/en
Publication of WO2008093075A3 publication Critical patent/WO2008093075A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to novel 5,6,7,8-tetrahydropteridine derivatives, their pharmaceutical compositions and methods of use.
  • the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these 5,6,7,8-tetrahydropteridine derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers.
  • HSP Heat shock proteins
  • Numerous HSP's are known and are classified according to their molecular weight.
  • HSP90 is a 90k Dalton protein chaperone that plays a central role in regulating, for example, protein homeostasis.
  • HSP90 regulates the stability of certain proteins ("client proteins") and maintains them in the appropriate three-dimensional conformation so they can perform their cellular functions.
  • client proteins proteins
  • HSP90 proteins stabilized by HSP90 are oncoproteins and cell-signalling proteins important in cancer cell proliferation and cancer cell survival, including many kinases and transcription factors including, but not limited to ErbB2, Raf-1, Akt/PKB, mutant p53, v-src, c-src, MEK, Focal adhesion kinase (FAK), P2 lObcr-abl, CDK4 and Epidermal growth factor receptor (EGFR).
  • kinases and transcription factors including, but not limited to ErbB2, Raf-1, Akt/PKB, mutant p53, v-src, c-src, MEK, Focal adhesion kinase (FAK), P2 lObcr-abl, CDK4 and Epidermal growth factor receptor (EGFR).
  • HSP90 has been implicated in cancer, and other diseases. HSP90 is therefore an important target for drugs that inhibit the function of HSP90 and its role in diseases such as cancer.
  • HSP90 is over expressed in cancer cells and is thought to be involved in various cellular processes, such as cell proliferation, differentiation and apoptosis. Inhibition of HSP90 is expected to result in the blockade of multiple cancer-causing pathways by promoting the degradation of many oncogenic HSP90 client proteins, therefore HSP90 inhibitors are expected to provide broad-spectrum antitumour activity.
  • HSP90 inhibitors may be useful in the treatment of other disorders, for example inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrogenetic disorders and metabolic diseases.
  • HSP90 inhibitors are known.
  • the benzoquinone ansamycin antibiotic, 17- allylamino-17-demethoxygeldanamycin (17- AAG) and derivatives thereof are currently in clinical trials an anticancer agent in patients with solid rumour disease.
  • WO 03/037860 discloses certain purine derivatives as HSP90 inhibitors.
  • WO 2005/021552 discloses certain pyrimidothiophene derivatives as HSP90 inhibitors.
  • WO 2005/028434 discloses certain pyrimidine derivatives as HSP90 inhibitors.
  • WO 2006/117669 discloses certain resorcinol pyrimidine derivatives as HSP90 inhibitors.
  • WO 2006/122631 discloses certain quinazoline derivatives as HSP90 inhibitors.
  • WO 2006/105372 discloses certain alkynyl pyrrolo[2,3-d]pyrimidine derivatives as HSP90 inhibitors.
  • WO 2007/035963 discloses certain heterocyclic compounds, such as 2- aminopurines, pyrazolopyrimidines, pyrrolopyrimidines, alkynyl pyrrolopyrimidine and triazopyrimidines as HSP90 inhibitors.
  • WO 2007/092496 discloses certain 7,9-dihydropurin-8-one compounds as HSP90 inhibitors.
  • novel 5,6,7, 8-tetrahydropteridine compounds, or pharmaceutically acceptable salts thereof which possess HSP90 inhibitory activity and are accordingly useful for their anti-proliferation and/or pro-apoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body.
  • the invention also relates to processes for the manufacture of said 5,6,7,8-tetrahydropteridine compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of, for example, an anti-proliferative and/or pro- apoptotic effect in warm-blooded animals such as man.
  • the applicants provide methods of using such 5,6,7,8-tetrahydropteridine compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
  • the compounds claimed in this invention are may to be of value in the treatment of disease states associated with cell proliferation and other conditions such as cancers (both solid tumours and leukaemia), f ⁇ broproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases, ocular diseases with retinal vessel proliferation, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases.
  • cancers both solid tumours and leukaemia
  • f ⁇ broproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation,
  • the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers including oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, endometrial cancer, uterine cancer, vulval cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, bile duct cancer, bone cancer, neuronal cancer, skin cancer, testicular cancer, lymphoma and leukaemia, multiple myeloma or lymphoma; particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and lung cancer - NSCLC and SCLC; more particularly melanoma, breast, ovarian, lung and gas
  • R 1 , R 2 and R 3 are independently selected from H, halo, cyano, nitro or a group of the formula:
  • X 1 is a direct bond, O, S or NR 8a
  • R 8a is H or Ci -6 alkyl
  • R 8 is selected from H, Ci- 6 alkyl, C 2-6 alkenyl, C 3 . 7 cycloalkyl and d- ⁇ alkynyl
  • R 1 , R 2 and R 3 may independently of each other be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, N-(Ci_ 6 alkyl)amino, NN-(C i.
  • R 4 and R 10 are independently selected from H, Ci- ⁇ alkyl, C 2 - 6 alkenyl and C 2 - 6 alkynyl, wherein R 4 and R 10 may, independently of each other, be optionally substituted on carbon by halo, hydroxy, amino, N-(Ci. 6 alkyl)amino and NN-(Ci. 6 alkyl) 2 amino;
  • R 5 and R 11 are independently selected from H, cyano, carboxy, carbamoyl, Ci- ⁇ alkyl, C 2-6 alkenyl, C 2 - 6 alkynyl, N-(Ci- 6 alkyi)carbamoyl, N N-(C i _ 6 alky l) 2 carbamoy 1, N-(C i . 4 alkoxy)carbamoy 1, N-(C i . 4 alkyl)-N-(C i .
  • R and R are independently selected from H, Ci_ 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci. 6 alkanoyl, Ci- 6 alkoxycarbonyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, carbocyclyl-X 5 -, heterocyclyl-X 6 - or heteroaryl-X 7 -, wherein X 5 , X 6 and X 7 are independently selected from a direct bond, -C(O)-, - ⁇ (R 12 )C(O)- and -SO 2 -; wherein R 12 is selected from hydrogen or and wherein R 6 and R 9 may, independently of each other, be optionally substituted on carbon by one or more R 16 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected
  • R 7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C 2- 6alkenyl, C 2- 6alkynyl, Ci- 6 alkylS(0) a wherein a is 0 to 2, wherein R 7 may be optionally substituted on carbon by one or more R 15 ;
  • R 13 , R 15 and R 16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci- 6 alkyl, C 2 .
  • R 14 , R 17 and R 19 are independently selected from Ci- ⁇ alkanoyl, Ci - ⁇ alkylsulfonyl, C i - ⁇ alkoxycarbonyl, carbamoyl, N-(C i - 6 alkyl)carbamoyl,
  • NN-(C i- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 , R 17 and R 19 independently of each other may be optionally substituted on carbon by one or more R 20 ;
  • X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and - ⁇ (R 22 )C(O)-; wherein R 22 is hydrogen or C ]-4 alkyl;
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O),-, -SO 2 N(R 24 )- and -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or and q is 0-2;
  • R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci- 6 alkanoyl, Ci- ⁇ alkanoyloxy, N-(Ci- 6 alkyl)amino, NN-(C i- 6 alkyl) 2 amino, Ci_ 6 alkanoylamino, N-(Ci_ 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, Ci- 6 alkylS(0) a wherein a is 0 to 2, N-(Ci_ 6 alkyl)sulfamoyl, NN-(Ci -6 alkyl) 2 sulfamoyl, Ci- 6 alkylsulfonylamino, carbocyclyl
  • R 20 , R 25 and R 27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethyls
  • the present invention further provides a compound of the formula I, wherein: R 1 , R 2 and R 3 are independently selected from H, halo or a group of the formula:
  • X 1 is a direct bond, O, S or ⁇ R 8a
  • R 8a is H or Ci. 6 alkyl
  • R 8 is selected from H, C 2 - 6 alkenyl, C 3 _ 7 cycloalkyl and C 2-6 alkynyl, and wherein R 1 , R 2 and R 3 may independently of each other be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, N-(C). 6 alkyl)amino, NN-(Ci.
  • R 6 alkyl 2 amino, C 3 -7Cycloalkyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl and N,N-(Ci_ 6 alkyl) 2 carbamoyl; p is 1 or 2; A is NR 9 or CR 10 R"; R 4 and R 10 are independently selected from H, Ci- ⁇ alkyl, C 2-6 alkenyl and
  • R 4 and R 10 may, independently of each other, be optionally substituted on carbon by halo, hydroxy, amino, Ci- ⁇ alkoxy, N-(Ci-6alkyl)amino and N, N-(C i - 6 alkyl) 2 amino;
  • R 5 and R 11 are independently selected from H, cyano, carboxy, carbamoyl, Ci- ⁇ alkyl, C 2- 6alkenyl, C 2- 6alkynyl, NN-(Ci- 6 alkyl) 2 carbamoyl, N-(Ci- 4 alkoxy)carbamoyl,
  • R 6 and R 9 are independently selected from H, C 2-6 alkenyl, C 2-6 alkynyl, Ci- ⁇ alkanoyl, Ci- ⁇ alkylsulfonyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, carbocyc IyI-X 5 -, heterocyc IyI-X 6 - or heteroaryl-X 7 -, wherein X 5 , X 6 and X 7 are independently selected from a direct bond, -C(O)-, - ⁇ (R 12 )C(O)- and -SO 2 -; wherein R 12 is selected from hydrogen or d ⁇ alkyl, and wherein R 6 and R 9 may, independently of each other, be optionally substituted on carbon by one or more R 16 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may
  • R 13 , R 15 and R 16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido, Ci_ 6 alkyl, C 2 . 6 alkenyl, C 2 - 6 alkynyl, C 2 -6alkenyloxy, C 2 - 6 alkynyloxy, Ci- ⁇ alkanoyloxy, N-(C].
  • Ci- 6 alkylsulfonyl Ci- ⁇ alkoxycarbonyl, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, NN-(Ci. 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 , R 17 and R 19 independently of each other may be optionally substituted on carbon by one or more R 20 ; X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O) 0 -SO 2 N(R 24 )- and -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or and q is 0-2; R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2 -6alkenyl, C 2-6 alkynyl, Ci_ 6 alkanoyl, Ci- ⁇ alkanoyloxy, N-(Ci -6 alkyl)amino, NN-(Ci.6alkyl)
  • R 26 is selected from Ci- ⁇ alkanoyl, Ci- ⁇ alkylsulfonyl, Ci_ 6 alkoxycarbonyl, carbamoyl, N-(Ci. 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R may be optionally substituted on carbon by one or more R 27 ; and R 20 , R 25 and R 27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl” are specific for the straight chain version only.
  • alkyl includes methyl, ethyl, propyl, isopropyl and f-butyl, sec-butyl, n-pentyl, n-hexyl and the like.
  • references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only.
  • references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only.
  • a similar convention applies to other radicals.
  • C m-n or "C m-n group” used alone or as a prefix, refers to any group having m to n carbon atoms.
  • alkylene is an alkyl, alkenyl, or alkynyl group that is positioned between and serves to connect two other chemical groups.
  • Ci- 6 alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, for example, methylene, ethylene, propylene, 2-methylpropylene, pentylene, and the like.
  • C 2-6 alkenylene means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched divalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, for example, as in ethenylene, 2,4-pentadienylene, and the like.
  • C 2-6 alkynylene means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched divalent hydrocarbon radical of three to six carbon atoms, containing at least one triple bond, for example, as in ethynylene, propynylene, and butynylene and the like.
  • C 3 _ 7 cycloalkyl means a hydrocarbon ring containing from 3 to 7 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl.
  • Cs. ⁇ cycloalkenyl means a hydrocarbon ring containing at least one double bond, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, such as 3- cyclohexen-1-yl, or cyclooctenyl.
  • C 3-7 CyC loalkyl-Ci. 6 alkylene means a C 3-7 cycloalkyl group covalently attached to a Ci_ 6 alkylene group, both of which are defined herein.
  • a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH 2 - group can optionally be replaced by a -C(O)-. Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
  • Carbocyclyl examples include C 3- 7 cycloalkyl, C3 -7 cycloalkenyl and aryl, for example “carbocyclyl” includes cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexenyl, 4-oxocyclohex- 1 -yl, 3-oxocyclohept-5-en- 1 -yl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
  • heterocyclyl means a non-aromatic saturated or partially unsaturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s).
  • Monocyclic heterocyclic rings contain from about 3 to 12 ring atoms, with from 1 to 5 heteroatoms selected from N, O, and S, and suitably from 3 to 7 member atoms, in the ring (for example a 5 or 6-membered monocyclic ring containing 1 or 2 heteroatoms selected from O, S and N).
  • Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring.
  • Bicyclic heterocycles contain from about 7 to about 17 ring atoms, suitably from 7 to 12 ring atoms. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems.
  • heterocyclic groups include cyclic ethers (oxiranes) such as ethyleneoxide, tetrahydrofuran, dioxane.
  • Heterocycles containing nitrogen include, for example, azetidine, pyrrolidine, piperidine, piperazine, tetrahydrotriazine, tetrahydropyrazole, and the like.
  • Typical sulfur containing heterocycles include tetrahydrothiophene, dihydro-l,3-dithiol-2-yl, and hexahydrothiepin-4-yl.
  • Other heterocycles include dihydro-oxathiol-4-yl, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl.
  • heterocycles containing sulfur the oxidized sulfur heterocycles containing SO or SO 2 groups are also included.
  • examples include the sulfoxide and sulfone forms of tetrahydrothiophene.
  • a suitable value for a heterocyclyl group which bears 1 or 2 oxo or thioxo substituents is, for example, 2- oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2- oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.
  • heterocyclyl used herein also covers polycyclic ring systems containing one or more heteroatoms selected from O, S and N, wherein at one or more ring is aromatic and at least one of the other rings is a non-aromatic, saturated or partially unsaturated ring optionally for example partially saturated bicyclic heteroaryl rings such as l,2,3,4-tetrahydro-l,8-naphthyridinyl, l,2,3,4-tetrahydropyrido[2,3-6]pyrazinyl and 3,4- dihydro-2H-pyrido[3,2-Z>][l,4]oxazinyl.
  • heterocycles include oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, tetrahydrothienyl, 1,1-dioxotetrahydrothienyl, tetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, aziridinyl, azetidinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, morpholinyl, tetrahydro-l,4-thiazinyl, l,l-dioxotetrahydro-l,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, 2-azabicyclo[2.2.1]hept
  • heterocycles include azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl or isoindolinyl.
  • any heterocycle may be linked to another group via. any suitable atom, such as via. a carbon or nitrogen atom.
  • a suitable value for such a heterocyclyl group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 4-oxo-l,4-dihydropyridinyl, 2,5- dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.
  • ⁇ eterocyclyl-Ci- 6 alkyl means a heterocyclyl group covalently attached to a Ci- ⁇ alkylene group, both of which are defined herein.
  • aryl means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon atoms.
  • aryl includes both monovalent species and divalent species.
  • Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like.
  • aryl-Ci. 6 alkyl means an aryl group covalently attached to a group, both of which are defined herein. Examples of aryl-Ci- ⁇ alkyl groups include benzyl, phenylethyl, and the like
  • heteroaryl means an aromatic mono-, bi-, or polycyclic ring incorporating one or more (for example 1-4) heteroatoms selected from N, O, and S.
  • heteroaryl includes both monovalent species and divalent species. Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, puriny
  • references herein to a "6,5" or “6,6" aryl or heteroaryl ring systems refer to 5 membered ring fused to another 6 membered ring such as a benzothienyl ring (a 6,5 ring); or one 6 membered ring fused to another 6 membered ring such as a naphthyl, quinolyl or quinazolinyl ring (a 6,6 ring). Unless stated otherwise, a 6,5 heteroaryl group may be attached via the 5 or the 6 membered ring.
  • Heteroaryl-Ci. 6 alkyl means an heteroaryl group covalently attached to a group, both of which are defined herein.
  • heteroaryl-Ci- 6 alkyl groups include pyridin-3-ylmethyl, 3-(benzofuran-2-yl)propyl, and the like.
  • Haloalkyl means alkyl substituted with one or more same or different halo atoms, e.g., -CH 2 Cl, -CF 3 , -CH 2 CF 3 , -CH 2 CCl 3 , and the like.
  • substituents within the compound of formula I include:- for halo fluoro, chloro, bromo and iodo; for Ci- 6 alkyl: methyl, ethyl, propyl, isopropyl and tert-butvl; for C 2 .
  • Ci- ⁇ alkanoylamino acetamido and propionamido
  • N-(C i - 6 alky I)-C i _ 6 alkanoylamino N-methylacetamido and N-methylpropionamido
  • N-(Ci- 6 alkyl)sulfamoyl N-methylsulfamoyl and N-ethylsulfamoyl
  • N-(l-6C)alkylureido N-methylureido and N-ethylureido
  • N,N'-di-[(l-6C)alkyl]ureido N,N'-dimethylureido, N-methyl-N'-ethylureido and N-ethyl-N'-methylureido
  • amino-Ci- 6 alkyl aminomethyl, 2-aminoethyl, 1-aminoethyl and
  • Ci- ⁇ alkylamino-Ci-ealkyl methylaminomethyl, ethylaminomethyl
  • N,N-(Ci -6 alkyl) 2 amino-Ci -6 alkyl dimethylaminomethyl, diethylaminomethyl
  • Ci-ealkanoylamino-Ci- ⁇ alkyl acetamidomethyl, propionamidomethyl
  • N-(N',N'-dimethylureido)ethyl for N-(C ⁇ - 6 alkyl)ureido-Ci. 6 alkyl: N-methylureidomethyl, 2-(N-methylureido)ethyl and l-(N-methylureido)ethyl; for NJf-(C i -6 alkyl) 2 ureido-C i -6 alkyl: N,N'-dimethylureidomethyl,
  • R 6 or R 9 is carbocyc IyI-X 5 -, heterocyclyl-X 6 - or heteroaryl-X 7 -, and, for example, X 5 , X 6 or X 7 is a - ⁇ (R I2 )C(O)- linking group, it is the nitrogen atom, not the carbon atom, of the -N(R 12 )C(O)- linking group which is attached to the carbocyclyl, heterocyclyl or heteroaryl group.
  • R or R 1 ' is, for example, heterocyclyl-X 3 - and X 3 is -N(R 22 )C(O)- the nitrogen atom of the -N(R 22 )C(O)- linker group is attached to the heterocyclyl.
  • heterocyclyl-X 3 - is heterocyclyl-N(R 22 )C(O)- and said heterocyclyl group is attached to the -N(R 22 )C(O)- group by a ring carbon.
  • R 5 or R 1 1 is heterocyclyl-X 3 - and X 3 is a direct bond
  • the heterocyclyl group is attached to the 5,6,7,8- tetrahydropteridine ring by a ring carbon atom in the heterocyclyl group.
  • the compound of formula I may be in the form of an N-oxide of the compound of formula I, this refers to a nitrogen of a heteroaryl or heterocyclyl group being in the form of its corresponding N-oxide, in particular the pyridyl nitrogen in the compound of formula I may form the N-oxide, thereby providing a compound of the formula:
  • isomers Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
  • the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof.
  • the compounds of this invention may possess an asymmetric center at the group A when A represents CR 10 R 11 and R 10 represents H and R 11 represents a group other than H as defined hereinbefore.
  • the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof.
  • the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J.
  • the present invention encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that possess HSP90 inhibitory activity.
  • the present invention also encompasses all tautomeric forms of the compounds of formula I that possess HSP90 inhibitory activity.
  • certain compounds of the formula I may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms that possess HSP90 inhibitory activity.
  • tautomerism may affect heteroaryl rings or heterocyclic groups within the compounds of formula I that bear 1 or 2 oxo or thioxo substituents.
  • R 4 is H and R 5 is hydroxy the compound is likely to tautomerise to the more stable oxo form:
  • the present invention includes in its definition any such tautomeric form, or a mixture thereof, which possesses the above-mentioned activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings or named in the Examples.
  • a tautomeric mixture of compounds comprising a lH-pyrazol-3-yl group and a lH-pyrazol-5-yl group may be present.
  • just one of any such tautomeric forms is named in the Examples that follow hereinafter or is presented in any relevant formulae drawings that follow hereinafter.
  • a “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use.
  • a “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
  • a “pharmaceutically acceptable counter ion” means an ion having a charge opposite to that of the substance with which it is associated and that is pharmaceutically acceptable. Representative examples include, but are not limited to, chloride, bromide, iodide, methanesulfonate, p-tolylsulfonate, trifluoroacetate, acetate, and the like.
  • a "pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • Such pharmaceutically-acceptable salts of a compound of the formula I is, for example, an acid-addition salt of a compound of the formula I, for example an acid- addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the formula I which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2- hydroxyethyl)amine.
  • Compounds of the invention may form internal salts or zwitterions, for example between a carboxy group and a sufficiently basic group in the compound of
  • Leaving group has the meaning conventionally associated with it in synthetic organic chemistry i.e., an atom or group capable of being displaced by a nucleophile and includes halogen (such as chloro, bromo, iodo), alkanesulfonyloxy (such as mesyloxy or trifluorosulfonyloxy) or arenesulfonyloxy (such as tosyloxy), and the like. Leaving Groups are well known in the art and are catalogued in "Protective Groups in Organic Synthesis 3 rd Ed.”, edited by Theodora Green and Peter Wuts (John Wiley, 1999).
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the formula I also forms an aspect of the present invention.
  • the compounds of the invention may be administered in the form of a prodrug, that is a compound that is broken down in the human or animal body to release a compound of the invention.
  • a pro-drug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the invention.
  • a pro-drug can be formed when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached.
  • pro-drugs examples include in vivo cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the formula I and in-vivo cleavable amide derivatives that may be formed at a carboxy group or an amino group in a compound of the formula I.
  • the present invention includes those compounds of the formula I as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the formula I that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the formula I may be a synthetically-produced compound or a metabolically-produced compound.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the formula I is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.
  • Various forms of pro-drug have been described, for example in the following documents :- a) Methods in Enzymology. Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H.
  • Bundgaard Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard p. 113- 191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences. 77, 285 (1988); f) N. Kakeya, et al, Chem. Pharm. Bull. 32, 692 (1984); g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the formula I that possesses a carboxy group is, for example, an in vivo cleavable ester thereof.
  • An in vivo cleavable ester of a compound of the formula I containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent acid.
  • Suitable pharmaceutically-acceptable esters for carboxy include esters such as methyl, ethyl and tert-butyl, Ci_ 6 alkoxymethyl esters such as methoxymethyl esters, Ci.6alkanoyloxymethyl esters such as pivaloyloxymethyl esters, 3-phthalidyl esters, Cs-scycloalkylcarbonyloxy- Ci. 6 alkyl esters such as
  • 2-oxo-l,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-l,3-dioxolen-4-ylmethyl esters and Ci- 6 alkoxycarbonyloxy- Ci. 6 alkyl esters such as methoxycarbonyloxymethyl and 1 -methoxycarbonyloxy ethyl esters.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the formula I thato possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof.
  • An in vivo cleavable ester or ether of a compound of the formula I containing a hydroxy group is, for example, a pharmaceutically-acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound.
  • Suitable pharmaceutically- acceptable ester forming groups for a hydroxy group include inorganic esters such ass phosphate esters (including phosphoramidic cyclic esters).
  • Suitable pharmaceutically-acceptable ester forming groups for a hydroxy group include Ci- ioalkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, Ci.ioalkoxycarbonyl groups such as ethoxycarbonyl, N 5 N-(C]- 6 ) 2 carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
  • ringo substituents on the phenylacetyl and benzoyl groups include aminomethyl, N- alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(Ci-4alkyl)piperazin-l-ylmethyl.
  • Suitable pharmaceutically-acceptable ether forming groups for a hydroxy group include ⁇ -acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the formula I that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a such as methylamine, a (Ci- 4 alkyl) 2 amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine, a Cj. 4alkoxy- C 2 - 4 alkylamine such as 2-methoxyethylamine, a such as0 benzylamine and amino acids such as glycine or an ester thereof.
  • an amine such as ammonia
  • a such as methylamine
  • a (Ci- 4 alkyl) 2 amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine
  • a Cj. 4alkoxy- C 2 - 4 alkylamine such as 2-methoxyethylamine
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the formula I that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof.
  • Suitable pharmaceutically-acceptable amides from an amino group include, for example an amide formed with C
  • ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C i ⁇ alky ⁇ piperazin- 1 -ylmethyl.
  • the in vivo effects of a compound of the formula / may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the formula I.
  • the in vivo effects of a compound of the formula I may also be exerted by way of metabolism of a precursor compound (a pro-drug).
  • Treating” or “treatment” of a disease includes:
  • a “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
  • novel compounds of the invention include, for example, compounds of the formula I, or pharmaceutically acceptable salts and pro-drugs thereof, wherein, unless otherwise stated, each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , p and A has any of the meanings defined hereinbefore or in any of paragraphs (1) to (87) hereinafter: - (1) R 1 , R 2 and R 3 are independently selected from H, halo or a group of the formula:
  • X 1 is a direct bond, O, S or NR 8a , wherein R 8a is H or C ]-4 alkyl, and R 8 is selected from H, Ci -4 alkyl, C 2 . 4 alkenyl, C 3 . 6 cycloalkyl and C 2-4 alkynyl, and wherein R 1 , R 2 and R 3 may independently of each other be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, carbamoyl, and NN-(C i -4 alkyl) 2 carbamoyl.
  • R 1 , R 2 and R 3 are independently selected from H, halo or a group of the formula:
  • X ! is a direct bond, O, S or ⁇ R 8a
  • R 8a is H or C M alkyl
  • R 8 is selected from H, C 2-4 alkenyl, C 3 . 6 cycloalkyl and C 2-4 alkynyl
  • R 1 , R 2 and R 3 may independently of each other be optionally substituted on carbon by one or more substituents selected from hydroxy, and C 3 . 6 cycloalkyl.
  • R 1 , R 2 and R 3 are independently selected from halo or a group of the formula: -X 1 -R 8 , wherein X 1 is a direct bond, O or S, and R 8 is selected from H and C M alkyl.
  • R 1 , R 2 and R 3 are independently selected from H, chloro, bromo, iodo, amino or a group of the formula:
  • X 1 is a direct bond, O or S, and R 8 is selected from H,
  • R 1 , R 2 and R 3 are each a group of the formula:
  • R 1 , R 2 and R 3 are each a group of the formula: -X 1 -R 8 , wherein X 1 is a direct bond or O, and R 8 is (particularly Ci -2 alkyl, for example methyl).
  • R 1 , R 2 and R 3 are independently selected from H, chloro, bromo, iodo, amino, methyl, ethyl, methoxy, ethoxy, isopropyloxy, isobutyloxy, allyloxy, methylthio, ethylthio, hydroxymethyl, 2-hydroxyethyl, 2-methoxyethoxy, 2-hydroxyethoxy and cyclopropylmethoxy.
  • R 1 , R 2 and R 3 are independently selected from methyl and methoxy.
  • R 1 is selected from H, halo, (10) R 1 is selected from H, halo and Ci -3 alkyl.
  • R 1 is selected from halo and Ci -3 alkyl.
  • R 1 is selected from chloro, bromo, methyl and methoxy.
  • R 1 is selected from chloro, bromo and methyl.
  • R 1 is Ci -3 alkyl.
  • R 1 is methyl.
  • R 2 is selected from H, halo, hydroxy, amino, Ci-4alkyl, N 1 N-(C i. 4 alkyl) 2 amino, wherein R 2 may be optionally substituted on carbon by one or more substituents selected from hydroxy and Ci. 4 alkoxy.
  • R 2 is selected from halo, hydroxy, Ci -3 alkoxy, wherein R 2 may be optionally substituted on carbon by one or more substituents selected from hydroxy
  • R 2 is selected from chloro, bromo, iodo, hydroxy, methoxy, methyl and methylthio.
  • R 2 is selected from chloro, bromo, iodo, methoxy, methyl and methylthio.
  • R 2 is Ci -3 alkoxy.
  • R 2 is selected from halo, Ci -3 alkoxy and (particularly bromo, methoxy and methylthio).
  • R 2 is methoxy
  • R 3 is selected from H, halo, hydroxy, Ci- 4 alkyl, Ci. 4 alkoxy and Ci -4 alkylthio, wherein R 3 may be optionally substituted on carbon by one or more substituents selected from hydroxy and
  • R 3 is selected from chloro, bromo, iodo, hydroxy, methoxy, methyl and methylthio.
  • p is 1 and R 3 is (particularly methyl).
  • R 1 is selected from H, halo and (particularly R 1 is halo or
  • R 2 is selected from halo, hydroxy, wherein R 2 may be optionally substituted on carbon by one or more substituents selected from hydroxy and Cioalkoxy; and p is 1, R 3 is in the meta-position to the pyridyl nitrogen, and R 3 is selected from H, halo, hydroxy, Ci. 4 alkyl, wherein R 3 may be optionally substituted on carbon by one or more substituents selected from hydroxy and Ci -3 alkoxy (particularly R 3 is selected from chloro, bromo, Ci -3 alkyl and
  • R 1 is selected from H, halo and (particularly R 1 is halo or
  • R 2 is selected from halo, Ci -3 alkoxy and (particularly R 2 is halo, Cioalkoxy or Ci -3 alkylthio, more particularly bromo, methoxy or methylthio), wherein R 2 is optionally substituted on carbon by one or more substituents selected from hydroxy and Ci -3 alkoxy; and p is 1, R 3 is in the meta-position to the pyridyl nitrogen, and R 3 is selected from H, halo, hydroxy, and wherein R 3 is optionally substituted on carbon by one or more substituents selected from hydroxy and (particularly R 3 is selected from chloro, bromo, Ci ⁇ alkyl and Ci -3 alkoxy).
  • R 1 is Ci -3 alkyl (particularly methyl);
  • R 2 is (particularly methoxy); and p is 1, R 3 is in the meta-position to the pyridyl nitrogen, and R 3 is Ci -3 alkyl (particularly methyl).
  • R 1 , R 2 , R 3 and p have any of the values defined herein, particularly those defined in (1) to (31) above.
  • A is CR 10 R", wherein R 10 and R 1 ' are as hereinbefore defined.
  • A is CR 10 R 1 1 , wherein R 10 is H or C M alkyl, and R 1 ' is as hereinbefore defined.
  • A is CR 10 R 1 ', wherein R 10 is H and R 1 ' is H, carboxy, carbamoyl, Ci -6 alkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, Cu ⁇ alkanoyl, N-(Ci. 6 alkyl)carbamoyl, N,N-(Ci. 6 alkyl) 2 carbamoyl, C].
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci. 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, Ci ⁇ alkoxy, Ci- 6 alkanoyl, Q- ⁇ alkanoyloxy, N-(Ci. 6 alkyl)amino, N,N-(Ci_6alkyl) 2 amino, Ci- ⁇ alkanoylamino, N-(Ci. 6 alkyl)carbamoyl, N,N-(Ci.6alkyl) 2 carbamoyl, Ci.
  • Ci_ 6 alkoxycarbonyl N-(C].
  • 6 alkyl)sulfamoyl N,N-(Ci. 6 alkyl) 2 Sulfamoyl, Ci.
  • R 14 and R 19 are independently selected from Ci- 6 alkyl, Ci_ 6 alkanoyl, Ci_ 6 alkylsulfonyl, Ci- 6 alkoxycarbonyl, carbamoyl, N-(Ci. 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 and R 19 may be optionally substituted on carbon by one or more R 20 ; R 18 is selected from halo, hydroxy, amino, N-(C).
  • A is CR 10 R 11 , wherein R 10 is H and R 11 is H, carbamoyl, sulfamoyl, d -6 alkyl,
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_ 4 alkyl, C 2 - 4 alkenyl, C 2 - 4 alkynyl, Ci -4 alkoxy, C M alkanoyl, Ci. 4 alkanoyloxy, N-(Ci- 4 alkyl)amino, NN-(C i -4 alkyl) 2 amino,
  • R 14 and R 19 are independently selected from carbamoyl, N-(Ci- 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, Ci -4 alkyl, N-(Ci- 4 alkyl)amino and N,N-(Ci- 4 alkyl) 2 amino;
  • A is CR 10 R 1 ', wherein R 10 is H and R 1 ' is H, C 1-6 alkyl, C 3 . 7 cycloalkyl-X 2 -, phenyl- X 2 , heterocyclyl-X 3 - or heteroaryl-X 4 -, wherein said heteroaryl is a monocyclic 5 or 6- membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and N, and said heterocyclyl is a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and N, wherein R 11 may be optionally substituted on carbon by one or more R 13 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 14 , and wherein any heterocyclyl group within R 1 ' may optionally bear 1 oxo substituent
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2 - 4 alkenyl, C 2 - 4 alkynyl, Ci- 4 alkoxy, Ci ⁇ alkanoyl, Ci_ 4 alkanoyloxy, N-(Ci- 4 alkyl)amino, N,N-(Ci. 4 alkyl) 2 amino,
  • R 14 and R 19 are independently selected from Ci. 4 alkylsulfonyl, carbamoyl, N-(Ci. 6 alkyl)carbamoyl, NN-(Ci - 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, N-(Ci- 4 alkyl)amino and N,N-(Ci- 4 alkyl) 2 amino;
  • A is CR 10 R 11 , wherein R 10 is H and R 1 1 is H, C,. 6 alkyl, C 3-7 cycloalkyl-X 2 -, phenyl- X 2 , heterocyclyl-X 3 - or heteroaryl-X 4 -, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrof ⁇ iranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrroliny
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci -4 alkyl, C 2-4 alkenyl, C 2 - 4 alkynyl, Ci -4 alkoxy, C 1-4 alkanoyl, Ci -4 alkanoyloxy, N-(Ci -4 alkyl)amino, NN-(C i -4 alkyl) 2 amino, C M alkanoylamino, N ⁇ Ci ⁇ alky ⁇ carbamoyl, NN-(C M alkyl ⁇ carbamoyl, Ci -4 alkylS(O) a wherein a is 0 to 2, NN-(Ci -4 alkyl) 2 Sulfamoyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a
  • R 14 and R 19 are independently selected from Ci. 4 alkyl, C ]-4 alkanoyl, C i ⁇ alkylsulfonyl, C i ⁇ alkoxycarbonyl, carbamoyl, N-(C i _ 6 alkyl)carbamoyl, NN-(C
  • R 18 is selected from halo, hydroxy, amino, Ci -4 alkyl, Ci -4 alkoxy, N-(Ci- 4 alkyl)amino and N,N-(Ci- 4 alkyl) 2 amino; and
  • X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and - ⁇ (R 22 )C(O)-, wherein R 22 is selected from hydrogen or Ci- 4 alkyl.
  • A is CR 10 R 1 ', wherein R 10 is H and R 1 ' is selected from H and C h alky., wherein R 1 ' is optionally substituted on carbon by one or more R 13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci -4 alkanoyl, Ci- 4 alkanoyloxy, N-(Ci -4 alkyl)amino, N,N-(Ci -4 alkyl) 2 amino, Ci -4 alkanoylamino, N,N-(Ci- 4 alkyl) 2 carbamoyl, C i.
  • R 1 ' is selected from H and (44)
  • A is CR 10 R 1 ', wherein R 10 is H and R 1 !
  • R 11 is H, Ci -6 alkyl or Ca- ⁇ cycloalkyl-X 2 -, wherein R 11 may be optionally substituted on carbon by one or more R 13 ;
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci -4 alkyl, C 2 - 4 alkenyl, C 2-4 alkynyl, Ci ⁇ alkoxy, C M alkanoyl, Ci ⁇ alkanoyloxy, N ⁇ C M alky ⁇ amino, NN-(C M alkyl ⁇ amino, C M alkanoylamino, N- ⁇ M alkyOcarbamoyl, NN-(C i -4 alkyl) 2 carbamoyl, C M aUCyIS(O) 3 wherein a is 0 to 2, N-(Ci- 4 alkyl)sulfamoy
  • R 19 is selected from C M alkylsulfonyl, C]. 4 alkoxycarbonyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, N-(C]. 4alkyl)amino and N,N-(Ci -4 alkyl) 2 amino; and X 2 is selected from a direct bond, -C(O)-, -N(R 22 )C(O)-; wherein R 22 is hydrogen
  • A is CR 10 R 1 ', wherein R 10 is H and R 1 ' is H or C,. 6 alkyl, wherein R 11 may be optionally substituted on carbon by one or more R 13 ; 5 R 13 is selected from fluoro, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2-4 alkenyl, C 2-4 alkynyl, Ci -4 alkoxy, Ci- 4 alkanoyl, N-(Ci -4 alkyl)amino, NN-(C M alkyrhamino, N-(Ci- 4 alkyl)carbamoyl, NN-(C i_ 4 alkyl) 2 carbamoyl, C i- 4 alkylS(0) a wherein a is 0 to 2, C M alkoxycarbonyl, N-(Ci_ 4 alkyl)sulfamoyl,
  • R 13 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that is nitrogen may be optionally substituted by a group selected from R 19 ; and wherein any heterocyclyl group within R 13 may optionally bear 1 oxo substituent;
  • R 19 is selected from Ci -4 alkyl, Ci- 4 alkanoyl, C M alkylsulfonyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, benzyl, 2o benzyloxycarbonyl and benzoyl; and
  • R 18 is selected from halo, hydroxy, amino, Ci -4 alkyl, Ci. 4 alkoxy, N-(Ci- 4 alkyl)amino and NN-(Ci -4 alkyl) 2 amino.
  • A is CR 10 R 11 , wherein R 10 is H and R 11 is H or C 1-6 alkyl, wherein R 1 ' may be optionally substituted on carbon by one or more R 13 ;
  • _5 R 13 is selected from fluoro, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2-4 alkenyl, C 2-4 alkynyl, Ci- 4 alkanoyl, N-(Ci- 4 alkyl)amino, NN-(Ci- 4 alkyl) 2 amino, Ci- 4 alkanoylamino, N-(Ci_ 4 alkyl)carbamoyl, NN-(C i- 4 alkyl) 2 carbamoyl, C h alky IS(O) 3 wherein a is 0 to 2, N-(Ci- 4 alkyl)sulfamoyl, N,N-(
  • A is CR 10 R 1 1 , wherein R 10 is H and R 11 is H or Ci -6 alkyl, wherein R 11 may be optionally substituted on carbon by one or more R 13 ; R 13 is selected from carboxy, carbamoyl, N-(Ci- 4 alkyl)carbamoyl,
  • R 18 is selected from halo, hydroxy, amino, Ci -4 alkyl, N-(Ci- 4 alkyl)amino and NN-(C i. 4 alkyl) 2 amino.
  • A is CR 10 R 1 1 , wherein R 10 is H and R 11 is H or Ci -6 alkyl, wherein R may be optionally substituted on carbon by one or more R ;
  • R 13 is selected from carboxy, carbamoyl, N-(Ci_ 4 alkyl)carbamoyl, Ci_ 4 alkoxycarbonyl and phenyl-, and wherein R 13 may be optionally substituted on carbon by one or more R 18 ; and R 18 is NN-(C i -4 alkyl) 2 amino.
  • A is CR 10 R 1 ' , wherein R 10 is H and R 1 ' is selected from H, methyl, propyl, 2- methylpropyl, benzyl, methoxycarbonylmethyl, carboxymethyl, carbamoylmethyl, N-[3- (dimethylamino)propyl]carbamoylmethyl and N-[2- (dimethylamino)ethyl]carbamoylmethyl.
  • A is CR 10 R 1 ', wherein R 10 is H and R 1 ' is H or Ci -4 alkyl, for example R 1 ' is H, methyl, ethyl or isopropyl.
  • A is NR 9 , wherein R 9 is as hereinbefore defined.
  • A is NR 9 , wherein R 9 is selected from H, C 3-7 CyC loalkyl, C 3 . 7 cycloalkyl- Ci- ⁇ alkanoyl, Ci. 6 alkylsulfonyl, Ci- 6 alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 9 may be optionally substituted on carbon by one or more R 16 ; and
  • R 16 is selected from halo, hydroxy, amino, N-(Q- 4 alkyl)amino and (53)
  • A is NR 9 , wherein R 9 is selected from H, C 3-7 cycloalkyl, C 3-7 cycloalkyl- C 4 alkyl, for example R 9 is selected from H, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl- C
  • R 4 is H and R 5 is H, carboxy, carbamoyl, sulfamoyl, C ⁇ aUcyl, C 2-6 alkenyl, C 2 - 6 alkynyl, Ci- ⁇ alkanoyl, N-(Ci- 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 Carbamoyl,
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci- ⁇ alkanoyl, Ci- ⁇ alkanoyloxy, N-(Ci_ 6 alkyl)amino, N,N-(Ci. 6 alkyl) 2 amino, Ci- ⁇ alkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(Ci -6 alkyl) 2 carbamoyl, Ci- 6 alkylS(O) a wherein a is 0 to 2, Ci- 6 alkoxycarbonyl, N-(Ci.
  • R 13 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 13 may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any aryl or heteroaryl group within R 13 may optionally bear a Ci- 3 alkylenedioxy group;
  • R 14 and R 19 are independently selected from C i ⁇ alkyl, C] - ⁇ alky lsulfony 1, C i . 6 alkoxycarbony 1, carbamoyl, N-(Ci - ⁇ alky l)carbamoyl,
  • R 14 and R 19 may be optionally substituted on carbon by one or more R 20 ;
  • R 18 is selected from halo, hydroxy, amino, Ci -4 alkyl, Ci_ 4 alkoxy, N-(Ci- 4 alkyl)amino and N,N-(Ci. 4 alkyl) 2 amino;
  • R 20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino;
  • X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)-, - ⁇ (R 22 )C(O)-; wherein R 22 is hydrogen or Ci -4 alkyl; and
  • R 4 is H and R 5 is H, carbamoyl, sulfamoyl, Ci -6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, Ci_ 6 alkanoyl, N-(Ci- 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, Ci- ⁇ alkoxycarbonyl, N-(C,. 6 alkyl)sulfamoyl, NN-(C,.
  • R 13 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 13 may optionally bear 1 oxo substituent;
  • R 14 and R 19 are independently selected from Ci -4 alkoxycarbonyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, N-(Ci- 4 alkyl)amino and
  • R 4 is H and R 5 is H, Ci -6 alkyl, Ca. ⁇ cycloalkyl-X 2 -, phenyl-X 2 , heterocyclyl-X 3 - or heteroaryl-X 4 -, wherein said heteroaryl is a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and N, and said heterocyclyl is a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and N, wherein R 5 may be optionally substituted on carbon by one or more R 13 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 14 , and wherein any heterocyclyl group within R 4 may optionally bear 1 oxo substituent, and wherein any phenyl or heteroaryl group within R 4 may optionally bear
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci.4alkanoyl, Ci ⁇ alkanoyloxy, N-(Ci- 4 alkyl)amino, N,N-(Ci- 4 alkyl) 2 amino, N-(Ci_ 4 alkyl)carbamoyl, N,N-(Ci- 4 alkyi) 2 Carbamoyl, Ci- 4 alkylS(0) a wherein a is 0 to 2, N-(Ci_ 4 alkyl)sulfamoyl, N,N-(Ci.
  • R 13 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R may optionally bear 1 oxo substituent, and wherein any aryl or heteroaryl group within R 13 may optionally bear a Ci.
  • R 14 and R 19 are independently selected from Ci -4 alkanoyl, Ci -4 alkoxycarbonyl, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, N 1 N-(C i. 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, Ci ⁇ alkyl, d ⁇ alkoxy, N-(Ci- 4 alkyl)amino and and X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and
  • R 4 is H and R 5 is H, Ci -6 alkyl, C 3 . 7 cycloalkyl-X 2 -, phenyl-X 2 , heterocyclyl-X 3 - or heteroaryl-X 4 -, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholin
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C M alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C ⁇ alkoxy, Ci- 4 alkanoyl, Ci_ 4 alkanoyloxy, N-(Ci.
  • R 14 and R 19 are independently selected from Ci -4 alkanoyl, Ci -4 alkoxycarbonyl, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, NN-(Ci.6alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, Ci -4 alkoxy, N-(Q- 4 alkyl)amino and NN-(C M alkyl ⁇ amino;
  • R 4 is H and R 5 is H, Ci -6 alkyl or Cj-vcycloalkyl-X 2 -, wherein R 5 may be optionally substituted on carbon by one or more R 13 ;
  • R 13 is selected from halo (such as fluoro), nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci ⁇ alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C M alkanoyloxy, N-(Ci- 4 alkyi)amino, NN-(Ci -4 alkyl) 2 amino, C M alkanoylamino, N-(C M alkyl)carbamoyl, NN-(C M alkyl) 2 carbamoyl, C h alky IS(O) 3 wherein a is 0 to 2, C M alkoxycarbonyl, NN-(Ci -4 alkyl) 2 Sulfamoyl, Ca- ⁇ cycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O
  • R 19 is selected from carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i -6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, Ci- 4 alkyl, N-(Ci- 4 alkyl)amino and NN-(Ci- 4 alkyl) 2 amino;
  • R 4 is H and R 5 is H, methyl, ethyl or isopropyl.
  • R 6 is selected from H, Ci- 6 alkyl, C 2 . 6 alkenyl, C 2-6 alkynyl, Ci- 6 alkanoyl, Ci- ⁇ alkylsulfonyl, Ci- ⁇ alkoxycarbonyl, carbamoyl, N-(Ci.
  • R 12 is selected from hydrogen or and wherein R 6 may be optionally substituted on carbon by one or more R 16 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 , and wherein any heterocyclyl group within R 6 may optionally bear 1 or 2 oxo or thioxo substituents;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2 - 6 alkenyl, C 2-6 alkynyl, Ci- ⁇ alkoxy, Ci- 6 alkanoyl, N-(Ci_ 6 alkyl)amino, N,N-(Ci.
  • R 16 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 16 may optionally bear 1 or 2 oxo or thioxo substituents;
  • R 17 and R 19 are independently selected from Ci- ⁇ alkanoyl, Ci- 6 alkylsulfonyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 17 and R 19 may be optionally substituted on carbon by one or more R 20 ;
  • R 18 is selected from halo, hydroxy, amino, N-(Ci- 4 alkyl)amino and N,N-(Ci- 4 alkyl) 2 amino;
  • R 20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino; and X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-,
  • R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or Ci ⁇ alkyl and q is 0-2.
  • R 6 is selected from H, C 2-6 alkenyl, Ci-6alkanoyl, Ci- ⁇ alkylsulfonyl, C]. 6 alkoxycarbonyl, carbamoyl, N-(Ci.
  • heteroaryl is a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and ⁇
  • said heterocyclyl is a monocyclic 5, 6 or 7- membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and ⁇ ; wherein X 5 , X 6 and X 7 are independently selected from a direct bond, -C(O)-,
  • R 12 is selected from hydrogen or C M alkyl, and wherein R 6 may be optionally substituted on carbon by one or more R 16 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 , and wherein any heterocyclyl group within R 6 may optionally bear 1 oxo substituent;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_ 6 alkyl, C 2-6 alkenyl, C 2 - 6 alkynyl, Ci ⁇ alkoxy, Ci- ⁇ alkanoyl, Ci- ⁇ alkanoyloxy, N-(C].
  • heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and ⁇ , heteroaryl-X 10 -, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and ⁇ , and wherein R 16 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 16 may optionally bear 1 oxo substituent;
  • R 17 and R 19 are independently selected from C ⁇ alkyl, carbamoyl, N,N-(Ci. 4 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, N-(Ci- 4 alkyl)amino and N, N-(C i ⁇ alky l) 2 amino ;
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, and -S(O) q -, wherein R 21 is selected from hydrogen or and q is 0-2.
  • R 6 is selected from H and Ci -6 alkyl, and wherein R 6 may be optionally substituted on carbon by one or more R 16 ;
  • R 16 is selected from fluoro, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2-6 alkenyl, C 2 - 6 alkynyl, Ci- ⁇ alkoxy, C].
  • heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and ⁇ , heteroaryl-X 10 -, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and ⁇ , and wherein R 16 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 16 may optionally bear 1 oxo substituent;
  • R 19 is independently selected from Ci -4 alkanoyl, carbamoyl, N-(Ci- 4 alkyl)carbamoyl, N,N-(Ci- 4 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, N-(Ci. 4alkyl)amino and
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, and -S(O) q -, wherein R 21 is selected from hydrogen or and q is 0-2. (65) R 6 is selected from H and and wherein R 6 may be optionally substituted on carbon by one or more R 16 ;
  • R 16 is selected from fluoro, N-(Ci. 6 alkyl)amino, NN-(C i_ 6 alkyl) 2 amino, C 3-7 cycloalkyl-X 8 - , phenyl-X 8 -, heterocyclyl-X 9 -, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and ⁇ , heteroaryl-X 10 -, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and ⁇ , and wherein R 16 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 16 may optional
  • R 18 is selected from halo, hydroxy, amino, N-(Ci- 4 alkyl)amino and N,N-(Ci_ 4 alkyl) 2 amino;
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, and -S(O) q -, wherein R 21 is selected from hydrogen or Ci. 4 alkyl and q is 0-2.
  • R 6 is selected from H and and wherein R 6 may be optionally substituted on carbon by one or more R 16 ;
  • R 16 is selected from fluoro, Ci -6 alkoxy, N,N-(Ci -6 alkyl) 2 amino, C 3-7 cycloalkyl-X 8 - , phenyl-X 8 -, heterocyclyl-X 9 -, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1 , 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and ⁇ , heteroaryl-X 10 -, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and ⁇ , and wherein any heterocyclyl group within R 16 may optionally bear 1 oxo substituent; and
  • X 8 , X 9 and X 10 are each a direct bond.
  • R 6 is selected from H, C 2-4 alkenyl, C M alkylsulfonyl, Ci- 4 alkoxycarbonyl, carbamoyl, N-(Ci_ 4 alkyl)carbamoyl, C 3 .
  • heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl and iso
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C M alkyl, C 2-4 alkenyl, C 2 - 4 alkynyl, Ci -4 alkoxy, N,N-(Ci- 4 alkyl) 2 amino, C M alkanoylamino, N-(Ci -4 alkyl)carbamoyl, NN-(Ci ⁇ alkyO ⁇ carbamoyl, Ci -4 alkylS(O) a wherein a is 0 to 2, N-(Ci -4 alkyl)sulfamoyl, NN-(Ci -4 alkyl) 2 Sulfamoyl, C M alkylsulfonylamino, cyclopropyl-X 8 -, cyclobutyl-X 8 -, cyclopentyl-X 8
  • R 17 and R 19 are independently selected from Ci -4 alkylsulfonyl, C M alkoxycarbonyl, carbamoyl, N-(Ci -4 alkyl)carbamoyl, NN-(C i- 4 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, N-(Ci-
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, and -S(O) q -, wherein R 21 is selected from hydrogen or Ci -4 alkyl and q is 0-2.
  • R 6 is selected from H, Ci -6 alkyl, C 3-7 cycloalkyl-X 5 -, phenyl-X 5 -, heterocyclyl-X 6 - and heteroaryl-X 7 -, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl,
  • R 16 is selected from halo, cyano, hydroxy, amino, mercapto, Ci ⁇ alkyl, C 2 - 4 alkenyl, C 2-4 alkynyl, N-(Ci - 4 alkyl)amino, NN-(Ci-4alkyl) 2 amino, Ci-4alkanoylamino, Ci-4alkylS(O) a wherein a is 0 to 2, cyclopropyl-X 8 -, cyclobutyl-X 8 -, cyclopentyl-X 8 -, cyclohexyl-X 8 -, phenyl-X 8 -, heterocyclyl-X 9 -, wherein said heterocyclyl is selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and heteroaryl-X 10 -, wherein said heteroaryl is selected from furyl, pyrrolyl, thieny
  • R 17 and R 19 are independently selected from Ci -4 alkyl, Ci ⁇ alkanoyl, Ci- 4 alkoxycarbonyl, carbamoyl, N-(C M alkyl)carbamoyl, N N-(C M alky ⁇ carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
  • R 18 is selected from halo, hydroxy, amino, Ci.4alkyl, Ci ⁇ alkoxy, N-(Ci- 4 alkyl)amino and NN-(Ci- 4 alkyl) 2 amino; and X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, and -S(O) q -, wherein R 21 is selected from hydrogen or Ci. 4 alkyl and q is 0-2.
  • R 6 is selected from H and d. 6 alkyl, and wherein R 6 may be optionally substituted on carbon by one or more R 16 ;
  • R 16 is selected from halo (particularly fluoro), cyclopropyl-X 8 -, phenyl-X 8 -, heterocyclyl-X 9 -, wherein said heterocyclyl is selected from imidazolidinyl, azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and heteroaryl-X 10 -, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl,
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, and -S(O) q -, wherein R 21 is selected from hydrogen or and q is 0-2 (particularly X 8 , X 9 and X 10 are each a direct bond).
  • R 6 is selected from H and Ci -6 alkyl, and wherein R 6 may be optionally substituted on carbon by one or more R 16 ;
  • R 16 is selected from halo (particularly fluoro), Ci ⁇ alkoxy, NN-(C M alkyl ⁇ amino, cyclopropyl-X 8 -, phenyl-X 8 -, heterocyclyl-X 9 -, wherein said heterocyclyl is selected from imidazolidinyl, pyrrolidinyl, morpholinyl and piperazinyl, and heteroaryl-X 10 -, wherein said heteroaryl is pyridyl, and wherein any heterocyclyl group within R 16 may optionally bear 1 oxo substituent; and
  • R 6 is selected from H, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl-Ci- 4 alkyl, cyclohexyl-Ci- 4 alkyl, pyrrolidinyl-C M alkyl, and piperazinyl-Ci ⁇ alkyl, wherein R 6 may be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, Ci_ 4 alkyl, Ci- 4 alkoxy, N-(Ci_ 4 alkyl)amino and NN-(Ci galley l) 2 amino, and wherein any -NH- in a azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperidinyl or piperazinyl group in R 6 is optionally substituted by and wherein any
  • R 6 is selected from H, Ci- ⁇ alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl-C M alkyl, piperidinyl-Ci- 4 alkyl, and pyridinyl-Ci.
  • R may be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, Ci_ 4 alkyl, C ⁇ alkoxy, N-(Ci. 4 alkyl)amino and
  • R 6 is selected from H, Ci- ⁇ alkyl, phenyl-Ci. 4 alkyl, pyrrolidinyl-Ci. 4 alkyl, morpholinyl-Ci -4 alkyl, imidazolidinyl-Ci ⁇ alkyl, piperazinyl- C 1-4 alkyl and wherein R 6 may be optionally substituted on carbon by one or more substituents selected from halo, Ci ⁇ alkoxy and NN-(Ci- 4 alkyl) 2 amino, and wherein any pyrrolidinyl, morpholinyl, imidazolidinyl or piperazinyl group in R 6 optionally bears 1 oxo substituent.
  • R 6 is selected from H, methyl, ethyl, 3-methoxypropyl, 2-phenylethyl, 2- piperazin-1-ylethyl, 2,2-difluoroethyl, 3-methylbutyl, propyl, benzyl, cyclopropylmethyl, 2-pyrrolidin-l-ylethyl, 2-(dimethylamino)-2-methylpropyl, 3-(dimethylamino)propyl, 2- mo ⁇ holin-4-ylethyl, 2-pyridin-4-ylethyl, 2-pyridin-3-ylethyl, 3-pyridin-3-ylpropyl, 2-(2- oxoimidazolidin-l-yl)ethyl and 2-(2-oxopyrrolidin-l-yl)ethyl.
  • R 6 is selected from H and
  • R 6 is selected from H, methyl or ethyl, particularly R 6 is H or methyl.
  • R 7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C 2 - 6 alkenyl, C 2 - 6 alkynyl, Ci_6alkylS(O) a wherein a is 0 to 2, wherein R 7 may be optionally substituted on carbon by one or more R 15 ;
  • R 15 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci- ⁇ alkyl, C 2 - 6 alkenyl, C 2 _ 6 alkynyl, N-(Ci-6alkyl)amino, NN-(Ci- 6 alkyl) 2 amino, Ci- ⁇ alkanoylamino, N-(Ci- 6 alkyl)carbamoyl, NN-(Ci.
  • R 15 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 15 may optionally bear 1 or 2 oxo substituents, and wherein any aryl or heteroaryl group within R 15 may optionally bear a Ci- 3 alkylenedioxy group; R 19 is selected from Ci- 6 alkanoyl, Ci_ 6 alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(Ci _6alkyl) 2 carbamoyl, benzyl, benzyloxy
  • R 18 is selected from halo, hydroxy, amino, Ci- 4 alkyl, Ci -4 alkoxy, N-(Ci- 4 alkyl)amino and NN-(C i - 4 alkyl) 2 amino;
  • R 20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino;
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O) q -, -SO 2 N(R 24 )- or -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or and q is 0-2.
  • R 7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C ⁇ alkyl, C 2- 6alkenyl, C 2-6 alkynyl, Ci ⁇ alkoxy, Ci.6alkylS(0) a wherein a is 0 to 2, wherein R 7 may be optionally substituted on carbon by one or more R 15 ;
  • R 15 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_6alkyl, C 2 -6alkenyl, C 2- 6alkynyl, Ci ⁇ aUcoxy, Ci_6alkanoyl, N-(Ci-6alkyl)amino, NN-(Ci-6alkyl) 2 amino, Ci -6 alkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(Ci-6alkyi)2carbamoyl, C].6alkylS(0) a wherein a is 0 to 2, Ci_ 6 alkoxycarbonyl, N-(Ci_ 6 alkyl)sulfamoyl, NN-(Ci.
  • R 15 may be optionally substituted on carbon by one or more R 18 , and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R !5 may optionally bear 1 or 2 oxo substituents, and wherein any aryl or heteroaryl group within R 15 may optionally bear a Ci- 3 alkylenedioxy group; R 19 is selected from Ci- ⁇ alkoxycarbonyl, carbamoyl, N-(Ci.
  • R 19 may be optionally substituted on carbon by one or more R 20 ;
  • R 18 is selected from halo, hydroxy, amino, Ci -4 alkoxy, N-(Ci- 4 alkyl)amino and NN-(Ci -4 alkyl) 2 amino;
  • R 20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino;
  • X 8 , X 9 and X 10 are independently selected from -O-, -N(R 21 )- or -S(O) q -; wherein R 21 is selected from hydrogen and Ci ⁇ alkyl and q is 0-2.
  • R 7 is selected from H, halo, hydroxy, mercapto, C h alky., C 2-4 alkenyl, C 2 - 4 alkynyl, and Ci- 4 alkyl-S-, wherein R 7 may be optionally substituted on carbon by one or more R 15 ;
  • R 15 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2 - 4 alkenyl, C 2-4 alkynyl, Ci -4 alkoxy, Ci -4 alkanoy 1, C i -4 alkanoy loxy, N-(Ci - 4 alkyl)amino, N, N-(C i ⁇ alky l) 2 amino,
  • R 19 is selected from carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, NN-(Ci-6alkyi) 2 carbamoyl, benzyl, benzyloxycarbonyl and benzoyl; and
  • R 18 is selected from halo, hydroxy, amino, Q ⁇ alkyl, Ci ⁇ alkoxy, N-(Ci- i o 4 alkyl)amino and NN-(C i . 4 alkyl) 2 amino.
  • R 7 is selected from H, halo, hydroxy, mercapto, S-, wherein R 7 may be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, C ⁇ alkoxy, N-(Ci_ 4 alkyl)amino and NN-(Ci.
  • R 7 is selected from H, halo, hydroxy, mercapto, C h alky., and S-, wherein R 7 may be optionally substituted on carbon by 1 or 2 substituents selected from halo, hydroxy, amino, Ci -4 alkyl, Ci ⁇ alkoxy, N ⁇ C M alkytyamino and NN-(C i- 4 alkyl) 2 amino.
  • R 7 is selected from H, halo, and (particularly H, halo and
  • R 7 is selected from H, chloro, methyl and methylthio (particularly H, chloro and methyl, more particularly H and chloro).
  • R 7 is selected from H, halo and
  • R 7 is H, fluoro, chloro, bromo, methyl or ethyl, particularly R 7 is H or methyl.
  • R 7 is H or halo (particularly R 7 is halo such as chloro or bromo, more particularly chloro. Alternatively R 7 is H).
  • A is CR 10 R 1 ', wherein R 10 is H and R 1 ' is selected from H or C, -6 alkyl, wherein R 1 ' may be optionally substituted on carbon by one or more R 13 ;
  • R 13 is selected from nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, C ⁇ aHcyl, C 2 - 4 alkenyl, C 2-4 alkynyl, C M alkanoyl, N-(C M alkyl)amino, N,N-(Ci- 4 alkyl) 2 amino, N-(Ci- 4 alkyl)carbamoyl, N,N-(Ci.
  • R 18 is selected from halo, hydroxy, amino, trifluoromethoxy, C ⁇ alkyl (which Ci- 4 alkyl is optionally substituted by fluoro), N-(Ci -4 alkyl)amino, N,N-(C M alkyl) 2 amino, C h alky IS(O) 3 wherein a is 0 to 2, N-(Ci- 4 alkyl)carbamoyl, N,N-(Ci-4alkyl) 2 carbamoyl, piperazinyl, pyrrolidinyl, piperidinyl and morpholinyl; and
  • R 19 is selected from Ci -4 alkylsulfonyl, N-(Ci. 4 alkyl)carbamoyl and NN-(Ci- 4 alkyl) 2 carbamoyl.
  • A is CR 10 R 1 1 , wherein R 10 is H and R 1 1 is selected from H, C,.
  • heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, ind
  • R 18 is selected from halo, hydroxy, amino, trifluoromethoxy, (which Ci- 4 alkyl is optionally substituted by fluoro), Ci -4 alkoxy, N-(Ci -4 alkyl)amino, NN-(Ci- 4 alkyl) 2 amino, Ci_ 4 alkylS(O) a wherein a is 0 to 2, N-(Ci- 4 alkyl)carbamoyl, NN-(C
  • R 19 is selected from Ci- 4 alkylsulfonyl, N-(Ci- 4 alkyl)carbamoyl and NN-(Ci -4 alkyl) 2 carbamoyl.
  • R 6 is selected from H, Ci- ⁇ alkyl and C 2-6 alkynyl (particularly H and Ci.
  • R 6 may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ; wherein R 16 is selected from fluoro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, N-(Ci_ 4 alkyl)amino, NN-(Ci. 4 alkyl) 2 amino, Ci_ 4 alkanoylamino,
  • R 17 is selected from Ci. 4 alkyl, Ci_ 4 alkylsulfonyl, N-(Ci-4alkyl)carbamoyl and N,N-(Ci-4alkyl) 2 carbamoyl.
  • R 6 is selected from H, C !-6 alkyl, Cs.ycycloalkyl-X 5 - , phenyl-X 5 -, heterocyclyl-X 6 - and heteroaryl-X 7 -, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and ⁇ , and wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and ⁇ , and wherein X 5 , X 6 and X 7 are each independently selected from a direct bond or - ⁇ (R 12 )C(0)-, wherein R 12 is hydrogen or C M alky, and wherein R 6 may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally
  • R 17 is selected from Ci- 4 alkylsulfonyl, N-(C M alkyl)carbamoyl and NN-(Ci -4 alkyl) 2 carbamoyl.
  • R 4 , R 5 , R 6 , R 7 , R 10 and R 1 1 have any of the meanings defined hereinbefore or hereinafter;
  • R 1 is selected from H, halo, Ci- 3 alkyl and Ci -3 alkoxy (for example R 1 is H, halo or
  • Cioalkyl particularly, R 1 is methyl, chloro or bromo
  • R 2 is selected from halo, and (for example R 1 is selected from chloro, bromo, iodo, methyl and methoxy); and
  • R 3 is selected from H, halo and Ci- 3 -alkyl; or an N-oxide thereof; or a pharmaceutically acceptable salt thereof.
  • R 4 , R 5 , R 6 , R 7 , R 10 and R 1 1 have any of the meanings defined hereinbefore or hereinafter; or a pharmaceutically acceptable salt thereof.
  • R 4 is H
  • R 5 is H or or R 4 and R 5 together form oxo (for example R 4 is H, R 5 is H or methyl, or R 4 and R 5 together form oxo);
  • R 6 is selected from H, C M alkyl, C 2 - 4 alkenyl, carbamoyl, and NN-(Ci - 4 alkyl) 2 carbamoyl
  • R 6 is H
  • R 7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C). 4 alkyl, C 2 - 4 alkenyl, C 2 - 4 alkynyl, wherein a is 0 to 2 (for example R 7 is selected from
  • R 7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R 7 is selected from H, chloro and bromo);
  • a in the compound of the formula I is CR 10 R 1 1 ;
  • R 10 in the compounds of the formulae I and IA is H; R 1 Sn the compounds of the formulae I and IA is selected from H, cyano, carboxy, carbamoyl, sulfamoyl, Ci- ⁇ alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, Ci_ 6 alkanoyl,
  • N-(C i - 6 alkyi)carbamoyl N-(C i - 6 alkyi)carbamoyl, NN-(C i . 6 alkyl) 2 carbamoyl, N-(C i -4 alkoxy)carbamoyl,
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido, Ci. 6 alkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, Ci -6 alkoxy, C 2-6 alkenyloxy, C 2 - 6 alkynyloxy, C ⁇ - 6 alkanoyl, Ci- ⁇ alkanoyloxy, N-(Ci- 6 alkyl)amino,
  • R 14 and R 19 are independently selected from Ci_ 6 alkanoyl, Ci- ⁇ alkylsulfonyl, Ci. 6 alkoxycarbonyl, carbamoyl, N-(Ci.6alkyi)carbamoyl, N,N-(Ci_ 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 may be optionally substituted on carbon by one or more R 20 ; X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and - ⁇ (R 22 )C(O)-; wherein R 22 is hydrogen or
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O) q -, -SO 2 N(R 24 )- or -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or and q is 0-2; R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci- ⁇ alkyl, C 2-6 alkenyl, C 2-6 alkynyl, N-(Ci_ 6 alkyl)amino, N,N-(Ci- 6 alkyl) 2 amino, Ci_6alkanoy
  • R 26 may be optionally substituted on carbon by one or more R 27 ; and R 20 , R 25 and R 27 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcar
  • R 11 in the compounds of the formulae I, IA and IB is H or Ci -4 alkyl, or R 10 and R 11 together form oxo;
  • R 6 is selected from H, C 2-4 alkenyl, Ci_ 4 alkanoyl, Ci_ 4 alkoxycarbonyl, carbamoyl, N-(C
  • R 7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C 2-4 alkenyl, C 2 - 4 alkynyl, Ci_ 4 alkylS(O) a wherein a is 0 to 2 (for example R 7 is selected from H, halo, hydroxy, Ci. 4 alkyl and particularly R 7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R 7 is selected from H, chloro and bromo); R 4 is H;
  • R 5 is selected from H, cyano, carboxy, carbamoyl, sulfamoyl, Ci -6 alkyl, C 2- 6alkenyl, C 2-6 alkynyl, Ci_ 6 alkanoyl, N-(Ci.
  • R 13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido, C 2 - 6 alkenyl, C 2-6 alkynyl, Ci- ⁇ alkoxy, C 2- 6alkenyloxy, C 2 -6alkynyloxy, Ci-6alkanoyl, N-(Ci- 6 alkyl)amino, NN-(C i- 6 alkyl) 2 amino, C i . ⁇ alkanoylamino, N-(C i .
  • Ci-6alkylS(O) a wherein a is 0 to 2, Ci- ⁇ alkoxycarbonyl, N-(Ci- 6 alkyl)sulfamoyl, N,N-(Ci-6alkyl) 2 sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl-X 8 -, heterocyclyl-X 9 - or heteroaryl-X 10 -, and wherein R 13 may be optionally substituted on carbon by one or more R 18 , and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 13 may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 13 may optionally bear 1 or 2 oxo or thioxo substituents, and where
  • R 14 and R 19 are independently selected from Ci -6 alkyl, Ci_ 6 alkanoyl, Ci- 6 alkylsulfonyl, Ci. 6 alkoxycarbonyl, carbamoyl, N-(C
  • -6 alkyl)carbamoyl, NN-(Ci_ 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 may be optionally substituted on carbon by one or more R 20 ; X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and - ⁇ (R 22 )C(O)-; wherein R 22 is hydrogen or Ci ⁇ alkyl; X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)
  • R 18 may be optionally substituted on carbon by one or more R 25 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 26 ; and wherein any heterocyclyl group within R 18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 18 may optionally bear a Ci_3alkylenedioxy group;
  • R 26 is selected from Ci- 6 alkanoyl, Ci- ⁇ alkoxycarbonyl, carbamoyl, N-(C].6alkyl)carbamoyl, NN-(Ci-6alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 26 may be optionally substituted on carbon by one or more R 27 ; and
  • R 20 , R 25 and R 27 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsul
  • R 5 include, for example any of those described in paragraphs (54) to (61) described hereinbefore.
  • R 4 and R 5 are independently H or or R 4 and R 5 together form oxo (for example R 4 is H, R 5 is Ci- 4 alkyl such as methyl, or R 4 and R 5 together form oxo);
  • a in the compound of the formula I is CR 10 R 1 ' ;
  • R 10 in the compounds of the formulae I, IA and IB is H
  • R 11 in the compounds of the formulae I, IA and IB is H or Ci. 4 alkyl
  • R 7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C 2 - 4 alkenyl,
  • R 7 is selected from H, halo, hydroxy, and Ci- 4 alkoxy, particularly R 7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R 7 is selected from H, chloro and bromo);
  • R 6 is selected from H, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 carbamoyl, carbocyclyl-X 5 -, heterocyclyl-X 6 - or heteroaryl-X 7 -, wherein X 5 , X 6 and X 7 are independently selected from a direct bond, -C(O)-,
  • R 12 is selected from hydrogen or Ci -4 alkyl, and wherein R 6 may be optionally substituted on carbon by one or more R 16 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 , and wherein any heterocyclyl group within R 6 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 6 may optionally bear a group; R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido, C 2- 6alkenyl, C 2-6 alkynyl, Ci_ 6 alkoxy, C 2-6 alkenyloxy, C 2
  • Ci-6alkanoyloxy N-(Ci-6alkyl)amino, N 1 N-(C i - 6 alkyl) 2 amino, C i -6 alkanoylamino, N-(C i _6alkyl)carbamoyl, N,N-(Ci.
  • Ci-6alkylS(O) a wherein a is 0 to 2, Ci -6 alkoxycarbonyl, N-(C
  • R 16 may be optionally substituted on carbon by one or more R 18 , and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 16 may optionally bear a group;
  • R 17 and R 19 are independently selected from Ci- ⁇ alkyl, Ci- 6 alkanoyl, Ci- ⁇ alkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, N,N-(Ci-6alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 17 may be optionally substituted on carbon by one or more R 20 ;
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O) q -, -SO 2 N(R 24 )- or -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or Ci -4 alkyl and q is 0-2; R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci- ⁇ alkanoyl, Ci-6alkanoyloxy, N-(Ci-6alkyl)amino, N,N-(Ci-6alkyl) 2 amino, Ci.6alkanoylamin
  • R 18 may be optionally substituted on carbon by one or more R 25 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 26 ; and wherein any heterocyclyl group within R 18 may optionally bear 1 or 2 oxo or thioxo substituents;
  • R 26 is selected from Ci_ 6 alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 26 may be optionally substituted on carbon by one or more R 27 ; and R 20 , R 25 and R 27 are independently selected from halo, nitro, cyano, hydroxy,
  • N-methyl-N-ethylcarbamoyl methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl,
  • R 6 include, for example any of those described in paragraphs (62) to (74), (86) and (87) described hereinbefore.
  • a compound of the formula I, IA or IB wherein A is CR 10 R 11 and R 10 is hydrogen, which is a compound selected from a compound of the formula I*, IA* and IB*, or a pharmaceutically acceptable salt or an ⁇ - oxide thereof:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 11 and p are as hereinbefore in relation to compounds of the formulae I, IA and IB respectively.
  • Particular compounds of the formula I, IA or IB are those wherein R 11 is hydrogen or Ci -4 alkyl (particularly R 11 is Ci- 4 alkyl).
  • R 7 is chloro.
  • R 4 is H, R 5 is Ci- 4 alkyl such as methyl, or R 4 and R 5 together form oxo);
  • a in the compound of the formula I is CR 10 R 1 ';
  • R 10 in the compounds of the formulae I, IA and IB is H
  • R 11 in the compounds of the formulae I, IA and IB is H or Ci -4 alkyl, wherein R 11 is optionally substituted on carbon by one or more R 13 selected from halo, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_ 4 alkoxy, N-(Ci_ 4 alkyl)amino,
  • R 6 is selected from H, Ci ⁇ alkyl, C 2-4 alkenyl, Ci -4 alkanoyl, Ci_ 4 alkylsulfonyl,
  • R 6 is H or Ci ⁇ alkyl
  • R 7 is selected from H, halo and (for example R 7 is selected from H, halo, hydroxy, particularly R 7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R 7 is selected from H, chloro and bromo); or a pharmaceutically acceptable salt thereof.
  • R 1 , R 2 and R 3 are independently selected from halo, cyano, nitro or a group of the formula:
  • X 1 is a direct bond, O or S and R 8 is Ci -4 alkyl, p is 1 or 2; 1 ; R 4 and R 10 are independently selected from H and
  • R 5 is selected from H, cyano, carboxy, carbamoyl, C 2 - 4 alkenyl, C 2-4 alkynyl, Ci. 4 alkanoyl and
  • R 11 is selected from H, cyano, carboxy, carbamoyl, C h alky!, C 2-6 alkenyl, C 2-6 alkynyl, Ci- ⁇ alkanoyl, N-(Ci- 6 alkyi)carbamoyl, NN-(C i. 6 alkyl) 2 carbamoyl, N-(C i -4 alkoxy)carbamoyl, N-(C i -4 alkyl)-N-(C i .
  • R 7 is selected from H, halo, Ci -4 alkyl and Ci -4 alkylS(O) a wherein a is 0,
  • R 13 and R 16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci- ⁇ alkyl, C 2- 6alkenyl, C 2 - 6 alkynyl, Ci ⁇ alkoxy, C 2 - 6 alkenyloxy, C 2 - 6 alkynyloxy, Ci- ⁇ alkanoyl, Q- ⁇ alkanoyloxy, N-(C]. 6 alkyl)amino, NN-(Ci.
  • R 13 and R 16 may be optionally substituted on carbon by one or more
  • heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 13 and R 16 may optionally bear 1 or 2 oxo or thioxo substituents;
  • R 14 , R 17 and R 19 are independently selected from Ci_ 6 alkylsulfonyl, Ci- 6 alkoxycarbonyl, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 , R 17 and R 19 independently of each other may be optionally substituted on carbon by one or more R 20 ;
  • X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and - ⁇ (R 22 )C(O)-; wherein R 22 is hydrogen or Ci -4 alkyl; X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O),-, -SO 2 N(R 24 )- and -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or and q is 0-2; R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_ 6 alkyl, C
  • R 20 , R 25 and R 27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethyls
  • R 7 is selected from H, chloro, methyl and methylthio, more particularly H and chloro, and even more particularly R 7 is chloro.
  • Particular compounds of the formula IC* are those wherein R 1 1 is H or Ci ⁇ alkyl, wherein R 1 1 is optionally substituted on carbon by one or more R 13 selected from halo, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
  • Other particular compounds of the formula IC* are those wherein R 7 is chloro.
  • R 7 wherein R 7 is chloro and R 11 is selected from H and (For example R 1 1 is methyl.
  • R 11 is hydrogen).
  • R 3 is selected from halo, cyano, nitro or i i group of the formula:
  • X 1 is a direct bond, O or S and R 8 is Ci -4 alkyl, p is 1 or 2; 1 ;
  • R 11 is selected from H, cyano, carboxy, carbamoyl, Ci- ⁇ alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, N-(Ci_ 6 alkyl)carbamoyl, NN-(Ci -6 alkyl) 2 carbamoyl, N-(C i -4 alkoxy)carbamoyl, N-(C i ⁇ alky I)-N-(C i -4 alkoxy)carbamoyl, C i . ⁇ alkoxycarbonyl, Ci-oalkylsulfonylaminocarbonyl, carbocyc IyI-X 2 -, heterocyc IyI-X 3 - or heteroaryl-X 4 -, wherein R 1 ' is optionally substituted on carbon by one or more R 13 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substitute
  • R 6 is selected from H, Ci ⁇ alkyl, C 2-6 alkenyl, C 2- 6alkynyl, Ci- 6 alkanoyl, Ci-6alkylsulfonyl, Ci-6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, N,N-(Ci.
  • R 13 and R 16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, C]. 6 alkyl, C 2 .
  • R 13 and R 16 may be optionally substituted on carbon by one or more
  • R 18 and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 13 and R 16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 13 and R 16 may optionally bear a Ci -3 alkylenedioxy group;
  • R 14 , R 17 and R 19 are independently selected from Ci_ 6 alkanoyl, Ci- 6 alkylsulfonyl, Ci- ⁇ alkoxycarbonyl, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, N,N-(Ci -6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 , R 17 and R 19 independently of each other may be optionally substituted on carbon by one or more R 20 ; X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and -N(R 22 )C(O)-; wherein R 22 is hydrogen or C M alkyl;
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O) q -, -SO 2 N(R 24 )- and -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or C ]-4 alkyl and q is 0-2;
  • R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 -6alkynyl, C !-6 alkoxy, Ci- 6 alkanoyl, Ci.6alkanoyloxy, N-(Ci. 6 alkyl)amino, N 1 N-(C i.
  • R 18 may be optionally substituted on carbon by one or more R 25 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 26 ; and wherein any heterocyclyl group within R 18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 18 may optionally bear a group;
  • R 26 is selected from Ci-ealkyl, Ci- ⁇ alkylsulfonyl, Ci_ 6 alkoxycarbonyl, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, NN-(C i. 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 26 may be optionally substituted on carbon by one or more R 27 ; and
  • R 20 , R 25 and R 27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethyls
  • R 7 is selected from H, chloro, methyl and methylthio. Particularly R 7 is chloro.
  • R 1 1 is selected from H and wherein R 11 is optionally substituted on carbon by one or more R 13 selected from halo, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_ 4 alkanoyl, NN-(C i -4 alkyl) 2 amino, Ci- 4 alkanoylamino, N-(Ci- 4 alkyl)carbamoyl, NN-(Ci -4 alkyl) 2 carbamoyl, Ci- 4 alkylS(0) a wherein a is 0 to 2, C M alkoxycarbonyl, N-(Ci_ 4 alkyl)sulfamoyl, NN-(C i -4 alkyl) 2 sulfamoyl, C M alkylsulfonylamino, phenyl, pyridyl and pyrimidinyl.
  • R 11 is
  • R 7 is chloro
  • R 1 ' is selected from H and Ci- 4 alkyl (For example R 1 1 is methyl. Alternatively R 1 1 is H).
  • R 11 is selected from H, cyano, carboxy, carbamoyl, C 2-6 alkenyl, C 2 - 6 alkynyl, Ci. 6 alkanoyl, N-(Ci. 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 carbamoyl, N-(C i - 4 alkoxy)carbamoy 1, N-(C i ⁇ alky I)-N-(C i - 4 alkoxy)carbamoyl, C i _6alkoxycarbonyl, Ci- ⁇ alkylsulfonylaminocarbonyl, carbocyclyl-X 2 -, heterocyclyl-X 3 - or heteroaryl-X 4 -, wherein R 1 ' is optionally substituted on carbon by one or more R 13 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by
  • R 6 is selected from H, C 2-6 alkenyl, C 2 - 6 alkynyl, Ci- 6 alkylsulfonyl, Ci- ⁇ alkoxycarbonyl, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, NN-(Ci.
  • R 13 and R 16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci- 6 alkyl, C 2 -6alkenyl, C 2 -6alkynyl, C 2-6 alkenyloxy, C 2 - 6 alkynyloxy, Ci- 6 alkanoyl, Ci- ⁇ alkanoyloxy, N-(Ci. 6 alkyl)amino, N,N-(Ci- 6 alkyl) 2 amino, Ci. 6 alkanoylamino, N-(Ci_6alkyl)carbamoyl, N 1 N-(C i. 6 alkyl) 2 carbamoyl,
  • R 13 and R 16 may be optionally substituted on carbon by one or more R 18 , and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 , and wherein any heterocyclyl group within R 13 and R 16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 13 and R 16 may optionally bear a group;
  • R 14 , R 17 and R 19 are independently selected from Ci_ 6 alkanoyl, Ci. 6 alkoxycarbonyl, carbamoyl, N-(Ci- 6 alkyl)carbamoyl, NN-(C i- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 , R 17 and R 19 independently of each other may be optionally substituted on carbon by one or more R 20 ;
  • X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and - ⁇ (R 22 )C(O)-; wherein R 22 is hydrogen or C 1-4 alkyl;
  • X 8 , X 9 and X 10 are independently selected from a direct bond, -O-, -N(R 21 )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O) q -, -SO 2 N(R 24 )- and -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or and q is 0-2; R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, Ci- 6 alkanoyl, Ci- ⁇ alkanoyloxy, N-(Ci.
  • R 18 may be optionally substituted on carbon by one or more R 25 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 26 ; and wherein any heterocyclyl group within R 18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 18 may optionally bear a C ⁇ alkylenedioxy group;
  • R 26 is selected from carbamoyl, N-(Ci- 6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 26 may be optionally substituted on carbon by one or more R 27 ; and
  • R 20 , R 25 and R 27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulf ⁇ nyl, ethylsulf ⁇ nyl, mesyl, e
  • Particular compounds of the formula IE* are those wherein R 1 1 is selected from H and wherein R 1 1 is optionally substituted on carbon by one or more R 13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, N-(Ci_ 4 alkyl)amino, N 1 N-(C i_ 4 alkyl) 2 amino, NN-(Ci- 4 alkyl) 2 carbamoyl, Ci_ 4 alkylS(0) a wherein a is 0 to 2, Ci -4 alkoxycarbonyl, N-(Ci- 4 alkyl)sulfamoyl, N N-(C i- 4 alky I) 2 sulfamoyl, Ci- 4 alkylsulfonylamino, phenyl, pyridyl and pyrimidinyl.
  • R 1 '
  • R 11 is selected from H, cyano, carboxy, carbamoyl, C 2 - 6 alkenyl, C 2-6 alkynyl, N-(Ci_6alkyl)carbamoyl, N ( N-(C]. 6 alkyl) 2 carbamoyl,
  • R 13 and R 16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci -6 alkyl, C 2-6 alkenyl, C 2 - 6 alkynyl, C 2-6 alkenyloxy, C 2 - 6 alkynyloxy, Ci_ 6 alkanoyl, Ci- ⁇ alkanoyloxy, N-(Ci. 6 alkyl)amino, NN-(Ci.6alkyl) 2 amino, C i _ 6 alkanoylamino, N-(C i .
  • 6 alkyl)carbamoyl NN-(C i -6alky ⁇ carbamoyl, N'-(C, -6 alkyl)ureido, N' ( N'-(Ci -6 alkyl) 2 ureido, N,N',N'-(Ci.6alkyl) 3 ureido, Ci. 6 alkylS(O) a wherein a is 0 to 2, N-(Ci- 6 alkyl)sulfamoyl, N,N-(C
  • R 13 and R 16 may be optionally substituted on carbon by one or more
  • R 14 , R 17 and R 19 are independently selected from Ci- 6 alkyl, d. 6 alkanoyl, Ci. 6 alkylsulfonyl, d- ⁇ alkoxycarbonyl, carbamoyl, N-(Ci. 6 alkyl)carbamoyl, NN-(Ci -6 alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 14 , R 17 and R 19 independently of each other may be optionally substituted on carbon by one or more R 20 ;
  • X 2 , X 3 and X 4 are independently selected from a direct bond, -C(O)- and - ⁇ (R 22 )C(O)-; wherein R 22 is hydrogen or Ci -4 alkyl;
  • X , X and X are independently selected from a direct bond, -O-, -N(R )-, -C(O)-, -N(R 22 )C(O)-, -C(O)N(R 23 )-, -S(O),-, -SO 2 N(R 24 )- and -N(R 25 )SO 2 -; wherein R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen or Ci -4 alkyl and q is 0-2;
  • R 18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci- ⁇ alkyl, C 2 . 6 alkenyl, C 2-6 alkynyl, Ci- ⁇ alkoxy, Ci- ⁇ alkanoyl, N-(Ci-6alkyl)amino, N,N-(Ci-6alkyl) 2 amino, Ci_6alkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(C i.6alkyl) 2 carbamoyl, Ci- 6 alkylS(0) a wherein a is 0 to 2, N-(Ci- 6 alkyl)sulfamoyl, NN-(C] .
  • R 18 may be optionally substituted on carbon by one or more R 25 ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 26 ; and wherein any heterocyclyl group within R may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R 18 may optionally bear a Ci_ 3 alkylenedioxy group;
  • R 26 is selected from Ci -6 alkyl, Ci -6 alkanoyl, Ci. 6 alkylsulfonyl, Ci -6 alkoxycarbonyl, carbamoyl, N-(Ci -6 alkyl)carbamoyl, N,N-(Ci-6alkyl) 2 carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R 26 may be optionally substituted on carbon by one or more R 27 ; and
  • R 20 , R 25 and R 27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethyls
  • Particular compounds of the formula IF* are those wherein R 1 ' is selected from H and Ci- 4 alkyl, wherein R 11 is optionally substituted on carbon by one or more R 13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci- 4 alkox N-(Ci.
  • R 1 1 is selected from H and
  • R 10 is H and R 1 1 is selected from H or wherein R 1 1 may be optionally substituted on carbon by one or more R 13 ;
  • R 13 is selected from nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, C 2-4 alkenyl, C 2-4 alkynyl, NN-(Ci -4 alkyl) 2 amino, wherein a is 0 to 2, C M alkoxycarbonyl, N-(C M alkyl)sulfamoyl, NN-(C i -4 alkyl) 2 sulfamoyl, C 3-7 cycloalkyl-X 8 -, phenyl-X 8 -, pyridinyl-X 10 -, pyrimidinyl-X 10 -, thiazolyl-X 10
  • R 18 is selected from halo, hydroxy, amino, trifluoromethoxy, (which Ci. 4 alkyl is optionally substituted by fluoro), Ci- 4 alkoxy, N-(C] -4 alkyl)amino, NN-(Ci- 4 alkyl) 2 amino, CMalkylS(O) a wherein a is 0 to 2, NN-(Ci -4 alkyl) 2 carbamoyl, piperazinyl-, pyrrolidinyl-, piperidinyl- and morpholinyl-,and R 19 is selected from C M alkanoyl, and NN-(Ci -4 alkyl) 2 carbamoyl.
  • R 10 is H and R 1 1 is selected from H, Ci ⁇ alkyl, C 3-7 cycloalkyl-X 2 -, phenyl-X 2 -, heterocyc IyI-X 3 - or heteroaryl-X 4 -, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothio
  • Ci_ 4 alkyl is optionally substituted by fluoro
  • Ci_ 4 alkoxy N-(Ci- 4 alkyl)amino, NN-(Ci- 4 alkyi) 2 amino
  • Ci- 4 alkylS(O) a wherein a is 0 to 2, N-(Ci_ 4 alkyl)carbamoyl, NN-(Ci- 4 alkyl) 2 carbamoyl, piperazinyl-, pyrrolidinyl-, piperidinyl- and morpholinyl-, and
  • R 19 is selected from N-(Ci- 4 alkyl)carbamoyl and NN-(Ci -4 alkyl) 2 carbamoyl.
  • R 10 is H and R 1 1 is selected from H and wherein R 1 ' is optionally substituted on carbon by one or more R 13 wherein R 13 is selected from carboxy, carbamoyl, N-(Ci_ 6 alkyl)carbamoyl, Ci_ 6 alkoxycarbonyl and carbocyclyl-X 8 - (such as phenyl-X 8 -), wherein X 8 represents a direct bond and wherein R 13 is optionally substituted on carbon by NN-(Ci_ 6 alkyl) 2 amino.
  • R 6 has any of the values defined hereinbefore, for example as defined in any of (62) to (74) above.
  • R 6 is selected from H, and C 2 - 6 alkynyl (particularly H and Ci ⁇ alkyl), and wherein R 6 may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ; wherein R is selected from fluoro, cyano, hydroxy, trifluoromethoxy, amino, io carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, C 2-4 alkynyl, N-(Ci_ 4 alkyl)amino, N,N-(Ci- 4 alkyi) 2 amino, Ci- 4 alkanoylamino, N-(Ci -4 alkyl)carbamoyl, N,
  • R 6 is selected from H, C 3-7 cycloalkyl-X 5 - , phenyl-X 5 -, heterocyclyl- X 6 - and heteroaryl-X 7 -, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and ⁇ , and wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and ⁇ ,
  • X 5 , X 6 and X 7 are each independently selected from a direct bond or -
  • R 12 is hydrogen or C )-4 alky, and wherein R 6 may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ; wherein R 16 is selected from fluoro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, C 2-4 alkenyl, C 2-4 alkynyl, Ci_ 4 alkanoyl, N-(Ci.
  • R 17 is selected from Ci -4 alkyl, N-(Ci -4 alkyl)carbamoyl and NN-(Ci. 4 alkyl) 2 carbamoyl.
  • R 6 is selected from H and Ci- ⁇ alkyl, wherein R 6 is optionally substituted on carbon by one or more R 16 , wherein R 16 is selected from fluoro, Ci ⁇ aUcoxy, NN-(Ci. 6 alkyl) 2 amino, carbocyclyl-X 8 -, heterocyclyl-X 9 - or heteroaryl-X 10 -, wherein X 8 , X 9 and X 10 each represents a direct bond and wherein any heterocyclyl group within R 16 optionally bears 1 or 2 oxo substituents.
  • R 6 has any of the values defined hereinbefore, for example as defined in any of (62) to (74) above; and R 11 is selected from H and wherein R 11 is optionally substituted on carbon by one or more R 13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci -4 alkoxy, Ci- 4 alkanoyl, N-(C M alkyl)amino, NN-(Ci.
  • a compound of the formula I selected from: (7S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one;
  • the compounds of the present invention can be prepared in a number of ways using methods analogous to well known methods of organic synthesis. More specifically, the novel compounds of this invention may be prepared using the reactions and techniques described herein. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are not compatible with the reaction conditions, will be apparent to one skilled in the art and alternate methods must then be used. It will be appreciated that during certain of the following processes certain substituents may require protection to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and later removed.
  • protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley Interscience (1991).
  • Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a ⁇ -butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia.
  • a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium- on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a 7-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. Resins may also be used as a protecting group.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • Compounds of the formula I, or pharmaceutically-acceptable salts or prodrugs thereof may be prepared by any process known to be applicable to the preparation of chemically-related compounds and intermediates, for example as described in WO 04/076454, WO 03/020722, WO 04/076454 and WO 03/020722.
  • Such processes, when used to prepare a compound of the formula I, or a pharmaceutically-acceptable salt or prodrug thereof, are provided as a further feature of the invention and are illustrated by the following representative examples.
  • Necessary starting materials may be obtained by standard procedures of organic chemistry (see, for example, Advanced Organic Chemistry (Wiley-Interscience), Jerry March). The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
  • R 1 , R 2 , R 3 , R 7 , R 10 , R 1 ' and p are as hereinbefore defined, except any functional group is protected if necessary; and Pgi is a suitable carboxy protecting group; or
  • R 1 , R 2 , R 3 , R 6 , R 7 , A and p are as hereinbefore defined, except any functional group is protected if necessary; or
  • R 1 , R 2 , R 3 , R 6 , R 7 , R 11 and p are as hereinbefore defined, except any functional group is protected if necessary and Lg 3 is a displaceable group; or
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A and p are as hereinbefore defined, except any functional group is protected if necessary and Lg 4 is a displaceable group; or
  • R 1 , R 2 , R 3 , R 6 , R 7 and p are as hereinbefore defined, except any functional group is protected if necessary and R 28 is a Ci ⁇ alkyl group; or Process (g) for the preparation of those compounds of the formula I wherein A in the compound of formula I is CHR 11 and R 11 is a Ci ⁇ alkyl group substituted by a carbamoyl, N-(Ci- 6 alkyi)carbamoyl or group, the coupling of a compound of the formula 1"" (or a suitable salt thereof) with ammonia or a N-(Ci_ 6 alkyl)amino or N 5 N-(C i. 6 alkyl) 2 amino group:
  • R 1 , R 2 , R 3 , R 6 , R 7 and p are as hereinbefore defined, except any functional group is protected if necessary; and thereafter, if necessary (in any order):
  • Pgi is a suitable carboxy protecting group such as Ci- ⁇ alkyl, for example methyl.
  • the reduction of the nitro group in the compound of formula II is conveniently carried out in the presence of a suitable reducing agent such as a transitions metal, for example iron in the presence of a suitable acid.
  • suitable acids include mineral acids such as hydrochloric acid or sulfuric acid or organic acids such as acetic acid or formic acid.
  • suitable reducing agents that may be used under neutral pH conditions include zinc, samarium-di-iodide and trivalent titanium.
  • the reaction is carried out in the presence of an inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one, dimethylsulfoxide or acetonitrile.
  • an inert solvent or diluent for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofur
  • the compound of formula II may be prepared using conventional methods, for example as illustrated in Reaction Scheme 1:
  • Reaction Scheme 1 wherein R 1 , R 2 , R 3 , R 7 , R 10 , R 1 1 and p are as hereinbefore defined, except any functional group is protected if necessary;
  • Pg 1 is a suitable carboxy protecting group such as Ci- ⁇ alkyl (for example methyl) or benzyl; and
  • Lg, Lg 1 and Lg 2 are suitable displaceable groups.
  • Lg is for example halo, such as chloro.
  • Suitable displaceable groups represented by Lg 1 and Lg 2 include, for example halo (particularly chloro), aryloxy, mercapto, alkylthio, alkylsulfonyl, arylsulfonyl, alkylsulfonyloxy or arylsulfonyloxy methanesuflonyloxy or toluene-4-sulfonyloxy group.
  • a particular displaceable group for Lg and Lg is chloro.
  • the coupling reaction is suitably carried out under Mitsunobu conditions as described in Hughes, D. L. et.al. Org. Prep. (1996), 28, 127-164.
  • the reaction is conveniently carried out in the presence of a suitable electrophilic activating agents, for example, diisopropyl azodicarboxylate (DIAD) or l,l'-(azodicarbonly)dipiperidine (ADDP) or 4,7-dimethyl-3,5,7-hexahydro-l,2,4,7-tetrazocin-3,8-dione (DHTD) in combination with a nucleophilic activating agent such as for example phosphorous based activating agent such as for example tributylphosphine, triphenylphosphine , or cyanomethylenetributylphosphorane.
  • a suitable electrophilic activating agents for example, diisopropyl azodicarboxylate (DIAD) or l,l'-(azo
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran or an aromatic solvent such as for example benzene or toluene or an non polar solvent such as acetonitirle.
  • a suitable inert solvent or diluent for example an ether such as tetrahydrofuran or an aromatic solvent such as for example benzene or toluene or an non polar solvent such as acetonitirle.
  • the reaction is conveniently carried out at temperatures in a range, for example, from below room temperature to elevated temperatures such as boiling point of solvent, conveniently at or near ambient temperature.
  • the phosphine coupling reagent is optionally immobilised on a solid support.
  • the reduction is carried out in the presence of a suitable reducing agent such as a borane-THF complex.
  • a suitable reducing agent such as a borane-THF complex.
  • the reaction is suitably carried out in a solvent such as an ether, for example tetrahydrofuran.
  • the reaction is conveniently performed at elevated temperature, for example, under reflux conditions.
  • Suitable displaceable groups represented by Lg 3 include for example halo such as bromo or iodo.
  • the deprotonation of the compound of formula I" may be achieved by formation of the alkali metal enolate of the compound of formula I" for example the lithium or potassium enolate.
  • the reaction is conveniently performed in the presence of a suitable base, for example, an alkali metal hydride such as sodium hydride, an alkali metal disalazide such as sodium hexamethyldisalazide or an organolitium reagent such as N-butyl-lithium or methyl-lithium.
  • a suitable base for example, an alkali metal hydride such as sodium hydride, an alkali metal disalazide such as sodium hexamethyldisalazide or an organolitium reagent such as N-butyl-lithium or methyl-lithium.
  • reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran or 1,4-dioxane, an aromatic solvent such a s toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N- dimethylacetamide, N-methylpyrrolidin-2-one, or dimethylsulfoxide.
  • a suitable inert solvent or diluent for example an ether such as tetrahydrofuran or 1,4-dioxane, an aromatic solvent such a s toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N- dimethylacetamide, N-methylpyrrolidin-2-one, or dimethylsulfoxide.
  • a suitable inert solvent or diluent for example an ether such as tetrahydrofuran or 1,4-
  • the reaction is suitably carried out at a temperature of from -80 0 C to 3O 0 C, conveniently at temperatures of-78°C.
  • Suitable reaction conditions for the deprotonation and reaction with R 11 -Lg 3 are known in the literature, for example as described in Bull et.al., Tetrahedron (2006), 62(33), 7911-25; or Viso et.al., Journal of Organic Chemistry (2006), 71(4), 1442-48.
  • s Lg 4 is a suitable displaceable group, for example, a halo (particularly chloro), aryloxy, mercapto, alkylthio, alkylsulfonyl, arylsulfonyl, alkylsulfonyloxy or arylsulfonyloxy or groups for example chloro, bromo, fluoro, methoxy, phenoxy, pentafluorophenoxy, methylthio, methanesulfonyl, methanesulfonyloxy or toluene-4- sulfonyloxy group.
  • a particular displaceable group Lg 4 is chloro. o
  • the reaction is conveniently carried out in the presence of base, acid or transition metal catalyst, particular conditions are the displacement of Lg 4 in the presence of base.
  • the amination reaction is conveniently performed in an inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, ans ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N- methylpyrrolidin-2-one, dimethylsulfoxide or acetonitrile.
  • Particular solvents are ethers such as tetrahydrofuran or 1,4-dioxane.
  • the reaction is conveniently carried out at a temperature in the range, for example, ⁇ 0 0 C to 180 0 C, particularly in the range ambient temperature to 8O 0 C or more particularly, at or near the reflux temperature of the solvent when used.
  • the amination reaction is carried out with ammonia, or a latent form of ammonia such a benzylamine or hydrazine derivative.
  • Conveniently amination may be carried out using a latent source of ammonia in the presence of a suitable transition metal 5 catalyst.
  • a suitable transition metal 5 catalyst For example benzophenonimine might be used as a latent source of ammonia in the presence of a palladium catalyst.
  • the amino group is liberated after the displacement reaction, for example with acids such as trifluorosulfonic acid, hydrochloric acid or sulfuric acid. It will be appreciated by those skilled in the art that in the liberation of latent amino functionalities might require the0 utility of aqueous acid.
  • Suitable aqueous acids include, for example hydrochloric acid, or and organic acid such as acetic acid a buffer may also be used to maintain pH at the desired level during the reaction.
  • a buffer may also be used to maintain pH at the desired level during the reaction.
  • the amination uses of ammonia, which may be conveniently dissolved in a suitable solvent such as for water or methanol.
  • the hydrolysis reaction is conveniently carried out in the presence of a suitable aqueous base or suitable aqueous acid.
  • Suitable aqueous bases include aqueous sodium hydroxide and potassium hydroxide.
  • Suitable aqueous acids include aqueous sulphuric acid.
  • the hydrolysis reaction is carried out in the presence of an inert solvent or diluent, for example water, an ester or an ether such as tetrahydrofuran or 1 ,4- dioxan.
  • an inert solvent or diluent for example water, an ester or an ether such as tetrahydrofuran or 1 ,4- dioxan.
  • a suitable solvent may be a mixture of water and tetrahydrofuran.
  • the reaction is conveniently carried out at a temperature in the range, for example, 0 0 C to
  • a suitable coupling agent is, for example, a suitable peptide coupling agent, such as O-(7-azabenzotriazol-l- hexafluoro-phosphate (HATU) or a carbodiimide such as dicyclohexylcarbodiimide or l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI).
  • HATU O-(7-azabenzotriazol-l- hexafluoro-phosphate
  • EDCI dicyclohexylcarbodiimide or l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • the reaction may conveniently be carried out in the presence of a suitable base.
  • a suitable base is, for example, an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, di-isopropylethylamine, ⁇ -methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or an alkali or alkaline earth metal carbonate, such as sodium carbonate, potassium carbonate, caesium carbonate or calcium carbonate.
  • organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, di-isopropylethylamine, ⁇ -methylmorpholine or diazabicyclo[5.4.0]undec-7-ene
  • an alkali or alkaline earth metal carbonate such as sodium carbonate, potassium carbonate, caesium carbonate or calcium carbonate.
  • reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ester such as ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or
  • reaction is conveniently carried out at a temperature in the range, for example, from 0 to 120 0 C, particularly at or near ambient temperature. Conveniently, this reaction may also be performed by heating the reactants in a sealed vessel using a suitable heating apparatus such as a microwave heater.
  • a suitable heating apparatus such as a microwave heater.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulfinyl or alkylsulfonyl.
  • a pharmaceutically acceptable salt of a compound of the formula I for example an acid or base addition salt
  • it may be obtained by, for example, reaction of the compound of formula I with a suitable acid or base using a conventional procedure.
  • Methods for the preparation of pharmaceutically acceptable salts are well known in the art.
  • following reaction of a compound of the formula I with an acid or base the required salt may be precipitated from solution by supersaturating the solution containing the compound of the formula I. Super saturation may be achieved using well-known techniques, for example by cooling the solution, by removing solvent by evaporation or by the addition of a suitable anti-solvent to precipitate the salt.
  • the compound may be prepared in the form of a salt that is not a pharmaceutically acceptable salt.
  • the resulting salt can then be modified by conventional techniques to give a pharmaceutically acceptable salt of the compound.
  • Such salt modification techniques are well known and include, for example ion exchange techniques or re-precipitation of the compound from solution in the presence of a pharmaceutically acceptable counter ion as described above, for example by re-precipitation in the presence of a suitable pharmaceutically acceptable acid to give the required pharmaceutically acceptable acid addition salt of a compound of the formula I.
  • Stereoisomers of compounds of formula I may be separated using conventional techniques, e.g. chromatography or fractional crystallisation.
  • the enantiomers may be isolated by separation of a racemate for example by fractional crystallisation, resolution or HPLC.
  • the diastereoisomers may be isolated by separation by virtue of the different physical properties of the diastereoisomers, for example, by fractional crystallisation, HPLC or flash chromatography.
  • particular stereoisomers may be made by chiral synthesis from chiral starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, with a chiral reagent.
  • a specific stereoisomer is isolated it is suitably isolated substantially free from other stereoisomers, for example containing less than 20%, particularly less than 10% and more particularly less than 5% by weight of other stereoisomers.
  • inert solvent refers to a solvent which does not react with the starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
  • the following assays can be used to measure the effects of the compounds of the present invention as HSP90 inhibitors.
  • Test (a) In vitro Binding Assay Test (a) measures the ability of a compound to bind to the ATP pocket of HSP90 ⁇ . 6His tagged HSP90 ⁇ protein (amino acids 2- 732) expressed in E.coli was purified and stored at -8O 0 C in aliquots. Assay measurements were performed in assay buffer comprising 2OmM HEPES pH 7.4, 5OmM KCl, 2OmM NaHMoO 4 , 0.01% Nonidet P40, 2mM DTT and 0. lmg/ml BSA.
  • the FP probe 3-[[5-(5- ethyl-2,4-dihydroxy-phenyl)-4-(4-methoxyphenyl)2H-pyrazole-3-carbonyl]amino]propyl- Cy3B-amide; 14-(2- ⁇ [3-( ⁇ [3-(5-ethyl-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-lH- pyrazol-5-yl]carbonyl ⁇ amino)propyl] amino ⁇ -2-oxoethyl)- 16,16,18,18-tetramethyl-2-sulfo- 6,7,7a,8a,9, 10,16,18-octahydrobenzo[2",3"]indolizino [8",7":5',6']pyrano[3',2':3,4]pyrido[l,2-a]indol-5-ium)
  • Test compounds were prepared by dilution in 100% DMSO to give the appropriate dose range and dispensed into a 384 well assay plate as a 6X concentrate.
  • FP probe was added and plates incubated at room temperature for 1 to 4 hours.
  • Final DMSO concentration was 1% in a total assay volume of 18 ⁇ l.
  • Fluorescence Polarisation measurements were made using a Tecan Ultra plate reader using an excitation wavelength of 530nm and an emission wavelength of 590nm. Millipolarisation (mP) values were estimated using Xfluor software.
  • N-(3-aminopropyl)-5-(5-ethyl-2,4-dihydroxy-phenyl)-4-(4-methoxyphenyl)- 2H-pyrazole-3-carboxamide starting material was prepared as follows:
  • Methyl 6-ethyl-7-hydroxy-3-(4-methoxyphenyl)-4-oxo-chromene-2-carboxylate (13.6g, 41.73mmol) was dissolved in acetone (200ml). Then a 2N aqueous solution of Sodium hydroxide (62.59ml, 125.19mmol) was added at room temperature. The resulting mixture was stirred at room temperature over night. After the reaction was complete the mixture was acidified under cooling with concentrated hydrochloric acid to pH 2.5. A solid precipitated from the solution. The solid was filtered off, washed with water and diethyl ether and dried at 40 0 C under vacuum to yield the title product as an off white solid (11.2g quantitative).
  • the resulting mixture was stirred at O 0 C for one our and at room temperature for 2.5hours.
  • The5 reaction mixture was washed with 50ml of 10% w/v aqueous citric acid solution, 50ml 20% aqueous KHCO3 solution and 50ml of distilled water.
  • the organic extracts were dried over MgSO4 and evaporated under reduced pressure.
  • the crude material was purified by automated column chromatography on a 4Og RediSepTM normal phase silica cartridge using an ISCO CompanionTM eluting with a mixture of 5% methanol in DCM0 was used.
  • the cartridge was washed with methanol before the product was eluted with a mixture of methanol and 7N ammonia.
  • the fractions containing the desired product were combined and evaporated under vacuum to give a light brown solid (326 mg).
  • the material was subsequently suspended with dry di- ethylether (50 mg) and stirred over night.
  • HSP90 mediated regulation of both Her2 and Androgen Receptor is well documented and assays to measure HSP90 inhibition are described in the literature.
  • Her2 down regulation in SKBr3 breast cell line can be monitored using an antibody in ELISA or Western blot analysis after exposure to an HSP90 inhibitor (Huezo et al, Chemistry and Biology, 2003, 10, 629-634).
  • a fluorescently labelled antibody can be used to detect Her2 levels using a plate reader.
  • Reduction of Androgen Receptor levels by HSP90 inhibitors, as measured by antibody detection, in prostate cell lines eg LNCaP, CWR22, can also be used to measure cellular activity (Solit et al, Clin. Can. Res., 2002, 8, 986-993).
  • Preferred compounds are those with an IC 50 of less that 5 ⁇ M, more preferably less than l ⁇ M.
  • activity for the following compounds was observed in Test (a):
  • the compounds of examples 5 and 6.1 exhibited low activity in the enzyme assay, test (a). Acordingly these compounds are not preferred compounds. Accordingly, in one embodiment the compounds of examples 5 and 6.1 are excluded ((75)-8-[(4-methoxy-3,5- dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin-2-amine and (75)-8-[(4- methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8-tetrahydropteridin-2- amine).
  • Pharmaceutical Compositions ((75)-8-[(4-methoxy-3,5- dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin-2-amine and (75)-8-[(4- methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8-t
  • a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof, as defined hereinbefore in association with a pharmaceutically acceptable diluent or carrier.
  • compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixir
  • compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • An effective amount of a compound of the present invention for use in therapy of infection is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of infection, to slow the progression of infection, or to reduce in patients with symptoms of infection the risk of getting worse.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • the size of the dose for therapeutic or prophylactic purposes of a compound of the formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
  • a daily dose in the range for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses.
  • a parenteral route is employed.
  • a dose in the range for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used.
  • a dose in the range for example, 0.05 mg/kg to 25 mg/kg body weight will be used.
  • Oral administration is however preferred, particularly in tablet form.
  • unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.
  • the compounds of the present invention are expected to possess, amongst others, anti-angiogenic properties such as anti-cancer properties that are believed to arise from their HSP90 inhibitory properties.
  • the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by HSP90, i.e. the compounds may be used to produce an HSP90 inhibitory effect in a warm-blooded animal in need of such treatment.
  • the compounds of the present invention provide a method for the treatment of malignant cells characterised by inhibition of HSP90.
  • the compounds of the invention may be used to produce an anti-tumour effect by means of anti-angiogenic and/or an anti-proliferative and/or anti-invasive effect and/or apoptotic and/or cell cycle arrest effect mediated alone or in part by the inhibition of HSP90.
  • the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours that are sensitive to inhibition of HSP90 that are involved in for example, angiogenesis, proliferation, cell cycle regulation, invasion and the signal transduction steps associated therewith. Accordingly the compounds of the present invention may be useful in the treatment of hyperproliferative disorders including psoriasis, benign prostatic hyperplasia (BPH) and cancer by providing an anti-proliferative effect and/or anti-invasive and/or anti-angiogenic effect and/or a pro-apoptotic effect, particularly in the treatment of HSP90 sensitive cancers.
  • BPH benign prostatic hyperplasia
  • Such benign or malignant tumours may affect any tissue and include non-solid tumours such as leukaemia, multiple myeloma or lymphoma, and also solid tumours, for example, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, endometrial cancer, uterine cancer, vulval cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, bile duct cancer, bone cancer, neuronal cancer, testicular cancer, particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and lung cancer - NSCLC and SCLC.
  • non-solid tumours such as leukaemia, multiple myeloma or lymphoma
  • the compounds of the invention may also be useful in the treatment of pathogenic angiogenesis, for example in the treatment of cancers as hereinbefore described and other diseases in which inappropriate, or pathogenic angiogenesis occurs, for example diabetic retinopathy.
  • the compounds of the invention may also be useful in the treatment or prophylaxis of other conditions in which HSP90 is implicated, for example inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases, such as multiple sclerosis, lupus, rheumatoid arthritis and irritable bowel syndrome CJD, Huntington's disease and Alzheimer's disease.
  • the compounds may also be useful for the protection of normal cells against chemotherapy induced toxicity,
  • a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof, as defined hereinbefore for use as a medicament.
  • the present invention provides the use of a compound of formula I or a pharmaceutically acceptable or salt N-oxide or prodrug thereof in the preparation of a medicament.
  • the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the treatment or prophylaxis of a cancer, for example a cancer involving a solid tumour.
  • the present invention provides a compound of formula 1 or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the treatment or prophylaxis of neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer), colon, rectum, prostate, bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, pancreas, skin, testes, thyroid, uterus, cervix, vulva or other tissues, as well as leukemias and lymphomas including CLL and CML, tumors of the central and peripheral nervous system, and other tumor types such as melanoma, multiple myeloma, fibrosarcoma and osteosarcoma, and malignant brain tumors.
  • neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell lung cancer and bronchioal
  • the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the treatment or prophylaxis of pathologically angiogenic diseases, inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases.
  • the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the inhibition of HSP90 activity.
  • the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use as an antiangiogenic agent in the treatment of a solid tumour.
  • the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for the treatment or prophylaxis of a cancer, for example a cancer involving a solid tumour.
  • the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for the treatment or prophylaxis of neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer), colon, rectum, prostate, bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, pancreas, skin, testes, thyroid, uterus, cervix, vulva or other tissues, as well as leukemias and lymphomas including CLL and CML, tumors of the central and peripheral nervous system, and other tumor types such as melanoma, multiple myeloma, fibrosarcoma and osteosarcoma, and malignant brain tumors.
  • neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell
  • the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for the treatment or prophylaxis of pathologically angiogenic diseases, inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases .
  • the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for use in the inhibition of HSP90 activity.
  • the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the manufacture of a medicament for use as an antiangiogenic agent in the treatment of a solid tumour.
  • a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the production of an HSP90 inhibitory effect in a warm-blooded animal such as man.
  • a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically acceptable diluent or carrier for use in the production of an anti-cancer effect in a warm-blooded animal such as man.
  • a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically acceptable diluent or carrier for use as an antiangiogenic agent in the treatment of a solid tumour.
  • a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment or prophylaxis of pathologically angiogenic diseases, inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases.
  • the present invention provides a method of inhibiting pathogenic angiogenesis in a human or animal comprising administering to said human or animal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof. In a further embodiment the present invention provides a method of inhibiting
  • HSP90 comprising administering to an animal or human in need of said inhibiting a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
  • the present invention provides a method of prophylaxis or treatment of a disease mediated in part or alone by HSP90 comprising administering to an animal or human in need of said inhibiting a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
  • the present invention provides a method of treatment of a human or animal suffering from a cancer comprising administering to said human or animal a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
  • the present invention provides a method of prophylaxis or treatment of cancer comprising administering to a human or animal in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
  • the present invention provides a method of treatment of a human or animal suffering from a neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer), colon, rectum, prostate, bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, pancreas, skin, testes, thyroid, uterus, cervix, vulva or other tissues, as well as leukemias and lymphomas including CLL and CML, tumors of the central and peripheral nervous system, and other tumor types such as melanoma, multiple myeloma, fibrosarcoma and osteosarcoma, and malignant brain tumors comprising administering to a human or animal in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
  • a neoplastic disease such as carcinoma
  • the present invention provides a method of treatment of a human or animal suffering from a pathologically angiogenic disease comprising administering to said human or animal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
  • anti-cancer treatment may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
  • chemotherapy may include one or more of the following categories of anti-tumour agents:-
  • antiproliferative/antineoplastic drugs and combinations thereof as used in medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin- C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblast
  • inhibitors of growth factor function include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti-erbBl antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern et al. Critical reviews in oncology/haematology, 2005, Vol. 54, pp 11-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-mo ⁇ holinopropoxy)quinazolin-4-amine (gefitinib, ZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3- morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AM ⁇ 107); inhibitors of serine/threonine kinases (for example Ras/R
  • an endothelin receptor antagonist for example zibotentan (ZD4054) or atrasentan
  • antisense therapies for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense
  • gene therapy approaches including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRC A2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy
  • immunotherapy approaches including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anerg
  • a pharmaceutical product comprising a compound of the formula I as defined hereinbefore and an additional anti-tumour agent as defined hereinbefore for the conjoint treatment of cancer.
  • a method of treatment of a human or animal suffering from a cancer comprising administering to said human or animal a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or prodrug or N-oxide thereof simultaneously, sequentially or separately with an additional anti-tumour agent as defined hereinbefore.
  • the compounds of the formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects HSP90. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
  • reaction times that are given are not necessarily the minimum attainable;
  • DIAD Diisopropyl azodicarboxylate
  • MeOH Methanol HATU: O-(7-Azabenzotriazol-l-yl)-N r N r /V,N'-Tetramethyluronium Hexafluoro-
  • Example 2 Using a similar procedure to that described in Example 1, the compounds shown in
  • Table 1 were prepared by cyclising the appropriate nitropyrimidine starting materials shown as "SM" in Table 1. Table 1
  • the Intermediate 4 used as the starting material was benzyl (2S)-2-[(2-amino-5-nitro- pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]pentanoate and was prepared as follows:
  • This material was treated with concentrated aqueous ammonia (20 mL) in THF (70 mL). The mixture was vigorously stirred for 2 hours before being partitioned between DCM and water. The organics were dried with magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica using gradient elution (30% ethyl acetate/isohexane to 100% ethyl acetate).
  • the Intermediate 6 used as the starting material was methyl 2-[(2-amino-5-nitro- pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]acetate and was prepared as follows:
  • Example 4 Using a similar procedure to that used for the synthesis of Example 3, the compounds shown in Table 2 were prepared from the appropriate 7,8-dihydropteridin-6-one (SM in Table 2) and appropriate alcohol (ROH in Table 2).
  • Example 1 is (75)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one (Example 1) (164 mg, 0.50 mmol) was stirred in THF (3 mL) and borane-THF complex (IM in THF, 2 mL, 2 mmol) was added slowly. The mixture was stirred at room temperature for 1 hour, then heated at reflux for 30 minutes. The mixture was slowly treated with hydrochloric acid (2M, 5 mL). The solution was loaded onto a
  • Example 5 Using a similar procedure to that used for the synthesis of Example 5, the compounds shown in Table 3 were prepared by reducing the appropriate 7,8-dihydropteridin-6-one (SM in Table 3).
  • the Intermediate 12 used as the starting material was methyl (2R)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]-4-methyl- pentanoate and was prepared as follows:
  • the Intermediate 13 used as the starting material was benzyl (2R)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]-3-phenyl- propanoate and was prepared as follows: lntermediate 18
  • the Intermediate 14 used as the starting material was dimethyl (2 ⁇ )-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]butanedioate and was prepared as follows:
  • the Intermediate 15 used as the starting material was benzyl (2R)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]pentanoate and was prepared as follows:
  • Example 5 Using a similar procedure to that used for the synthesis of Example 3, the compounds shown in Table 5 were prepared from the appropriate 7,8-dihydropteridin-6-one (SM in Table 5) and appropriate alcohol (ROH in Table 5). Either THF or DCM could be used as solvent, as indicated in Table 5. Additional quantities of triphenylphosphine and DIAD were added (typically 4 equivalents of each added every 2 hours) until most of the starting materials were consumed. In all cases excess of these reagents were removed during the SCX purification step (as described for Example 10).
  • O-alkylated isomers were hydrolysed at ambient temperature with hydrochloric acid and methanol (as described for Example 10), prior to purification by MPLC or preparative reverse phase HPLC. Purification, in some instances, could also be achieved by fractional crystallisation. The choice of purification method was determined based on ease of separation, as judged from TLC and LCMS analysis.
  • HATU (128 mg, 0.34 mmol) was added to a mixture of 2- ⁇ (7 ⁇ )-2-amino-8-[(4- methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8-tetrahydropteridin-7- yl ⁇ acetamide (106 mg, 0.28 mmol) (Example 12) and diisopropylethylamine (0.1 mL) in
  • Example 4 Using a similar procedure to that described in Example 10, the compounds shown in Table 4 were prepared by coupling Example 12 with the amines shown as "SM" in Table 4.

Abstract

The present invention relates to compounds that inhibit HSP90 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases such as for the treatment of solid tumours.

Description

5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS
FIELD OF THE INVENTION
The present invention relates to novel 5,6,7,8-tetrahydropteridine derivatives, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these 5,6,7,8-tetrahydropteridine derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers.
BACKGROUND OF THE INVENTION
Heat shock proteins (hereafter HSP) are chaperone proteins which regulate the conformational stability and maturation of many cellular proteins. Numerous HSP's are known and are classified according to their molecular weight. HSP90 is a 90k Dalton protein chaperone that plays a central role in regulating, for example, protein homeostasis. HSP90 regulates the stability of certain proteins ("client proteins") and maintains them in the appropriate three-dimensional conformation so they can perform their cellular functions. In humans, there are two HSP90 isoforms in the cytosol, HSP90α and HSP90β. These proteins are closely related and, to date, no differences in their activities have been identified. In addition to normal cellular function, certain HSP90 client proteins are associated with abnormal cellular function. For example many of the proteins stabilized by HSP90 are oncoproteins and cell-signalling proteins important in cancer cell proliferation and cancer cell survival, including many kinases and transcription factors including, but not limited to ErbB2, Raf-1, Akt/PKB, mutant p53, v-src, c-src, MEK, Focal adhesion kinase (FAK), P2 lObcr-abl, CDK4 and Epidermal growth factor receptor (EGFR).
Accordingly, HSP90 has been implicated in cancer, and other diseases. HSP90 is therefore an important target for drugs that inhibit the function of HSP90 and its role in diseases such as cancer.
HSP90 is over expressed in cancer cells and is thought to be involved in various cellular processes, such as cell proliferation, differentiation and apoptosis. Inhibition of HSP90 is expected to result in the blockade of multiple cancer-causing pathways by promoting the degradation of many oncogenic HSP90 client proteins, therefore HSP90 inhibitors are expected to provide broad-spectrum antitumour activity.
The anti-cancer effects of HSP90 inhibition have been demonstrated both in vitro and in vivo for a variety of different hematologic and solid tumours including multiple myeloma (Vilenchik et al, Chem & Bio, 2004 Jun, 11 , 787-797; Solit et al, Clin Can Res, 2002 May, 8, 986-993, Beliocoff et al, Anticancer Drugs 2004 Aug;15(7):651-62; Bagatel et al, Molecular Cancer Therapeutics, 2004 Aug;3(8): 1021-30; and Cullinan et al., Seminars in Oncology, 2006 Aug; 33(4):457-65).
HSP90 inhibitors may be useful in the treatment of other disorders, for example inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrogenetic disorders and metabolic diseases.
Various HSP90 inhibitors are known. The benzoquinone ansamycin antibiotic, 17- allylamino-17-demethoxygeldanamycin (17- AAG) and derivatives thereof are currently in clinical trials an anticancer agent in patients with solid rumour disease. WO 03/037860 discloses certain purine derivatives as HSP90 inhibitors.
WO 2005/021552 discloses certain pyrimidothiophene derivatives as HSP90 inhibitors.
WO 2005/028434 discloses certain pyrimidine derivatives as HSP90 inhibitors.
WO 2006/117669 discloses certain resorcinol pyrimidine derivatives as HSP90 inhibitors.
WO 2006/122631 discloses certain quinazoline derivatives as HSP90 inhibitors.
WO 2006/105372 discloses certain alkynyl pyrrolo[2,3-d]pyrimidine derivatives as HSP90 inhibitors.
WO 2007/035963 discloses certain heterocyclic compounds, such as 2- aminopurines, pyrazolopyrimidines, pyrrolopyrimidines, alkynyl pyrrolopyrimidine and triazopyrimidines as HSP90 inhibitors.
WO 2007/092496 discloses certain 7,9-dihydropurin-8-one compounds as HSP90 inhibitors.
Kasibhatla et al. (J. Med. Chem., 2007, 50(12), 2767-2778) discloses certain purine derivatives as HSP90 inhibitors.
There remains, however, a need to develop alternative HSP90 inhibitors. SUMMARY OF THE INVENTION
In accordance with the present invention, the applicants have discovered novel 5,6,7, 8-tetrahydropteridine compounds, or pharmaceutically acceptable salts thereof, which possess HSP90 inhibitory activity and are accordingly useful for their anti-proliferation and/or pro-apoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said 5,6,7,8-tetrahydropteridine compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of, for example, an anti-proliferative and/or pro- apoptotic effect in warm-blooded animals such as man.
Also in accordance with the present invention the applicants provide methods of using such 5,6,7,8-tetrahydropteridine compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
The compounds claimed in this invention are may to be of value in the treatment of disease states associated with cell proliferation and other conditions such as cancers (both solid tumours and leukaemia), fϊbroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases, ocular diseases with retinal vessel proliferation, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases.
Furthermore, the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers including oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, endometrial cancer, uterine cancer, vulval cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, bile duct cancer, bone cancer, neuronal cancer, skin cancer, testicular cancer, lymphoma and leukaemia, multiple myeloma or lymphoma; particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and lung cancer - NSCLC and SCLC; more particularly melanoma, breast, ovarian, lung and gastric cancers. DETAILED DESCRIPTION OF THE INVENTION
Accordingly the present invention provides a compound of the formula I:
Figure imgf000005_0001
I wherein:
R1, R2 and R3 are independently selected from H, halo, cyano, nitro or a group of the formula:
-X'-R8, wherein X1 is a direct bond, O, S or NR8a, wherein R8a is H or Ci-6alkyl, and R8 is selected from H, Ci-6alkyl, C2-6alkenyl, C3.7cycloalkyl and d-όalkynyl, and wherein R1, R2 and R3 may independently of each other be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, N-(Ci_6alkyl)amino, NN-(C i.6alkyl)2amino, Ci_6alkoxy, C3-7CyC loalkyl, carbamoyl, N-(Ci.6alkyl)carbamoyl and NN-(C].6alkyl)2carbamoyl; p is 1 or 2;
A iS NR9 Or CR10R1 1;
R4 and R10 are independently selected from H, Ci-βalkyl, C2-6alkenyl and C2-6alkynyl, wherein R4 and R10 may, independently of each other, be optionally substituted on carbon by halo, hydroxy, amino,
Figure imgf000005_0002
N-(Ci.6alkyl)amino and NN-(Ci.6alkyl)2amino;
R5 and R11 are independently selected from H, cyano, carboxy, carbamoyl, Ci-όalkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000005_0003
N-(Ci-6alkyi)carbamoyl, N N-(C i _6alky l)2carbamoy 1, N-(C i .4alkoxy)carbamoy 1, N-(C i .4alkyl)-N-(C i .4alkoxy)carbamoyl, C \ _6alkoxycarbonyl, Ci-ealkylsulfonylaminocarbonyl, carbocyclyl-X2-, heterocyclyl-X3- or heteroaryl-X4-, wherein R5 and R." may independently of each other be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R5 and R1 ' may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R and R may optionally bear a
Figure imgf000006_0001
group; or R4 and R5 together form oxo (=O); or R10 and R11 together form oxo (=0); or one of the following pairs of substituents (i) R4 and R6, (ii) R4 and R10 or (iii) R4 and R9 together form a bond;
R and R are independently selected from H, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, Ci.6alkanoyl,
Figure imgf000006_0002
Ci-6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, carbocyclyl-X5-, heterocyclyl-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-, -Ν(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or
Figure imgf000006_0003
and wherein R6 and R9 may, independently of each other, be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 and R9 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R6 and R9 may optionally bear a
Figure imgf000006_0004
group;
R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto,
Figure imgf000006_0005
C2-6alkenyl, C2-6alkynyl,
Figure imgf000006_0006
Ci-6alkylS(0)a wherein a is 0 to 2, wherein R7 may be optionally substituted on carbon by one or more R15; R13, R15 and R16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci-6alkyl, C2.6alkenyl, C2-6alkynyl, Ci-βalkoxy, C2.6alkenyloxy, C2-6alkynyloxy, Ci-βalkanoyl, Ci-βalkanoyloxy, N-(Ci-6alkyl)amino, N,N-(Ci.6alkyl)2amino, C i ^alkanoy lamino, N-(C i -βalky l)carbamoy 1, NN-(Ci ^alky l)2carbamoy 1, N'-(C,-6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido, N,N',N'-(C1-6alkyl)3ureido, C ,-6alky IS(O)3 wherein a is 0 to 2,
Figure imgf000007_0001
N-(Ci_6alkyl)sulfamoyl, NN-(Ci-6alkyl)2sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13, R15 and R16 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R!9, and wherein any heterocyclyl group within R13, R15 and R16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R13, R15 and R16 may optionally bear a
Figure imgf000007_0002
group;
R14, R17 and R19 are independently selected from
Figure imgf000007_0003
Ci-βalkanoyl, Ci -βalkylsulfonyl, C i -βalkoxycarbonyl, carbamoyl, N-(C i -6alkyl)carbamoyl,
NN-(C i-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14, R17 and R19 independently of each other may be optionally substituted on carbon by one or more R20;
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or C]-4alkyl;
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O),-, -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000007_0004
and q is 0-2;
R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000007_0005
Ci-6alkanoyl, Ci-βalkanoyloxy, N-(Ci-6alkyl)amino, NN-(C i-6alkyl)2amino, Ci_6alkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2,
Figure imgf000007_0006
N-(Ci_6alkyl)sulfamoyl, NN-(Ci-6alkyl)2sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R18 may optionally bear a
Figure imgf000008_0001
group; R26 is selected from
Figure imgf000008_0002
Ci_6alkylsulfonyl, Ci-βalkoxycarbonyl, carbamoyl,
Figure imgf000008_0003
NN-(C i.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and
R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, NN-dimethylsulfamoyl, NN-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof.
The present invention further provides a compound of the formula I, wherein: R1, R2 and R3 are independently selected from H, halo or a group of the formula:
-X1 -R8, wherein X1 is a direct bond, O, S or ΝR8a, wherein R8ais H or Ci.6alkyl, and R8 is selected from H,
Figure imgf000008_0004
C2-6alkenyl, C3_7cycloalkyl and C2-6alkynyl, and wherein R1, R2 and R3 may independently of each other be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, N-(C).6alkyl)amino, NN-(Ci.6alkyl)2amino,
Figure imgf000008_0005
C3-7Cycloalkyl, carbamoyl, N-(Ci-6alkyl)carbamoyl and N,N-(Ci_6alkyl)2carbamoyl; p is 1 or 2; A is NR9 or CR10R"; R4 and R10 are independently selected from H, Ci-βalkyl, C2-6alkenyl and
C2-6alkynyl, wherein R4 and R10 may, independently of each other, be optionally substituted on carbon by halo, hydroxy, amino, Ci-βalkoxy, N-(Ci-6alkyl)amino and N, N-(C i -6alkyl)2amino;
R5 and R11 are independently selected from H, cyano, carboxy, carbamoyl, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000009_0001
NN-(Ci-6alkyl)2carbamoyl, N-(Ci-4alkoxy)carbamoyl,
N-(C i .4alkyl)-N-(C i ^alkoxy)carbamoyl, C i _6alkoxycarbonyl, Ci-oalkylsulfonylaminocarbonyl, carbocyc IyI-X2-, heterocyc IyI-X3- or heteroaryl-X4-, wherein R5 and R1 ' may independently of each other be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyc IyI or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R5 and R1 ' may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R5 and R1 ' may optionally bear a C^alkylenedioxy group; or R4 and R5 together form oxo (=0); or R10 and R11 together form oxo (=0); or one of the following pairs of substituents (i) R4 and R6, (ii) R4 and R10 or (iii) R4 and R9 together form a bond;
R6 and R9 are independently selected from H,
Figure imgf000009_0002
C2-6alkenyl, C2-6alkynyl, Ci-βalkanoyl, Ci-όalkylsulfonyl,
Figure imgf000009_0003
carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, carbocyc IyI-X5-, heterocyc IyI-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-, -Ν(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or d^alkyl, and wherein R6 and R9 may, independently of each other, be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 and R9 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R6 and R9 may optionally bear a
Figure imgf000009_0004
group; R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto,
Figure imgf000010_0001
C2-6alkenyl, C2-6alkynyl,
Figure imgf000010_0002
Ci-6alkylS(O)a wherein a is 0 to 2, wherein R7 may be optionally substituted on carbon by one or more R15;
R13, R15 and R16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido, Ci_6alkyl, C2.6alkenyl, C2-6alkynyl,
Figure imgf000010_0003
C2-6alkenyloxy, C2-6alkynyloxy,
Figure imgf000010_0004
Ci-βalkanoyloxy, N-(C].6alkyl)amino, NN-(C i.6alkyl)2amino, Ci-βalkanoylamino, N-(C i -6alkyl)carbamoyl, NN-(C i -δalkyl^carbamoyl, N-(C i .6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido, N,N',N '-(Ci-6alkyl)3ureido, C!-6alkylS(O)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, N-(Ci.6alkyl)sulfamoyl, NN-(Ci.6alkyl)2sulfamoyl,
Ci-βalkylsulfonylamino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13, R15 and R16 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13, R15 and R16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R13, R15 and R16 may optionally bear a
Figure imgf000010_0005
group; R14, R17 and R19 are independently selected from
Figure imgf000010_0006
Ci-βalkanoyl,
Ci-6alkylsulfonyl, Ci-βalkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, NN-(Ci.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14, R17 and R19 independently of each other may be optionally substituted on carbon by one or more R20; X2, X3 and X4 are independently selected from a direct bond, -C(O)- and
-Ν(R22)C(O)-; wherein R22 is hydrogen or
Figure imgf000010_0007
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)0 -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000010_0008
and q is 0-2; R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000010_0009
Ci_6alkanoyl, Ci-όalkanoyloxy, N-(Ci-6alkyl)amino, NN-(Ci.6alkyl)2amino, Ci-βalkanoylamino, N-(C].6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, Ci.6alkylS(O)a wherein a is 0 to 2, Ci-βalkoxycarbonyl, N-(Ci-6alkyl)sulfamoyl, N,N-(Ci.6alkyl)2sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R18 may optionally bear a
Figure imgf000011_0001
group;
R26 is selected from
Figure imgf000011_0002
Ci-βalkanoyl, Ci-βalkylsulfonyl, Ci_6alkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R may be optionally substituted on carbon by one or more R27; and R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfϊnyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof. Unless otherwise stated, the following terms used in this specification and claims have the following meanings. Definitions
Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups, "halo" means fluoro, chloro, bromo or iodo. In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "Ci-βalkyl" and
Figure imgf000012_0001
include methyl, ethyl, propyl, isopropyl and f-butyl, sec-butyl, n-pentyl, n-hexyl and the like. However, references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only. A similar convention applies to other radicals.
The term "Cm-n" or "Cm-n group" used alone or as a prefix, refers to any group having m to n carbon atoms.
An "alkylene," "alkenylene," or "alkynylene" group is an alkyl, alkenyl, or alkynyl group that is positioned between and serves to connect two other chemical groups. Thus, "Ci-6alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, for example, methylene, ethylene, propylene, 2-methylpropylene, pentylene, and the like. "C2-6alkenylene" means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched divalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, for example, as in ethenylene, 2,4-pentadienylene, and the like. "C2-6alkynylene" means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched divalent hydrocarbon radical of three to six carbon atoms, containing at least one triple bond, for example, as in ethynylene, propynylene, and butynylene and the like.
"C3_7cycloalkyl" means a hydrocarbon ring containing from 3 to 7 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl.
"Cs.γcycloalkenyl" means a hydrocarbon ring containing at least one double bond, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, such as 3- cyclohexen-1-yl, or cyclooctenyl.
"C3-7CyC loalkyl-Ci.6alkylene" means a C3-7cycloalkyl group covalently attached to a Ci_6alkylene group, both of which are defined herein.
A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include C3- 7cycloalkyl, C3-7cycloalkenyl and aryl, for example "carbocyclyl" includes cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexenyl, 4-oxocyclohex- 1 -yl, 3-oxocyclohept-5-en- 1 -yl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
The term "heterocyclyl" means a non-aromatic saturated or partially unsaturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain from about 3 to 12 ring atoms, with from 1 to 5 heteroatoms selected from N, O, and S, and suitably from 3 to 7 member atoms, in the ring (for example a 5 or 6-membered monocyclic ring containing 1 or 2 heteroatoms selected from O, S and N). Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring. Bicyclic heterocycles contain from about 7 to about 17 ring atoms, suitably from 7 to 12 ring atoms. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers (oxiranes) such as ethyleneoxide, tetrahydrofuran, dioxane. Heterocycles containing nitrogen include, for example, azetidine, pyrrolidine, piperidine, piperazine, tetrahydrotriazine, tetrahydropyrazole, and the like. Typical sulfur containing heterocycles include tetrahydrothiophene, dihydro-l,3-dithiol-2-yl, and hexahydrothiepin-4-yl. Other heterocycles include dihydro-oxathiol-4-yl, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2 groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothiophene. A suitable value for a heterocyclyl group which bears 1 or 2 oxo or thioxo substituents is, for example, 2- oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2- oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.
The term "heterocyclyl" used herein also covers polycyclic ring systems containing one or more heteroatoms selected from O, S and N, wherein at one or more ring is aromatic and at least one of the other rings is a non-aromatic, saturated or partially unsaturated ring optionally for example partially saturated bicyclic heteroaryl rings such as l,2,3,4-tetrahydro-l,8-naphthyridinyl, l,2,3,4-tetrahydropyrido[2,3-6]pyrazinyl and 3,4- dihydro-2H-pyrido[3,2-Z>][l,4]oxazinyl.
Particular heterocycles include oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, tetrahydrothienyl, 1,1-dioxotetrahydrothienyl, tetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, aziridinyl, azetidinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, morpholinyl, tetrahydro-l,4-thiazinyl, l,l-dioxotetrahydro-l,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, 2-azabicyclo[2.2.1]heptyl, quinuclidinyl, chromanyl, isochromanyl, indolinyl, isoindolinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl. Other particular heterocycles include azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl or isoindolinyl.
As the skilled person would appreciate, any heterocycle may be linked to another group via. any suitable atom, such as via. a carbon or nitrogen atom. A suitable value for such a heterocyclyl group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 4-oxo-l,4-dihydropyridinyl, 2,5- dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.
"Ηeterocyclyl-Ci-6alkyl" means a heterocyclyl group covalently attached to a Ci- βalkylene group, both of which are defined herein.
The term "aryl" means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon atoms. The term aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like. The term "aryl-Ci.6alkyl" means an aryl group covalently attached to a
Figure imgf000014_0001
group, both of which are defined herein. Examples of aryl-Ci-βalkyl groups include benzyl, phenylethyl, and the like
The term "heteroaryl" means an aromatic mono-, bi-, or polycyclic ring incorporating one or more (for example 1-4) heteroatoms selected from N, O, and S. The term heteroaryl includes both monovalent species and divalent species. Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3- bjfuranyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, lH-pyrazolo[4,3-d]- oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,l-b]thiazolyl, imidazo[ 1 ,2-b] [ 1 ,2,4]triazinyl.
References herein to a "6,5" or "6,6" aryl or heteroaryl ring systems refer to 5 membered ring fused to another 6 membered ring such as a benzothienyl ring (a 6,5 ring); or one 6 membered ring fused to another 6 membered ring such as a naphthyl, quinolyl or quinazolinyl ring (a 6,6 ring). Unless stated otherwise, a 6,5 heteroaryl group may be attached via the 5 or the 6 membered ring.
"Heteroaryl-Ci.6alkyl" means an heteroaryl group covalently attached to a
Figure imgf000015_0001
group, both of which are defined herein. Examples of heteroaryl-Ci-6alkyl groups include pyridin-3-ylmethyl, 3-(benzofuran-2-yl)propyl, and the like.
"Haloalkyl" means alkyl substituted with one or more same or different halo atoms, e.g., -CH2Cl, -CF3, -CH2CF3, -CH2CCl3, and the like.
Examples for the substituents within the compound of formula I include:- for halo fluoro, chloro, bromo and iodo; for Ci-6alkyl: methyl, ethyl, propyl, isopropyl and tert-butvl; for C2.6alkenyl: vinyl, isopropenyl, allyl and but-2-enyl; for C2-6alkynyl: ethynyl, 2-propynyl and but-2-ynyl; for Ci_6alkoxy: methoxy, ethoxy, propoxy, isopropoxy and butoxy; for C2-6alkenyloxy: vinyloxy and allyloxy; for C2-6alkynyloxy: ethynyloxy and 2-propynyloxy; for Ci-όalkylthio: methylthio, ethylthio and propylthio; for Ci-6alkylsulfinyl: methylsulfinyl and ethylsulfinyl; for Ci-6alkylsulfonyl: methylsulfonyl and ethylsulfonyl; for N-(Ci-6alkyl)amino: methylamino, ethylamino, propylamino, isopropylamino and butylamino; for N,N-(Ci.6alkyl)2amino: dimethylamino, diethylamino, N-ethyl- N-methylamino and diisopropylamino; for Ci-όalkoxycarbonyl: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and tert-butoxycarbonyl; for N-(Ci_6alkyl)carbamoyl: N-methylcarbamoyl, N-ethylcarbamoyl and
N-propylcarbamoyl; for N,N-(Ci-6alkyl)2carbamoyl: N,N-dimethylcarbamoyl, N-ethyl-
N-methylcarbamoyl and NN-diethylcarbamoyl; for Ci-βalkanoyl: formyl, acetyl and propionyl; for
Figure imgf000016_0001
acetoxy and propionyloxy;
10 for Ci-βalkanoylamino: acetamido and propionamido; for N-(C i -6alky I)-C i _6alkanoylamino : N-methylacetamido and N-methylpropionamido; for N-(Ci-6alkyl)sulfamoyl: N-methylsulfamoyl and N-ethylsulfamoyl; for N,N-(Ci.6alkyl)2sulfamoyl: N,N-dimethylsulfamoyl; for Ci-6alkylsulfonylamino: methanesulfonylamino and ethanesulfonylamino;
15 for N^Ci-όalkyO-Ci-όalkylsulfonylamino: N-methylmethanesulfonylamino and
N-methylethanesulfonylamino; for C i .βalkylsulfonylaminocarbonyl: methylsulfonylaminocarbonyl; for N'-(Ci_6alkyl)ureido: N'-methylureido and N'-ethylureido; for N',N'-di-[(l-6C)alkyl]ureido: N',N'-dimethylureido and N'-methyl-N'-
20 ethylureido; for N-(l-6C)alkylureido: N-methylureido and N-ethylureido; for N,N'-di-[(l-6C)alkyl]ureido: N,N'-dimethylureido, N-methyl-N'-ethylureido and N-ethyl-N'-methylureido; for N,N',N'-di-[(l-6C)alkyl]ureido: N,N',N'-trimethylureido;
25 for amino-Ci-6alkyl: aminomethyl, 2-aminoethyl, 1-aminoethyl and
3-aminopropyl; for Ci-βalkylamino-Ci-ealkyl: methylaminomethyl, ethylaminomethyl,
1 -methylaminoethyl, 2-methylaminoethyl,
2-ethylaminoethyl and 3-methylaminopropyl;
30 for N,N-(Ci-6alkyl)2amino-Ci-6alkyl: dimethylaminomethyl, diethylaminomethyl,
1-dimethylaminoethyl, 2-dimethylaminoethyl and
3 -dimethy laminopropyl; for hydroxy-Ci-6alkyl: hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl and 3-hydroxypropyl; for Ci-6alkoxy-Ci.6alkyl: methoxymethyl, ethoxymethyl, 1-methoxyethyl,
2-methoxyethyl, 2-ethoxyethyl and
5 3-methoxypropyl; for cyano-Ci_6alkyl: cyanomethyl, 2-cyanoethyl, 1-cyanoethyl and
3-cyanopropyl; for mercapto-(l-6C)alkyl: mercaptomethyl, 2-mercaptoethyl, 1- mercaptoethyl and 3-mercaptopropyl; io for
Figure imgf000017_0001
methylthiomethyl, ethylthiomethyl,
2-methylthioethyl, 1-methylthioethyl and
3-methylthiopropyl; for Ci.6alkylsulfϊnyl-Ci.6alkyl: methylsulfinylmethyl, ethylsulfinylmethyl,
2-methylsulfinylethyl, 1-methylsulfinylethyl and
15 3-methylsulfinylpropyl; for Ci-βalkylsulfonyl-Ci-ealkyl: methylsulfonylmethyl, ethylsulfonylmethyl,
2-methylsulfonylethyl, 1-methylsulfonylethyl and
3-methylsulfonylpropyl; for Ci-ealkanoylamino-Ci-βalkyl: acetamidomethyl, propionamidomethyl and
20 2-acetamidoethyl ; for ureido-
Figure imgf000017_0002
ureidomethyl, 2-ureidoethyl and 1-ureidoethyl; for N'-(C i _6alkyl)ureido-C i ^alkyl: N'-methylureidomethyl, 2-(N'- methylureido)ethyl and l-(N'-methylureido)ethyl; for N',N'-(Ci.6alkyl)2ureido-Ci.6alkyl: N' Jf -dimethy lureidomethy 1,
25 2-(N',N'-dimethylureido)ethyl and
1 -(N',N'-dimethylureido)ethyl; for N-(Cι-6alkyl)ureido-Ci.6alkyl: N-methylureidomethyl, 2-(N-methylureido)ethyl and l-(N-methylureido)ethyl; for NJf-(C i -6alkyl)2ureido-C i-6alkyl: N,N'-dimethylureidomethyl,
30 2-(N,N'-dimethylureido)ethyl and
1 -(N,N'-dimethylureido)ethyl; for N,N' ,N' -(C i ^alky l)3ureido-C i ^alkyl: N,N' ,N' -trimethy lureidomethy 1,
2-(N,N',N'-trimethylureido)ethyl and l-(N,N',N'-trimethylureido)ethyl; for carboxy-Ci-6alkyl: carboxymethyl, 1-carboxyethyl, 2-carboxyethyl, 3-carboxypropyl and 4-carboxybutyl; for C i -ealkoxycarbonylamino-C i_6alkyl: methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl, tert-butoxycarbonylaminomethyl and 2-methoxycarbonylaminoethyl. The term
Figure imgf000018_0001
includes for example, methylenedioxy, ethylidenedioxy, isopropylidenedioxy or ethylenedioxy and the oxygen atoms thereof occupy adjacent ring positions.
The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted. When, as defined herein that, for example, R6 or R9 is carbocyc IyI-X5-, heterocyclyl-X6- or heteroaryl-X7-, and, for example, X5, X6 or X7 is a -Ν(RI2)C(O)- linking group, it is the nitrogen atom, not the carbon atom, of the -N(R12)C(O)- linking group which is attached to the carbocyclyl, heterocyclyl or heteroaryl group. The same principle applies to the other groups defined herein, for example when, for example, R or R1 ' is, for example, heterocyclyl-X3- and X3 is -N(R22)C(O)- the nitrogen atom of the -N(R22)C(O)- linker group is attached to the heterocyclyl. As will be realised, when for example, heterocyclyl-X3- is heterocyclyl-N(R22)C(O)- and said heterocyclyl group is attached to the -N(R22)C(O)- group by a ring carbon. Similarly, when R5 or R1 1 is heterocyclyl-X3- and X3 is a direct bond, the heterocyclyl group is attached to the 5,6,7,8- tetrahydropteridine ring by a ring carbon atom in the heterocyclyl group.
In structural formula I, it is to be understood that where it is stated that "one of the following pairs of substituents (i) R4 and R6, (ii) R4 and R10 or (iii) R4 and R9 together form a bond" only 1 bond is formed in the compound of the formula I, to give compounds of the following formulae:
Figure imgf000019_0001
In structural formula I, it is to be understood that where it is stated that "R4 and R5 together form oxo (=O), or R10 and R1 ' together form oxo (=O), the oxo group is attached to the ring for to give, for example, a compound of the formula:
Figure imgf000019_0002
In structural formula I, it is to be understood that where it is stated that the compound of formula I may be in the form of an N-oxide of the compound of formula I, this refers to a nitrogen of a heteroaryl or heterocyclyl group being in the form of its corresponding N-oxide, in particular the pyridyl nitrogen in the compound of formula I may form the N-oxide, thereby providing a compound of the formula:
Figure imgf000019_0003
Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. For example, the compounds of this invention may possess an asymmetric center at the group A when A represents CR10R11 and R10 represents H and R11 represents a group other than H as defined hereinbefore. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form. Some of the compounds of the invention may have geometric isomeric centres (E- and Z- isomers). It is to be understood that the present invention encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that possess HSP90 inhibitory activity. The present invention also encompasses all tautomeric forms of the compounds of formula I that possess HSP90 inhibitory activity. It is also to be understood that certain compounds of the formula I may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms that possess HSP90 inhibitory activity.
It is also to be understood that certain compounds of the formula I may exhibit polymorphism, and that the invention encompasses all such forms that possess HSP90 inhibitory activity.
It is to be understood that certain compounds of formula I defined above may exhibit the phenomenon of tautomerism. In particular, tautomerism may affect heteroaryl rings or heterocyclic groups within the compounds of formula I that bear 1 or 2 oxo or thioxo substituents. For example when R4 is H and R5 is hydroxy the compound is likely to tautomerise to the more stable oxo form:
Figure imgf000021_0001
It is to be understood that the present invention includes in its definition any such tautomeric form, or a mixture thereof, which possesses the above-mentioned activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings or named in the Examples. For example, where the compound of formula I carries a pyrazolyl group, a tautomeric mixture of compounds comprising a lH-pyrazol-3-yl group and a lH-pyrazol-5-yl group may be present. In general, just one of any such tautomeric forms is named in the Examples that follow hereinafter or is presented in any relevant formulae drawings that follow hereinafter.
A "pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use. A "pharmaceutically acceptable excipient" as used in the specification and claims includes both one and more than one such excipient. A "pharmaceutically acceptable counter ion" means an ion having a charge opposite to that of the substance with which it is associated and that is pharmaceutically acceptable. Representative examples include, but are not limited to, chloride, bromide, iodide, methanesulfonate, p-tolylsulfonate, trifluoroacetate, acetate, and the like. A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such pharmaceutically-acceptable salts of a compound of the formula I is, for example, an acid-addition salt of a compound of the formula I, for example an acid- addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the formula I which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2- hydroxyethyl)amine. Compounds of the invention may form internal salts or zwitterions, for example between a carboxy group and a sufficiently basic group in the compound of formula I.
"Leaving group" has the meaning conventionally associated with it in synthetic organic chemistry i.e., an atom or group capable of being displaced by a nucleophile and includes halogen (such as chloro, bromo, iodo), alkanesulfonyloxy (such as mesyloxy or trifluorosulfonyloxy) or arenesulfonyloxy (such as tosyloxy), and the like. Leaving Groups are well known in the art and are catalogued in "Protective Groups in Organic Synthesis 3rd Ed.", edited by Theodora Green and Peter Wuts (John Wiley, 1999).
It is further to be understood that a suitable pharmaceutically-acceptable pro-drug of a compound of the formula I also forms an aspect of the present invention. Accordingly, the compounds of the invention may be administered in the form of a prodrug, that is a compound that is broken down in the human or animal body to release a compound of the invention. A pro-drug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the invention. A pro-drug can be formed when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached. Examples of pro-drugs include in vivo cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the formula I and in-vivo cleavable amide derivatives that may be formed at a carboxy group or an amino group in a compound of the formula I.
Accordingly, the present invention includes those compounds of the formula I as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the formula I that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the formula I may be a synthetically-produced compound or a metabolically-produced compound.
A suitable pharmaceutically-acceptable pro-drug of a compound of the formula I is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity. Various forms of pro-drug have been described, for example in the following documents :- a) Methods in Enzymology. Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard p. 113- 191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences. 77, 285 (1988); f) N. Kakeya, et al, Chem. Pharm. Bull. 32, 692 (1984); g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987. A suitable pharmaceutically-acceptable pro-drug of a compound of the formula I that possesses a carboxy group is, for example, an in vivo cleavable ester thereof. An in vivo cleavable ester of a compound of the formula I containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically-acceptable esters for carboxy include esters such as methyl, ethyl and tert-butyl, Ci_6alkoxymethyl esters such as methoxymethyl esters, Ci.6alkanoyloxymethyl esters such as pivaloyloxymethyl esters, 3-phthalidyl esters, Cs-scycloalkylcarbonyloxy- Ci.6alkyl esters such as
5 cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl esters,
2-oxo-l,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-l,3-dioxolen-4-ylmethyl esters and Ci-6alkoxycarbonyloxy- Ci.6alkyl esters such as methoxycarbonyloxymethyl and 1 -methoxycarbonyloxy ethyl esters.
A suitable pharmaceutically-acceptable pro-drug of a compound of the formula I thato possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof. An in vivo cleavable ester or ether of a compound of the formula I containing a hydroxy group is, for example, a pharmaceutically-acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound. Suitable pharmaceutically- acceptable ester forming groups for a hydroxy group include inorganic esters such ass phosphate esters (including phosphoramidic cyclic esters). Further suitable pharmaceutically-acceptable ester forming groups for a hydroxy group include Ci- ioalkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, Ci.ioalkoxycarbonyl groups such as ethoxycarbonyl, N5N-(C]- 6)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ringo substituents on the phenylacetyl and benzoyl groups include aminomethyl, N- alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(Ci-4alkyl)piperazin-l-ylmethyl. Suitable pharmaceutically-acceptable ether forming groups for a hydroxy group include α-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups. 5 A suitable pharmaceutically-acceptable pro-drug of a compound of the formula I that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a
Figure imgf000024_0001
such as methylamine, a (Ci-4alkyl)2amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine, a Cj. 4alkoxy- C2-4alkylamine such as 2-methoxyethylamine, a
Figure imgf000024_0002
such as0 benzylamine and amino acids such as glycine or an ester thereof.
A suitable pharmaceutically-acceptable pro-drug of a compound of the formula I that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof. Suitable pharmaceutically-acceptable amides from an amino group include, for example an amide formed with C|.ioalkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C i ^alky^piperazin- 1 -ylmethyl.
The in vivo effects of a compound of the formula / may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the formula I. As stated hereinbefore, the in vivo effects of a compound of the formula I may also be exerted by way of metabolism of a precursor compound (a pro-drug).
"Treating" or "treatment" of a disease includes:
1. preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease;
2. inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or
3. relieving the disease, i.e., causing regression of the disease or its clinical symptoms. A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
The phrase "compound of the invention" means those compounds which are disclosed herein, both generically and specifically.
Particular novel compounds of the invention include, for example, compounds of the formula I, or pharmaceutically acceptable salts and pro-drugs thereof, wherein, unless otherwise stated, each of R1, R2, R3, R4, R5, R6, R7, p and A has any of the meanings defined hereinbefore or in any of paragraphs (1) to (87) hereinafter: - (1) R1, R2 and R3 are independently selected from H, halo or a group of the formula:
-X1 -R8, wherein X1 is a direct bond, O, S or NR8a, wherein R8ais H or C]-4alkyl, and R8 is selected from H, Ci-4alkyl, C2.4alkenyl, C3.6cycloalkyl and C2-4alkynyl, and wherein R1, R2 and R3 may independently of each other be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino,
Figure imgf000026_0001
carbamoyl,
Figure imgf000026_0002
and NN-(C i-4alkyl)2carbamoyl.
(2) R1, R2 and R3 are independently selected from H, halo or a group of the formula:
-X1 -R8, wherein X! is a direct bond, O, S or ΝR8a, wherein R8a is H or CMalkyl, and R8 is selected from H,
Figure imgf000026_0003
C2-4alkenyl, C3.6cycloalkyl and C2-4alkynyl, and wherein R1, R2 and R3 may independently of each other be optionally substituted on carbon by one or more substituents selected from hydroxy,
Figure imgf000026_0004
and C3.6cycloalkyl.
(3) R1, R2 and R3 are independently selected from halo or a group of the formula: -X1 -R8, wherein X1 is a direct bond, O or S, and R8 is selected from H and CMalkyl.
(4) R1, R2 and R3 are independently selected from H, chloro, bromo, iodo, amino or a group of the formula:
-X -R8, wherein X1 is a direct bond, O or S, and R8 is selected from H,
Figure imgf000026_0005
C^alkenyl and C3.6cycloalkyl, and wherein R1, R2 and R3 may independently of each other be optionally substituted on carbon by one or more substituents selected from hydroxy, Ci-3alkoxy C3-6cycloalkyl. (5) R1, R2 and R3 are each a group of the formula:
-X1 -R8, wherein X1 is a direct bond or O, and R8 is
Figure imgf000026_0006
(particularly Ci-2alkyl, for example methyl), and wherein R1, R2 and R3 may independently of each other be optionally substituted on carbon by one or more substituents selected from hydroxy,
Figure imgf000026_0007
C3.6cycloalkyl. (6) R1, R2 and R3 are each a group of the formula: -X1 -R8, wherein X1 is a direct bond or O, and R8 is
Figure imgf000027_0001
(particularly Ci-2alkyl, for example methyl).
(7) R1, R2 and R3 are independently selected from H, chloro, bromo, iodo, amino, methyl, ethyl, methoxy, ethoxy, isopropyloxy, isobutyloxy, allyloxy, methylthio, ethylthio, hydroxymethyl, 2-hydroxyethyl, 2-methoxyethoxy, 2-hydroxyethoxy and cyclopropylmethoxy.
(8) R1, R2 and R3 are independently selected from methyl and methoxy.
(9) R1 is selected from H, halo,
Figure imgf000027_0002
(10) R1 is selected from H, halo and Ci-3alkyl.
(11) R1 is selected from halo and Ci-3alkyl.
(12) R1 is selected from chloro, bromo, methyl and methoxy.
(13) R1 is selected from chloro, bromo and methyl.
(14) R1 is Ci-3alkyl. (15) R1 is methyl.
(16) R2 is selected from H, halo, hydroxy, amino, Ci-4alkyl,
Figure imgf000027_0003
Figure imgf000027_0004
N1N-(C i.4alkyl)2amino, wherein R2 may be optionally substituted on carbon by one or more substituents selected from hydroxy and Ci.4alkoxy.
(17) R2 is selected from halo, hydroxy,
Figure imgf000027_0005
Ci-3alkoxy,
Figure imgf000027_0006
wherein R2 may be optionally substituted on carbon by one or more substituents selected from hydroxy
Figure imgf000027_0007
(18) R2 is selected from chloro, bromo, iodo, hydroxy, methoxy, methyl and methylthio.
(19) R2 is selected from chloro, bromo, iodo, methoxy, methyl and methylthio.
(20) R2 is Ci-3alkoxy. (21) R2 is selected from halo, Ci-3alkoxy and
Figure imgf000027_0008
(particularly bromo, methoxy and methylthio).
(22) R2 is methoxy.
(23) p is 1 or 2 (particularly 1) and R3 is selected from H, halo, hydroxy, Ci-4alkyl, Ci. 4alkoxy and Ci-4alkylthio, wherein R3 may be optionally substituted on carbon by one or more substituents selected from hydroxy and
(24) p is 1 and R3 is selected from chloro, bromo, iodo, hydroxy, methoxy, methyl and methylthio. (25) p is 1 and R3 is
Figure imgf000028_0001
(particularly methyl).
(26) p is 1, R3 is
Figure imgf000028_0002
and R3 is in the meta-position to the pyridyl nitrogen.
(27) p is 1 , R3 is methyl and R3 is in the meta-position to the pyridyl nitrogen.
(28) at least 1 of R1 , R2 and R3 is not H. (29) R1 is selected from H, halo and
Figure imgf000028_0003
(particularly R1 is halo or
Figure imgf000028_0004
R2 is selected from halo, hydroxy,
Figure imgf000028_0005
wherein R2 may be optionally substituted on carbon by one or more substituents selected from hydroxy and Cioalkoxy; and p is 1, R3 is in the meta-position to the pyridyl nitrogen, and R3 is selected from H, halo, hydroxy, Ci.4alkyl,
Figure imgf000028_0006
wherein R3 may be optionally substituted on carbon by one or more substituents selected from hydroxy and Ci-3alkoxy (particularly R3 is selected from chloro, bromo, Ci-3alkyl and
Figure imgf000028_0007
(30) R1 is selected from H, halo and
Figure imgf000028_0008
(particularly R1 is halo or
Figure imgf000028_0009
R2 is selected from halo,
Figure imgf000028_0010
Ci-3alkoxy and
Figure imgf000028_0011
(particularly R2 is halo, Cioalkoxy or Ci-3alkylthio, more particularly bromo, methoxy or methylthio), wherein R2 is optionally substituted on carbon by one or more substituents selected from hydroxy and Ci-3alkoxy; and p is 1, R3 is in the meta-position to the pyridyl nitrogen, and R3 is selected from H, halo, hydroxy,
Figure imgf000028_0012
and
Figure imgf000028_0013
wherein R3 is optionally substituted on carbon by one or more substituents selected from hydroxy and
Figure imgf000028_0014
(particularly R3 is selected from chloro, bromo, Ci^alkyl and Ci-3alkoxy).
(31) R1 is Ci-3alkyl (particularly methyl);
R2 is
Figure imgf000028_0015
(particularly methoxy); and p is 1, R3 is in the meta-position to the pyridyl nitrogen, and R3 is Ci-3alkyl (particularly methyl).
(32) The pyridyl group in formula I is in the form of the N-oxide of the formula:
Figure imgf000028_0016
wherein R1, R2, R3 and p have any of the values defined herein, particularly those defined in (1) to (31) above.
(33) The pyridyl group in formula I is of the formula:
Figure imgf000029_0001
is selected from 4-methoxy-3,5-dimethylpyridin-2-yl, 4-chloro-3,5-dimethylpyridin-2-yl, 4-chloro-3,5-dimethyl- 1 -oxypyridin-2-yl, 4-methoxy-3, 5 -dimethyl- l-oxypyridin-2-yl, 4- bromo-3,5-dimethylpyridin-2-yl, 4-bromo-3,5-dimethyl- 1 -oxy-pyridin-2-yl, 4-iodo-3,5- dimethyl-l-oxy-pyridin-2-yl, 4-iodo-3,5-dimethylpyridin-2-yl, 3-bromo-4,5,6- trimethoxypyridin-2-yl, 3-chloro-4,5,6-trimethoxypyridin-2-yl, 3,4,5-trimethylpyridin-2-yl, 3,4,5-trimethyl-l-oxypyridin-2-yl, 3,4,5-trimethoxypyridin-2-yl, 6-chloro-4-methoxy-3,5- dimethylpyridin-2-yl, 6-bromo-4-methoxy-3,5-dimethylpyridin-2-yl, 6-chloro-4-methoxy- 3,5-dimethyl-l-oxy-pyridin-2-yl, 6-bromo-4-methoxy-3,5-dimethyl-l-oxy-pyridin-2-yl, 6,4-dimethoxy-3,5-dimethylpyridin-2-yl, 6,4-dimethoxy-3,5-dimethyl-l-oxy-pyridin-2-yl, 3-bromo-4,5,6-trimethoxy-l-oxy-pyridin-2-yl and 3-chloro-4,5,6-trimethoxy-l-oxy- pyridin-2-yl.
(34) The pyridyl group in formula I is of the formula:
Figure imgf000029_0002
is selected from 4-methoxy-3,5-dimethylpyridin-2-yl, 4-chloro-3,5-dimethylpyridin-2-yl, 4-chloro-3, 5 -dimethyl- 1 -oxypyridin-2-yl, 4-methoxy-3,5-dimethyl- 1 -oxypyridin-2-yl, 4- bromo-3,5-dimethylpyridin-2-yl, 4-methylthio-3,5-dimethylpyridin-2-yl, 4-bromo-3,5- dimethyl- 1 -oxy-pyridin-2-yl, 4-methylthio-3,5-dimethyl- 1 -oxy-pyridin-2-yl, 4-iodo-3,5- dimethyl-1 -oxy-pyridin-2-yl, 4-iodo-3,5-dimethylpyridin-2-yl, 3-bromo-4,5,6- trimethoxypyridin-2-yl, 3-chloro-4,5,6-trimethoxypyridin-2-yl, 3,4,5-trimethylpyridin-2-yl, 3,4,5-trimethyl-l-oxypyridin-2-yl, 3,4,5-trimethoxypyridin-2-yl, 6-chloro-4-methoxy-3,5- dimethylpyridin-2-yl, 6-bromo-4-methoxy-3,5-dimethylpyridin-2-yl, 6-chloro-4-methoxy- 3,5-dimethyl-l-oxy-pyridin-2-yl, 6-bromo-4-methoxy-3,5-dimethyl-l-oxy-pyridin-2-yl, 6,4-dimethoxy-3,5-dimethylpyridin-2-yl, 6,4-dimethoxy-3,5-dimethyl- 1 -oxy-pyridin-2-yl, 3-bromo-4,5,6-trimethoxy-l-oxy-pyridin-2-yl and 3-chloro-4,5,6-trimethoxy-l-oxy- pyridin-2-yl. (35) The pyridyl group in formula I of the formula:
Figure imgf000030_0001
is selected from 4-methoxy-3,5-dimethylpyridin-2-yl, 4-chloro-3,5-dimethylpyridin-2-yl, 4-chloro-3,5-dimethyl-l-oxypyridin-2-yl, 4-methoxy-3,5-dimethyl-l-oxypyridin-2-yl, 4- bromo-3,5-dimethylpyridin-2-yl, 4-bromo-3,5-dimethyl-l -oxy-pyridin-2-yl, 4-iodo-3,5- dimethyl- 1 -oxy-pyridin-2-yl, 4-iodo-3,5-dimethylpyridin-2-yl and 3-bromo-4,5,6- trimethoxypyridin-2-yl. (36) The pyridyl group in formula I of the formula:
Figure imgf000030_0002
is selected from 4-methoxy-3,5-dimethylpyridin-2-yl, 4-chloro-3,5-dimethylpyridin-2-yl, 4-chloro-3,5-dimethyl-l-oxypyridin-2-yl, 4-methoxy-3,5-dimethyl-l-oxypyridin-2-yl, 4- bromo-3,5-dimethylpyridin-2-yl, 4-methylthio-3,5-dimethylpyridin-2-yl, 4-bromo-3,5- dimethyl-1 -oxy-pyridin-2-yl, , 4-methylthio-3,5-dimethyl-l-oxy-pyridin-2-yl, 4-iodo-3,5- dimethyl- 1 -oxy-pyridin-2-yl, 4-iodo-3 ,5 -dimethylpyridin-2-yl, 3-bromo-4,5 ,6- trimethoxypyridin-2-yl, 6-chloro-4-methoxy-3,5-dimethylpyridin-2-yl and 6-bromo-4- methoxy-3,5-dimethylpyridin-2-yl. (37) the group of the formula: in formula I is of the formula:
Figure imgf000031_0001
wherein "^^ indicates the point of attachment to the nitrogen in formula I. (38) A is CR10R", wherein R10 and R1 ' are as hereinbefore defined. (39) A is CR10R1 1, wherein R10 is H or CMalkyl, and R1 ' is as hereinbefore defined. (40) A is CR10R1 ', wherein R10 is H and R1 ' is H, carboxy, carbamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Cuόalkanoyl, N-(Ci.6alkyl)carbamoyl, N,N-(Ci.6alkyl)2carbamoyl, C].6alkoxycarbonyl, Ci-oalkylsulfonylaminocarbonyl, C3-7CyC loalkyl-X2-, aryl-X2, C3- 7cycloalkenyl-X2-, heterocyclyl-X3- or heteroaryl-X4-, wherein X2, X3 and X4 are selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or
Figure imgf000031_0002
wherein R1 ' may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any aryl or heteroaryl group within R1 1 may optionally bear a Cj. 3alkylenedioxy group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci.6alkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci-6alkanoyl, Q-όalkanoyloxy, N-(Ci.6alkyl)amino, N,N-(Ci_6alkyl)2amino, Ci-βalkanoylamino, N-(Ci.6alkyl)carbamoyl, N,N-(Ci.6alkyl)2carbamoyl, Ci.6alkylS(O)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, N-(C].6alkyl)sulfamoyl, N,N-(Ci.6alkyl)2Sulfamoyl, Ci.6alkylsulfonylamino, C3-7cycloalkyl-X8-, aryl-X8-, heterocyclyl-X9- or heteroaryl-X10-, wherein X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O),-, -SO2N(R24)- or -N(R25)SO2-, wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000032_0001
and q is 0-2, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any aryl or heteroaryl group within R13 may optionally bear a Ci. 3alkylenedioxy group;
R14 and R19 are independently selected from Ci-6alkyl, Ci_6alkanoyl, Ci_6alkylsulfonyl, Ci-6alkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14 and R19 may be optionally substituted on carbon by one or more R20; R18 is selected from halo, hydroxy, amino,
Figure imgf000032_0002
N-(C).
4alkyl)amino and NN-(Ci-4alkyl)2amino; and
R is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino; or R10 and R1 ' together form oxo (=0). (41) A is CR10R11, wherein R10 is H and R11 is H, carbamoyl, sulfamoyl, d-6alkyl,
C2-6alkenyl, C2-6alkynyl, Ci_6alkanoyl, N-(Ci_6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl,
Figure imgf000032_0003
N-(Ci-6alkyl)sulfamoyl, NN-(Ci.6alkyl)2Sulfamoyl, Ca.γcycloalkyl-X2- , phenyl-X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms (suitably 1 or 2 heteroatoms) selected from O, S and Ν, and said heterocyclyl is a monocyclic 5, 6 or 7- membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2 heteroatoms) heteroatoms selected from O, S and Ν, wherein R11 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 oxo substituent, and wherein any phenyl or heteroaryl group within R1 ' may optionally bear a Ci- 3alkylenedioxy group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_4alkyl, C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, CMalkanoyl, Ci.4alkanoyloxy, N-(Ci-4alkyl)amino, NN-(C i-4alkyl)2amino,
Ci-4alkanoylamino, N-(Ci-4alkyl)carbamoyl,
Figure imgf000033_0001
CMalkylS(O)a wherein a is 0 to 2,
Figure imgf000033_0002
N-(Ci_4alkyl)sulfamoyl, NN-(C i-4alkyl)2sulfamoyl, C3_7cycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent, and wherein any aryl or heteroaryl group within R13 may optionally bear a Ci- 3alkylenedioxy group;
R14 and R19 are independently selected from
Figure imgf000033_0003
Figure imgf000033_0004
carbamoyl, N-(Ci-6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino, Ci-4alkyl,
Figure imgf000033_0005
N-(Ci- 4alkyl)amino and N,N-(Ci-4alkyl)2amino; and
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)- wherein R22 is selected from hydrogen or
Figure imgf000033_0006
or R10 and R1 ' together form oxo (=0).
(42) A is CR10R1 ', wherein R10 is H and R1 ' is H, C1-6alkyl, C3.7cycloalkyl-X2-, phenyl- X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is a monocyclic 5 or 6- membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and N, and said heterocyclyl is a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and N, wherein R11 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 oxo substituent, and wherein any phenyl or heteroaryl group within R1 ' may optionally bear a Ci- 3alkylenedioxy group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000034_0001
C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, Ci^alkanoyl, Ci_4alkanoyloxy, N-(Ci-4alkyl)amino, N,N-(Ci.4alkyl)2amino,
Ci_4alkanoylamino, N-(Ci_4alkyl)carbamoyl, N,N-(Ci.4alkyl)2carbamoyl,
Figure imgf000034_0002
wherein a is 0 to 2, Ci_4alkoxycarbonyl, N-(Ci-4alkyl)sulfamoyl, N,N-(Ci-4alkyl)2Sulfamoyl, Cs.γcycloalkyi, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1 , 2 or 3 heteroatoms selected from O, S and Ν, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R14 and R19 are independently selected from
Figure imgf000034_0003
Ci.4alkylsulfonyl,
Figure imgf000034_0004
carbamoyl, N-(Ci.6alkyl)carbamoyl, NN-(Ci -6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000034_0005
N-(Ci- 4alkyl)amino and N,N-(Ci-4alkyl)2amino; and
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-, wherein R22 is selected from hydrogen or
Figure imgf000034_0006
or R10 and R1 ' together form oxo (=0).
(43) A is CR10R11, wherein R10 is H and R1 1 is H, C,.6alkyl, C3-7cycloalkyl-X2-, phenyl- X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofϊiranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein said C3-7cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and wherein R11 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 oxo substituent;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, C1-4alkanoyl, Ci-4alkanoyloxy, N-(Ci-4alkyl)amino, NN-(C i-4alkyl)2amino, CMalkanoylamino, N^Ci^alky^carbamoyl, NN-(C Malkyl^carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2,
Figure imgf000035_0001
NN-(Ci-4alkyl)2Sulfamoyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a heteroaryl selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and a heterocyclyl selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R14 and R19 are independently selected from Ci.4alkyl, C]-4alkanoyl, C i ^alkylsulfonyl, C i ^alkoxycarbonyl, carbamoyl, N-(C i _6alkyl)carbamoyl, NN-(C |.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl; R18 is selected from halo, hydroxy, amino, Ci-4alkyl, Ci-4alkoxy, N-(Ci- 4alkyl)amino and N,N-(Ci-4alkyl)2amino; and
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-, wherein R22 is selected from hydrogen or Ci-4alkyl. (43a) A is CR10R1 ', wherein R10 is H and R1 ' is selected from H and Chalky., wherein R1 ' is optionally substituted on carbon by one or more R13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000036_0001
Ci-4alkanoyl, Ci-4alkanoyloxy, N-(Ci-4alkyl)amino, N,N-(Ci-4alkyl)2amino, Ci-4alkanoylamino,
Figure imgf000036_0002
N,N-(Ci-4alkyl)2carbamoyl, C i.4alky IS(O)3 wherein a is 0 to 2, C]-4alkoxycarbonyl, N-(Ci- 4alkyl)sulfamoyl, N,N-(Ci-4alkyl)2sulfamoyl,
Figure imgf000036_0003
phenyl, pyridyl and pyrimidinyl. For example, R1 ' is selected from H and
Figure imgf000036_0004
(44) A is CR10R1 ', wherein R10 is H and R1 ! is H, Ci-6alkyl or Ca-γcycloalkyl-X2-, wherein R11 may be optionally substituted on carbon by one or more R13; R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, Ci^alkoxy, CMalkanoyl, Ci^alkanoyloxy, N^CMalky^amino, NN-(C Malkyl^amino, CMalkanoylamino, N-^MalkyOcarbamoyl, NN-(C i-4alkyl)2carbamoyl, CMaUCyIS(O)3 wherein a is 0 to 2,
Figure imgf000036_0005
N-(Ci-4alkyl)sulfamoyl, NN-(Ci-4alkyl)2sulfamoyl, C3-7cycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1 , 2 or 3 heteroatoms selected from O, S and Ν, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R19 is selected from
Figure imgf000036_0006
CMalkylsulfonyl, C].4alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl,
Figure imgf000036_0007
benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000036_0008
N-(C]. 4alkyl)amino and N,N-(Ci-4alkyl)2amino; and X2 is selected from a direct bond, -C(O)-, -N(R22)C(O)-; wherein R22 is hydrogen
Figure imgf000037_0001
(45) A is CR10R1 ', wherein R10 is H and R1 ' is H or C,.6alkyl, wherein R11 may be optionally substituted on carbon by one or more R13; 5 R13 is selected from fluoro, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000037_0002
C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, Ci-4alkanoyl,
Figure imgf000037_0003
N-(Ci-4alkyl)amino, NN-(C Malkyrhamino,
Figure imgf000037_0004
N-(Ci-4alkyl)carbamoyl, NN-(C i_4alkyl)2carbamoyl, C i-4alkylS(0)a wherein a is 0 to 2, CMalkoxycarbonyl, N-(Ci_4alkyl)sulfamoyl, NN-(C i.4alkyl)2sulfamoyl, io C3_7cycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1 , 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that is nitrogen may be optionally substituted by a group selected from R19; and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R19 is selected from Ci-4alkyl, Ci-4alkanoyl, CMalkylsulfonyl,
Figure imgf000037_0005
carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, benzyl, 2o benzyloxycarbonyl and benzoyl; and
R18 is selected from halo, hydroxy, amino, Ci-4alkyl, Ci.4alkoxy, N-(Ci- 4alkyl)amino and NN-(Ci-4alkyl)2amino.
(46) A is CR10R11, wherein R10 is H and R11 is H or C1-6alkyl, wherein R1 ' may be optionally substituted on carbon by one or more R13; _5 R13 is selected from fluoro, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000037_0006
C2-4alkenyl, C2-4alkynyl,
Figure imgf000037_0007
Ci-4alkanoyl,
Figure imgf000037_0008
N-(Ci-4alkyl)amino, NN-(Ci-4alkyl)2amino, Ci-4alkanoylamino, N-(Ci_4alkyl)carbamoyl, NN-(C i-4alkyl)2carbamoyl, Chalky IS(O)3 wherein a is 0 to 2,
Figure imgf000037_0009
N-(Ci-4alkyl)sulfamoyl, N,N-(Ci_4alkyl)2sulfamoyl, 30 C3-7cycloalkyl and phenyl, and wherein R13 may be optionally substituted on carbon by one or more R18; and R18 is selected from halo, hydroxy, amino, Ci-4alkyl, Ci-4alkoxy, N-(Ci- 4alkyl)amino and NN-(C].4alkyl)2amino. (47) A is CR10R1 1, wherein R10 is H and R11 is H or Ci-6alkyl, wherein R11 may be optionally substituted on carbon by one or more R13; R13 is selected from carboxy, carbamoyl, N-(Ci-4alkyl)carbamoyl,
NN-(CMalkyl)2carbamoyl, Ci_4alkoxycarbonyl and phenyl, and wherein R13 may be optionally substituted on carbon by one or more R18; and
R18 is selected from halo, hydroxy, amino, Ci-4alkyl,
Figure imgf000038_0001
N-(Ci- 4alkyl)amino and NN-(C i.4alkyl)2amino. (48) A is CR10R1 1, wherein R10 is H and R11 is H or Ci-6alkyl, wherein R may be optionally substituted on carbon by one or more R ;
R13 is selected from carboxy, carbamoyl, N-(Ci_4alkyl)carbamoyl, Ci_4alkoxycarbonyl and phenyl-, and wherein R13 may be optionally substituted on carbon by one or more R18; and R18 is NN-(C i-4alkyl)2amino.
(49) A is CR10R1 ' , wherein R10 is H and R1 ' is selected from H, methyl, propyl, 2- methylpropyl, benzyl, methoxycarbonylmethyl, carboxymethyl, carbamoylmethyl, N-[3- (dimethylamino)propyl]carbamoylmethyl and N-[2- (dimethylamino)ethyl]carbamoylmethyl. (50) A is CR10R1 ', wherein R10 is H and R1 ' is H or Ci-4alkyl, for example R1 ' is H, methyl, ethyl or isopropyl.
(51) A is NR9, wherein R9 is as hereinbefore defined.
(52) A is NR9, wherein R9 is selected from H,
Figure imgf000038_0002
C3-7CyC loalkyl, C3.7cycloalkyl- Ci-βalkanoyl, Ci.6alkylsulfonyl, Ci-6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl,
Figure imgf000038_0003
benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R9 may be optionally substituted on carbon by one or more R16; and
R16 is selected from halo, hydroxy, amino,
Figure imgf000038_0004
N-(Q- 4alkyl)amino and
Figure imgf000038_0005
(53) A is NR9, wherein R9 is selected from H, C3-7cycloalkyl, C3-7cycloalkyl- C4alkyl, for example R9 is selected from H, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
Figure imgf000038_0006
cyclopentyl- C|-4alkyl and
Figure imgf000039_0001
More particularly R9 is selected from H, methyl and ethyl.
(54) R4 is H and R5 is as hereinbefore defined, or R4 and R5 together form oxo (=0).
(55) R4 is H and R5 is H, carboxy, carbamoyl, sulfamoyl, C^aUcyl, C2-6alkenyl, C2-6alkynyl, Ci-βalkanoyl, N-(Ci-6alkyl)carbamoyl, N,N-(Ci-6alkyl)2Carbamoyl,
C i _6alkoxycarbonyl, N-(C i _6alkyl)sulfamoyl, N1N-(C i _6alkyl)2sulfamoyl, Ci-δalkylsulfonylaminocarbonyl, C3-7cycloalkyl-X2-, aryl-X2, C3-7cycloalkenyl-X2- or heterocyclyl-X3- or heteroaryl-X4-, wherein R5 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R5 may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any aryl or heteroaryl group within R5 may optionally bear a Ci- 3alkylenedioxy group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000039_0002
Ci-βalkanoyl, Ci-βalkanoyloxy, N-(Ci_6alkyl)amino, N,N-(Ci.6alkyl)2amino, Ci-βalkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(Ci -6alkyl)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, Ci-6alkoxycarbonyl, N-(Ci.6alkyl)sulfamoyl, NN-(Ci.6alkyl)2Sulfamoyl, Ci-6alkylsulfonylamino, Cs^cycloalkyl-X8-, aryl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any aryl or heteroaryl group within R13 may optionally bear a Ci- 3alkylenedioxy group;
R14 and R19 are independently selected from C
Figure imgf000039_0003
i^alkyl, C] -βalky lsulfony 1, C i .6alkoxycarbony 1, carbamoyl, N-(Ci -όalky l)carbamoyl,
NN-(C i_6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14 and R19 may be optionally substituted on carbon by one or more R20; R18 is selected from halo, hydroxy, amino, Ci-4alkyl, Ci_4alkoxy, N-(Ci- 4alkyl)amino and N,N-(Ci.4alkyl)2amino;
R20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino; X2, X3 and X4 are independently selected from a direct bond, -C(O)-, -Ν(R22)C(O)-; wherein R22 is hydrogen or Ci-4alkyl; and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)0 -SO2N(R24)- or -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000040_0001
and q is 0-2; or R4 and R5 together form oxo (=0).
(56) R4 is H and R5 is H, carbamoyl, sulfamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkanoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, Ci-βalkoxycarbonyl, N-(C,.6alkyl)sulfamoyl, NN-(C,.6alkyl)2sulfamoyl, C3-7cycloalkyl-X2-, phenyl-X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is a monocyclic 5 or 6- membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and said heterocyclyl is a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, wherein R5 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R5 may optionally bear 1 oxo substituent, and wherein any phenyl or heteroaryl group within R5 may optionally bear a Ci- 3alkylenedioxy group; R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000040_0002
Ci-4alkanoyl, Ci-4alkanoyloxy, N-^Malky^amino, NN-^Malkyl^amino, Ci-4alkanoylamino, N-(Ci4alkyl)carbamoyl, NN-(Ci_4alkyl)2carbamoyl,
Figure imgf000040_0003
wherein a is 0 to 2, Ci_4alkoxycarbonyl, N-(CMalkyl)sulfamoyl, N,N-(Ci.4alkyl)2sulfamoyl, C3-7cycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1 , 2 or 3 heteroatoms selected from O, S and Ν, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R14 and R19 are independently selected from
Figure imgf000041_0001
Figure imgf000041_0002
Ci-4alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000041_0003
N-(Ci- 4alkyl)amino and
Figure imgf000041_0004
and
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or CMalkyl; or R4 and R5 together form oxo (=0).
(57) R4 is H and R5 is H, Ci-6alkyl, Ca.γcycloalkyl-X2-, phenyl-X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and N, and said heterocyclyl is a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and N, wherein R5 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R4 may optionally bear 1 oxo substituent, and wherein any phenyl or heteroaryl group within R4 may optionally bear a Ci- 3alkylenedioxy group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000041_0005
Ci.4alkanoyl, Ci^alkanoyloxy, N-(Ci-4alkyl)amino, N,N-(Ci-4alkyl)2amino,
Figure imgf000041_0006
N-(Ci_4alkyl)carbamoyl, N,N-(Ci-4alkyi)2Carbamoyl, Ci-4alkylS(0)a wherein a is 0 to 2,
Figure imgf000041_0007
N-(Ci_4alkyl)sulfamoyl, N,N-(Ci.4alkyl)2sulfamoyl, C3-7cycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and N, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and N, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R may optionally bear 1 oxo substituent, and wherein any aryl or heteroaryl group within R13 may optionally bear a Ci. 3alkylenedioxy group; R14 and R19 are independently selected from
Figure imgf000042_0001
Ci-4alkanoyl,
Figure imgf000042_0002
Ci-4alkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, N1N-(C i.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino, Ci^alkyl, d^alkoxy, N-(Ci- 4alkyl)amino and
Figure imgf000042_0003
and X2, X3 and X4 are independently selected from a direct bond, -C(O)- and
-Ν(R22)C(O)-; wherein R22 is hydrogen or CMalkyl; or R4 and R5 together form oxo (=0).
(58) R4 is H and R5 is H, Ci-6alkyl, C3.7cycloalkyl-X2-, phenyl-X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein said C3-7cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and wherein R5 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R5 may optionally bear 1 oxo substituent, and wherein any phenyl or heteroaryl group within R5 may optionally bear a Ci- 3alkylenedioxy group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, CMalkyl, C2-4alkenyl, C2-4alkynyl, C^alkoxy, Ci-4alkanoyl, Ci_4alkanoyloxy, N-(Ci.4alkyl)amino, NN-(C Malkyl)2amino,
Figure imgf000043_0001
Chalky IS(O)3 wherein a is 0 to 2, Ci_4alkoxycarbonyl,
Figure imgf000043_0002
NN-(C Malkyl)2sulfamoyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a heteroaryl selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and a heterocyclyl selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R14 and R19 are independently selected from
Figure imgf000043_0003
Ci-4alkanoyl,
Figure imgf000043_0004
Ci-4alkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, NN-(Ci.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000043_0005
Ci-4alkoxy, N-(Q- 4alkyl)amino and NN-(C Malkyl^amino; and
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or CMalkyl; or R4 and R5 together form oxo (=0).
(59) R4 is H and R5 is H, Ci-6alkyl or Cj-vcycloalkyl-X2-, wherein R5 may be optionally substituted on carbon by one or more R13;
R13 is selected from halo (such as fluoro), nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci^alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000043_0006
CMalkanoyloxy, N-(Ci-4alkyi)amino, NN-(Ci-4alkyl)2amino, CMalkanoylamino, N-(CMalkyl)carbamoyl, NN-(C Malkyl)2carbamoyl, Chalky IS(O)3 wherein a is 0 to 2, CMalkoxycarbonyl,
Figure imgf000043_0007
NN-(Ci-4alkyl)2Sulfamoyl, Ca-γcycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and N, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and N, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R19 is selected from
Figure imgf000044_0001
carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino, Ci-4alkyl,
Figure imgf000044_0002
N-(Ci- 4alkyl)amino and NN-(Ci-4alkyl)2amino; and
X2 is selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or C i ^alkyl; or R4 and R5 together form oxo (=0). (60) R4 is H and R5 is H or Ci-4alkyl, or R4 and R5 together form oxo (=0).
For example R4 is H and R5 is H, methyl, ethyl or isopropyl. Alternatively, R4 and R5 together form oxo (=0). (61) R4 and R5 are both H, or R4 and R5 together form oxo (=0).
(62) R6 is selected from H, Ci-6alkyl, C2.6alkenyl, C2-6alkynyl, Ci-6alkanoyl, Ci-βalkylsulfonyl, Ci-δalkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, C3-7cycloalkyl-X5-, Cs-γcycloalkenyl-X5-, aryl-X5-, heterocyclyl-X6- and heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-,
-Ν(R12)C(0)- and -SO2-; wherein R12 is selected from hydrogen or
Figure imgf000044_0003
and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 or 2 oxo or thioxo substituents; R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000045_0001
C2-6alkenyl, C2-6alkynyl, Ci-βalkoxy, Ci-6alkanoyl,
Figure imgf000045_0002
N-(Ci_6alkyl)amino, N,N-(Ci.6alkyl)2amino, Ci-6alkanoylamino, N-(Ci_6alkyl)carbamoyl, N,N-(Ci.6alkyl)2Carbamoyl, Ci.6alkylS(O)a wherein a is 0 to 2, Ci-όalkoxycarbonyl, N-(Ci-6alkyl)sulfamoyl, NN-(Ci.6alkyl)2Sulfamoyl, Ci-βalkylsulfonylamino, C3-7cycloalkyl-X8-, aryl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 or 2 oxo or thioxo substituents;
R17 and R19 are independently selected from
Figure imgf000045_0003
Ci-βalkanoyl, Ci-6alkylsulfonyl,
Figure imgf000045_0004
carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R17 and R19 may be optionally substituted on carbon by one or more R20;
R18 is selected from halo, hydroxy, amino,
Figure imgf000045_0005
N-(Ci- 4alkyl)amino and N,N-(Ci-4alkyl)2amino;
R20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino; and X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-,
-C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)q-, -SO2N(R24)- or -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or Ci^alkyl and q is 0-2. (63) R6 is selected from H,
Figure imgf000045_0006
C2-6alkenyl, Ci-6alkanoyl, Ci-βalkylsulfonyl, C].6alkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, Cs-γcycloalkyl-X5-, phenyl-X5-, heterocyclyl-X6- and heteroaryl-X7-, wherein said heteroaryl is a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and said heterocyclyl is a monocyclic 5, 6 or 7- membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν; wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-,
-Ν(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or CMalkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 oxo substituent;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci-όalkanoyl, Ci-βalkanoyloxy, N-(C].6alkyl)amino, NN-(Ci-6alkyl)2amino, Ci_6alkanoylamino, N-(Ci.6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, Ci_6alkylS(O)a wherein a is 0 to 2, Ci.6alkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl, N,N-(Ci_6alkyl)2Sulfamoyl, Ci.6alkylsulfonylamino, Cs.γcycloalkyl-X8- , phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, heteroaryl-X10-, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent;
R17 and R19 are independently selected from C
Figure imgf000046_0001
^alkyl,
Figure imgf000046_0002
carbamoyl,
Figure imgf000046_0003
N,N-(Ci.4alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000046_0004
N-(Ci- 4alkyl)amino and N, N-(C i ^alky l)2amino ; and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or
Figure imgf000046_0005
and q is 0-2. (64) R6 is selected from H and Ci-6alkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; R16 is selected from fluoro, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C2-6alkenyl, C2-6alkynyl, Ci-βalkoxy, C].6alkanoyl, C|_6alkanoyloxy, N-(Ci-6alkyl)amino, NN-(C i.6alkyl)2amino, Ci-6alkanoylamino, N-(Ci_6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, Ci.6alkylS(O)a wherein a is 0 to 2, Ci-βalkoxycarbonyl, N-(Ci-6alkyl)sulfamoyl, N,N-(Ci.6alkyl)2Sulfamoyl, Ci-βalkylsulfonylamino, Cs.γcycloalkyl-X8- , phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, heteroaryl-X10-, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent;
R19 is independently selected from
Figure imgf000047_0001
Ci-4alkanoyl,
Figure imgf000047_0002
Figure imgf000047_0003
carbamoyl, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000047_0004
N-(Ci. 4alkyl)amino and
Figure imgf000047_0005
and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or
Figure imgf000047_0006
and q is 0-2. (65) R6 is selected from H and
Figure imgf000047_0007
and wherein R6 may be optionally substituted on carbon by one or more R16;
R16 is selected from fluoro,
Figure imgf000047_0008
N-(Ci.6alkyl)amino, NN-(C i_6alkyl)2amino, C3-7cycloalkyl-X8- , phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, heteroaryl-X10-, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent; R19 is independently selected from
Figure imgf000048_0002
Ci-4alkanoyl,
Figure imgf000048_0001
C).4alkoxycarbonyl, carbamoyl, N-(Ci_4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000048_0003
N-(Ci- 4alkyl)amino and N,N-(Ci_4alkyl)2amino; and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or Ci.4alkyl and q is 0-2.
(66) R6 is selected from H and
Figure imgf000048_0004
and wherein R6 may be optionally substituted on carbon by one or more R16; R16 is selected from fluoro, Ci-6alkoxy, N,N-(Ci-6alkyl)2amino, C3-7cycloalkyl-X8- , phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1 , 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, heteroaryl-X10-, wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent; and
X8, X9 and X10 are each a direct bond.
(67) R6 is selected from H,
Figure imgf000048_0005
C2-4alkenyl,
Figure imgf000048_0006
CMalkylsulfonyl, Ci-4alkoxycarbonyl, carbamoyl, N-(Ci_4alkyl)carbamoyl,
Figure imgf000048_0007
C3.7cycloalkyl-X5-, phenyl-X5-, heterocyclyl-X6- and heteroaryl-X7-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein said C3-7cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)- and -Ν(RI 2)C(O)-, wherein R12 is selected from hydrogen or Ci^alkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 oxo substituent;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, CMalkyl, C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy,
Figure imgf000049_0001
N,N-(Ci-4alkyl)2amino, CMalkanoylamino, N-(Ci-4alkyl)carbamoyl, NN-(Ci ^alkyO∑carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2,
Figure imgf000049_0002
N-(Ci-4alkyl)sulfamoyl, NN-(Ci-4alkyl)2Sulfamoyl, CMalkylsulfonylamino, cyclopropyl-X8-, cyclobutyl-X8-, cyclopentyl-X8-, cyclohexyl-X8-, phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and heteroaryl-X10-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent;
R17 and R19 are independently selected from
Figure imgf000049_0003
Ci-4alkylsulfonyl, CMalkoxycarbonyl, carbamoyl, N-(Ci-4alkyl)carbamoyl, NN-(C i-4alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl; R18 is selected from halo, hydroxy, amino,
Figure imgf000049_0004
N-(Ci-
4alkyl)amino and N,N-(Ci-4alkyl)2amino; and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or Ci-4alkyl and q is 0-2. (67a) R6 is selected from H, Ci-6alkyl, C3-7cycloalkyl-X5-, phenyl-X5-, heterocyclyl-X6- and heteroaryl-X7-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)- and -N(R12)C(O)-, wherein R12 is selected from hydrogen or Ci-4alkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 oxo substituent;
R16 is selected from halo, cyano, hydroxy, amino, mercapto, Ci^alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000050_0001
N-(Ci -4alkyl)amino, NN-(Ci-4alkyl)2amino, Ci-4alkanoylamino, Ci-4alkylS(O)a wherein a is 0 to 2,
Figure imgf000050_0002
cyclopropyl-X8-, cyclobutyl-X8-, cyclopentyl-X8-, cyclohexyl-X8-, phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and heteroaryl-X10-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent;
R17 and R19 are independently selected from Ci-4alkyl, Ci^alkanoyl,
Figure imgf000050_0003
Ci-4alkoxycarbonyl, carbamoyl, N-(CMalkyl)carbamoyl, N N-(C Malky ^carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino, Ci.4alkyl, Ci^alkoxy, N-(Ci- 4alkyl)amino and NN-(Ci-4alkyl)2amino; and X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or Ci.4alkyl and q is 0-2.
(68) R6 is selected from H and d.6alkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; R16 is selected from halo (particularly fluoro),
Figure imgf000051_0001
cyclopropyl-X8-, phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is selected from imidazolidinyl, azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and heteroaryl-X10-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent; and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or
Figure imgf000051_0002
and q is 0-2 (particularly X8, X9 and X10 are each a direct bond).
(69) R6 is selected from H and Ci-6alkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; R16 is selected from halo (particularly fluoro), Ci^alkoxy, NN-(C Malkyl^amino, cyclopropyl-X8-, phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is selected from imidazolidinyl, pyrrolidinyl, morpholinyl and piperazinyl, and heteroaryl-X10-, wherein said heteroaryl is pyridyl, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent; and
X8, X9 and X10 are each a direct bond. (70) R6 is selected from H,
Figure imgf000051_0003
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
Figure imgf000051_0004
cyclopentyl-Ci-4alkyl, cyclohexyl-Ci-4alkyl,
Figure imgf000051_0005
pyrrolidinyl-CMalkyl,
Figure imgf000051_0006
and piperazinyl-Ci^alkyl, wherein R6 may be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, Ci_4alkyl, Ci-4alkoxy, N-(Ci_4alkyl)amino and NN-(Ci galley l)2amino, and wherein any -NH- in a azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperidinyl or piperazinyl group in R6 is optionally substituted by
Figure imgf000052_0001
and wherein any azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperidinyl or piperazinyl group in R6 optionally bears 1 oxo substituent. (71) R6 is selected from H, Ci-βalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
Figure imgf000052_0002
cyclohexyl-CMalkyl,
Figure imgf000052_0003
piperidinyl-Ci-4alkyl,
Figure imgf000052_0004
and pyridinyl-Ci.
4alkyl, wherein R may be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, Ci_4alkyl, C^alkoxy, N-(Ci.4alkyl)amino and
N, N-(C i -4alky l)2amino, and wherein any -NH- in a azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolidinyl, piperidinyl or piperazinyl group in R6 is optionally substituted by
Figure imgf000052_0005
and wherein any azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperidinyl or piperazinyl group in R6 optionally bears 1 oxo substituent.
(72) R6 is selected from H, Ci-βalkyl,
Figure imgf000052_0006
phenyl-Ci.4alkyl, pyrrolidinyl-Ci.4alkyl, morpholinyl-Ci-4alkyl, imidazolidinyl-Ci^alkyl, piperazinyl- C1-4alkyl and
Figure imgf000052_0007
wherein R6 may be optionally substituted on carbon by one or more substituents selected from halo, Ci^alkoxy and NN-(Ci-4alkyl)2amino, and wherein any pyrrolidinyl, morpholinyl, imidazolidinyl or piperazinyl group in R6 optionally bears 1 oxo substituent.
(73) R6 is selected from H, methyl, ethyl, 3-methoxypropyl, 2-phenylethyl, 2- piperazin-1-ylethyl, 2,2-difluoroethyl, 3-methylbutyl, propyl, benzyl, cyclopropylmethyl, 2-pyrrolidin-l-ylethyl, 2-(dimethylamino)-2-methylpropyl, 3-(dimethylamino)propyl, 2- moφholin-4-ylethyl, 2-pyridin-4-ylethyl, 2-pyridin-3-ylethyl, 3-pyridin-3-ylpropyl, 2-(2- oxoimidazolidin-l-yl)ethyl and 2-(2-oxopyrrolidin-l-yl)ethyl.
(74) R6 is selected from H and
Figure imgf000052_0008
For example R6 is selected from H, methyl or ethyl, particularly R6 is H or methyl.
(75) R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto,
Figure imgf000052_0009
C2-6alkenyl, C2-6alkynyl,
Figure imgf000052_0010
Ci_6alkylS(O)a wherein a is 0 to 2, wherein R7 may be optionally substituted on carbon by one or more R15;
R15 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci-βalkyl, C2-6alkenyl, C2_6alkynyl,
Figure imgf000053_0001
Figure imgf000053_0002
N-(Ci-6alkyl)amino, NN-(Ci-6alkyl)2amino, Ci-όalkanoylamino, N-(Ci-6alkyl)carbamoyl, NN-(Ci.6alkyl)2carbamoyl, C l-βalky IS(O)3 wherein a is 0 to 2, Ci-βalkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl, NN-(C i,6alkyl)2sulfamoyl, Ci.6alkylsulfonylamino, Cs.γcycloalkyl-X8-, aryl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R15 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R15 may optionally bear 1 or 2 oxo substituents, and wherein any aryl or heteroaryl group within R15 may optionally bear a Ci- 3alkylenedioxy group; R19 is selected from
Figure imgf000053_0003
Ci-6alkanoyl,
Figure imgf000053_0004
Ci_6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(Ci _6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R19 may be optionally substituted on carbon by one or more R20;
R18 is selected from halo, hydroxy, amino, Ci-4alkyl, Ci-4alkoxy, N-(Ci- 4alkyl)amino and NN-(C i -4alkyl)2amino;
R20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino; and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)q-, -SO2N(R24)- or -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000053_0005
and q is 0-2. (76) R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C^alkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci.6alkylS(0)a wherein a is 0 to 2, wherein R7 may be optionally substituted on carbon by one or more R15;
R15 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, Ci^aUcoxy, Ci_6alkanoyl,
Figure imgf000053_0006
N-(Ci-6alkyl)amino, NN-(Ci-6alkyl)2amino, Ci-6alkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(Ci-6alkyi)2carbamoyl, C].6alkylS(0)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl, NN-(Ci.6alkyl)2Sulfamoyl, Ci_6alkylsulfonylamino, Ca.ycycloalkyl-X8-, aryl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R15 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R!5 may optionally bear 1 or 2 oxo substituents, and wherein any aryl or heteroaryl group within R15 may optionally bear a Ci- 3alkylenedioxy group; R19 is selected from
Figure imgf000054_0001
Ci-βalkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl, N1N-(C i.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R19 may be optionally substituted on carbon by one or more R20;
R18 is selected from halo, hydroxy, amino,
Figure imgf000054_0002
Ci-4alkoxy, N-(Ci- 4alkyl)amino and NN-(Ci-4alkyl)2amino;
R20 is selected from halo, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino; and
X8, X9 and X10 are independently selected from -O-, -N(R21)- or -S(O)q-; wherein R21 is selected from hydrogen and Ci^alkyl and q is 0-2. (77) R7 is selected from H, halo, hydroxy, mercapto, Chalky., C2-4alkenyl, C2-4alkynyl, and Ci-4alkyl-S-, wherein R7 may be optionally substituted on carbon by one or more R15;
R15 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000054_0003
C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, Ci -4alkanoy 1, C i -4alkanoy loxy, N-(Ci -4alkyl)amino, N, N-(C i ^alky l)2amino,
Ci_4alkanoylamino, N-(Ci-4alkyl)carbamoyl, N,N-(Ci.4alkyl)2carbamoyl, Chalky IS(O)3 wherein a is 0 to 2, CMalkoxycarbonyl, N-(CMalkyl)sulfamoyl, NN-(C] ^alkyl^sulfamoyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a heteroaryl selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and a heterocyclyl selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and wherein R15 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; and wherein any heterocyclyl group within R15 may optionally bear 1 oxo 5 substituent;
R19 is selected from carbamoyl, N-(Ci_6alkyl)carbamoyl, NN-(Ci-6alkyi)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl; and
R18 is selected from halo, hydroxy, amino, Q^alkyl, Ci^alkoxy, N-(Ci- i o 4alkyl)amino and NN-(C i .4alkyl)2amino.
(78) R7 is selected from H, halo, hydroxy, mercapto,
Figure imgf000055_0002
S-, wherein R7 may be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, C^alkoxy, N-(Ci_4alkyl)amino and NN-(Ci.4alkyl)2amino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, 15 pyrrolidinyl, moφholinyl, piperidinyl and piperazinyl, and wherein any -NH- in a azetidinyl, pyrrolidinyl, piperidinyl, moφholinyl, piperidinyl or piperazinyl group in R7 is optionally substituted by Ci-4alkyl, and wherein any azetidinyl, pyrrolidinyl, piperidinyl, moφholinyl, piperidinyl or piperazinyl group in R7 optionally bears 1 oxo substituent.
20 (79) R7 is selected from H, halo, hydroxy, mercapto, Chalky.,
Figure imgf000055_0003
and
Figure imgf000055_0004
S-, wherein R7 may be optionally substituted on carbon by 1 or 2 substituents selected from halo, hydroxy, amino, Ci-4alkyl, Ci^alkoxy, N^CMalkytyamino and NN-(C i-4alkyl)2amino.
(80) R7 is selected from H, halo,
Figure imgf000055_0006
and
Figure imgf000055_0005
(particularly H, halo and
Figure imgf000055_0007
(81) R7 is selected from H, chloro, methyl and methylthio (particularly H, chloro and methyl, more particularly H and chloro).
(82) R7 is selected from H, halo and
Figure imgf000055_0008
For example, R7 is H, fluoro, chloro, bromo, methyl or ethyl, particularly R7 is H or methyl.
30 (83) R7 is H or halo (particularly R7 is halo such as chloro or bromo, more particularly chloro. Alternatively R7 is H). (84) A is CR10R1 ', wherein R10 is H and R1 ' is selected from H or C,-6alkyl, wherein R1 ' may be optionally substituted on carbon by one or more R13;
R13 is selected from nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, C^aHcyl, C2-4alkenyl, C2-4alkynyl, CMalkanoyl,
Figure imgf000056_0001
N-(CMalkyl)amino, N,N-(Ci-4alkyl)2amino,
Figure imgf000056_0002
N-(Ci-4alkyl)carbamoyl, N,N-(Ci.4alkyl)2carbamoyl, Chalky IS(O)3 wherein a is 0 to 2,
Figure imgf000056_0003
N-(Ci-4alkyl)sulfamoyl, NN-(Ci.4alkyl)2Sulfamoyl, C3-7cycloalkyl-X8-, phenyl-X8-, pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9-, piperidinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R18 is selected from halo, hydroxy, amino, trifluoromethoxy, C^alkyl (which Ci- 4alkyl is optionally substituted by fluoro),
Figure imgf000056_0004
N-(Ci-4alkyl)amino, N,N-(CMalkyl)2amino, Chalky IS(O)3 wherein a is 0 to 2, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, piperazinyl, pyrrolidinyl, piperidinyl and morpholinyl; and
R19 is selected from
Figure imgf000056_0005
Ci-4alkylsulfonyl, N-(Ci.4alkyl)carbamoyl and NN-(Ci-4alkyl)2carbamoyl. (85) A is CR10R1 1, wherein R10 is H and R1 1 is selected from H, C,.6alkyl, C3- 7cycloalkyl-X2-, phenyl-X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein said C3-7cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-, wherein R22 is hydrogen or C1-4alkyl; wherein R1 ' may be optionally substituted on carbon by one or more R13; R13 is selected from nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000057_0001
C2-4alkenyl, C2_4alkynyl,
Figure imgf000057_0002
Ci-4alkanoyloxy, N-(Ci-4alkyl)amino, NN-(Ci.4alkyi)2amino, Ci-4alkanoylamino,
Figure imgf000057_0003
Chalky IS(O)3 wherein a is 0 to 2,
Figure imgf000057_0004
NN-(Ci -4alkyl)2sulfamoyl, C3-7cycloalkyl-X8-, phenyl-X8-, pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9-, piperidinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R may be optionally substituted on carbon by one or more R , and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R18 is selected from halo, hydroxy, amino, trifluoromethoxy,
Figure imgf000057_0005
(which Ci- 4alkyl is optionally substituted by fluoro), Ci-4alkoxy, N-(Ci-4alkyl)amino, NN-(Ci-4alkyl)2amino, Ci_4alkylS(O)a wherein a is 0 to 2, N-(Ci-4alkyl)carbamoyl, NN-(C|-4alkyl)2carbamoyl, piperazinyl, pyrrolidinyl, piperidinyl and morpholinyl; and
R19 is selected from
Figure imgf000057_0006
Ci-4alkylsulfonyl, N-(Ci-4alkyl)carbamoyl and NN-(Ci-4alkyl)2carbamoyl. (86) R6 is selected from H, Ci-βalkyl and C2-6alkynyl (particularly H and Ci.6alkyl), and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ; wherein R16 is selected from fluoro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000057_0007
N-(Ci_4alkyl)amino, NN-(Ci.4alkyl)2amino, Ci_4alkanoylamino,
Figure imgf000057_0008
NN-(C i_4alkyl)2carbamoyl, Ci.4alkylS(O)a wherein a is 0 to 2, CMalkoxycarbonyl, iV-(C|-4alkyl)sulfamoyl, NN-(C Malkyl)2sulfamoyl, C3.7cycloalkyl-X8-, phenyl-X8-, pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9-, piperidinyl-X9- and morpholinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R16 is optionally substituted with one or more R18; wherein R18 is selected from halo, hydroxy, amino, trifluoromethoxy, Ci-4alkyl (which Ci.4alkyl is optionally substituted by fluoro), Ci_4alkoxy, N-(Ci-4alkyl)amino and N,N-(Ci-4alkyl)2amino; and wherein R17 is selected from Ci.4alkyl,
Figure imgf000058_0001
Ci_4alkylsulfonyl, N-(Ci-4alkyl)carbamoyl and N,N-(Ci-4alkyl)2carbamoyl.
(87) R6 is selected from H, C!-6alkyl, Cs.ycycloalkyl-X5- , phenyl-X5-, heterocyclyl-X6- and heteroaryl-X7-, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, and wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and wherein X5, X6 and X7 are each independently selected from a direct bond or - Ν(R12)C(0)-, wherein R12 is hydrogen or CMalky, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; wherein R16 is selected from fluoro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000058_0002
Ci_4alkanoyloxy, N-(Ci-4alkyl)amino, NN-(C i-4alkyi)2amino, CMalkanoylamino,
Figure imgf000058_0003
NN-(Ci-4alkyi)2carbamoyl,
Figure imgf000058_0004
wherein a is 0 to 2, CMalkoxycarbonyl, N-(C1-4alkyl)sulfamoyl,
Figure imgf000058_0005
C3-7cycloalkyl-X8-, phenyl-X8-, pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9-, piperidinyl-X9- and morpholinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R16 is optionally substituted with one or more R18; wherein R18 is selected from halo, hydroxy, amino, trifluoromethoxy, Ci-4alkyl (which is optionally substituted by fluoro),
Figure imgf000058_0006
and N,N-(Ci-4alkyl)2amino; and
R17 is selected from
Figure imgf000058_0007
Ci-4alkylsulfonyl, N-(CMalkyl)carbamoyl and NN-(Ci-4alkyl)2carbamoyl.
In an embodiment of the invention there is provided a compound of the formula 1 which is of the formula IA:
Figure imgf000059_0001
IA wherein R4, R5, R6, R7, R10 and R1 1 have any of the meanings defined hereinbefore or hereinafter; R1 is selected from H, halo, Ci-3alkyl and Ci-3alkoxy (for example R1 is H, halo or
Cioalkyl, particularly, R1 is methyl, chloro or bromo);
R2 is selected from halo,
Figure imgf000059_0002
and
Figure imgf000059_0003
(for example R1 is selected from chloro, bromo, iodo, methyl and methoxy); and
R3 is selected from H, halo and Ci-3-alkyl; or an N-oxide thereof; or a pharmaceutically acceptable salt thereof.
In another embodiment of the invention there is provided a compound of the formula I which is of the formula IB:
Figure imgf000059_0004
IB wherein R4, R5, R6, R7, R10 and R1 1 have any of the meanings defined hereinbefore or hereinafter; or a pharmaceutically acceptable salt thereof. In one embodiment of the invention there is provided a compound of the formula 1 or formula IA or formula IB as hereinbefore defined wherein:
R4 is H;
R5 is H or
Figure imgf000060_0001
or R4 and R5 together form oxo (for example R4 is H, R5 is H or methyl, or R4 and R5 together form oxo);
R6 is selected from H, CMalkyl, C2-4alkenyl,
Figure imgf000060_0002
Figure imgf000060_0004
carbamoyl,
Figure imgf000060_0003
and NN-(Ci -4alkyl)2carbamoyl
(for example R6 is H or
Figure imgf000060_0005
R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, C).4alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000060_0006
wherein a is 0 to 2 (for example R7 is selected from
H, halo, hydroxy,
Figure imgf000060_0007
and
Figure imgf000060_0008
particularly R7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R7 is selected from H, chloro and bromo);
A in the compound of the formula I is CR10R1 1;
R10 in the compounds of the formulae I and IA is H; R1Sn the compounds of the formulae I and IA is selected from H, cyano, carboxy, carbamoyl, sulfamoyl, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkanoyl,
N-(C i -6alkyi)carbamoyl, NN-(C i .6alkyl)2carbamoyl, N-(C i -4alkoxy)carbamoyl,
N-(Ci-4alkyl)-N-(Ci-4alkoxy)carbamoyl, Ci.6alkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl,
NN-(C].6alkyl)2sulfamoyl, Ci-βalkylsulfonylaminocarbonyl, carbocyclyl-X2-, heterocyclyl-X3- or heteroaryl-X4-, wherein R11 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R1 ' may optionally bear a
Figure imgf000060_0009
group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido, Ci.6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Cι-6alkanoyl, Ci-όalkanoyloxy, N-(Ci-6alkyl)amino,
NN-(Ci -6alky l)2amino, C i ^alkanoy lamino, N-(C i -βalky l)carbamoy 1,
NN-(C,-6alkyl)2carbamoyl, N'-(C1.6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido, N,N',N-(Ci-6alkyl)3ureido, Ci.6alkylS(O)a wherein a is 0 to 2, Ci-6alkoxycarbonyl, N-(C].6alkyl)sulfamoyl, N,N-(Ci-6alkyl)2Sulfamoyl, Ci-βalkylsulfonylamino, carbocyc IyI-X8-, heterocyc IyI-X9- or heteroaryl-X10-, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any carbocyc IyI, heterocyclyl or heteroaryl group within R13 may optionally bear a
Figure imgf000061_0001
group;
R14 and R19 are independently selected from
Figure imgf000061_0002
Ci_6alkanoyl, Ci-βalkylsulfonyl, Ci.6alkoxycarbonyl, carbamoyl, N-(Ci.6alkyi)carbamoyl, N,N-(Ci_6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14 may be optionally substituted on carbon by one or more R20; X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or
Figure imgf000061_0003
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)q-, -SO2N(R24)- or -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000061_0004
and q is 0-2; R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000061_0005
Figure imgf000061_0006
N-(Ci_6alkyl)amino, N,N-(Ci-6alkyl)2amino, Ci_6alkanoylamino, N-(Ci-6alkyl)carbamoyl, N,N-(Ci.6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2, Ci-6alkoxycarbonyl,
Figure imgf000061_0007
N,N-(Ci-6alkyl)2sulfamoyl, Ci-όalkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R18 may optionally bear a
Figure imgf000061_0008
group; R26 is selected from
Figure imgf000062_0001
Ci-6alkanoyl, Ci-βalkylsulfonyl,
Figure imgf000062_0002
carbamoyl, N-(Ci.6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and R20, R25 and R27 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, NN-dimethylsulfamoyl, N,N-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof. In this embodiment particular values for R11 include, for example any of those described in paragraphs (40) to (50), (84) and (85) described hereinbefore.
In another embodiment of the invention there is provided a compound of the formula I or formula IA of formula IB as hereinbefore defined wherein: A in the compound of the formula I is CR10R11; R10 in the compounds of the formulae I, IA and IB is H;
R11 in the compounds of the formulae I, IA and IB is H or Ci-4alkyl, or R10 and R11 together form oxo;
R6 is selected from H,
Figure imgf000062_0003
C2-4alkenyl, Ci_4alkanoyl,
Figure imgf000062_0004
Ci_4alkoxycarbonyl, carbamoyl, N-(C|-4alkyl)carbamoyl and N,N-(Ci-4alkyl)2carbamoyl (for example R6 is H or C^aUcyl);
R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto,
Figure imgf000062_0005
C2-4alkenyl, C2-4alkynyl,
Figure imgf000062_0006
Ci_4alkylS(O)a wherein a is 0 to 2 (for example R7 is selected from H, halo, hydroxy, Ci.4alkyl and
Figure imgf000062_0007
particularly R7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R7 is selected from H, chloro and bromo); R4 is H;
R5 is selected from H, cyano, carboxy, carbamoyl, sulfamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkanoyl, N-(Ci.6alkyl)carbamoyl, N,N-(Ci.6alkyi)2carbamoyl, N-(C i _4alkoxy)carbamoyl, N-(C i -4alkyl)-N-(C i ^alkoxy)carbamoyl, C i -6alkoxycarbonyl, N-(Ci.6alkyl)sulfamoyl, NN-(Ci-6alkyl)2sulfamoyl, Ci-ealkylsulfonylaminocarbonyl, carbocyclyl-X2-, heterocyclyl-X3- or heteroaryl-X4-, wherein R5 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R5 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R5 may optionally bear a
Figure imgf000063_0001
group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido,
Figure imgf000063_0002
C2-6alkenyl, C2-6alkynyl, Ci-βalkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Ci-6alkanoyl,
Figure imgf000063_0003
N-(Ci-6alkyl)amino, NN-(C i-6alkyl)2amino, C i .βalkanoylamino, N-(C i .6alkyl)carbamoyl, NN-(Ci-6alkyl)2carbamoyl, N'-(d.6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido,
N,N',N'-(Ci-6alkyl)3ureido, Ci-6alkylS(O)a wherein a is 0 to 2, Ci-όalkoxycarbonyl, N-(Ci-6alkyl)sulfamoyl, N,N-(Ci-6alkyl)2sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 or 2 oxo or thioxo substituents, and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R13 may optionally bear a C^alkylenedioxy group;
R14 and R19 are independently selected from Ci-6alkyl, Ci_6alkanoyl, Ci-6alkylsulfonyl, Ci.6alkoxycarbonyl, carbamoyl, N-(C|-6alkyl)carbamoyl, NN-(Ci_6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14 may be optionally substituted on carbon by one or more R20; X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or Ci^alkyl; X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O),-, -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or Ci-4alkyl and q is 0-2; R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000064_0001
C2-6alkenyl, C2-6alkynyl, Ci-βalkoxy, Ci-βalkanoyl, Ci_6alkanoyloxy, N-(Ci_6alkyl)amino, N,N-(Ci.6alkyl)2amino, Ci-βalkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(Ci -6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl, N,N-(C].6alkyl)2Sulfamoyl, Ci.6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R18 may optionally bear a Ci_3alkylenedioxy group;
R26 is selected from
Figure imgf000064_0002
Ci-6alkanoyl,
Figure imgf000064_0003
Ci-όalkoxycarbonyl, carbamoyl, N-(C].6alkyl)carbamoyl, NN-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and
R20, R25 and R27 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, NN-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof.
In this embodiment particular values for R5 include, for example any of those described in paragraphs (54) to (61) described hereinbefore. In another embodiment of the invention there is provided a compound of the formula I, formula IA or formula IB as hereinbefore defined wherein: R4 and R5 are independently H or
Figure imgf000065_0001
or R4 and R5 together form oxo (for example R4 is H, R5 is Ci-4alkyl such as methyl, or R4 and R5 together form oxo); A in the compound of the formula I is CR10R1 ' ;
R10 in the compounds of the formulae I, IA and IB is H;
R11 in the compounds of the formulae I, IA and IB is H or Ci.4alkyl;
R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto,
Figure imgf000065_0002
C2-4alkenyl,
C2-4alkynyl,
Figure imgf000065_0003
Ci-4alkylS(O)a wherein a is 0 to 2 (for example R7 is selected from H, halo, hydroxy,
Figure imgf000065_0004
and Ci-4alkoxy, particularly R7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R7 is selected from H, chloro and bromo); R6 is selected from H,
Figure imgf000065_0005
Figure imgf000065_0006
carbamoyl, N-(Ci_6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, carbocyclyl-X5-, heterocyclyl-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-,
-Ν(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or Ci-4alkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R6 may optionally bear a
Figure imgf000065_0007
group; R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, ureido,
Figure imgf000065_0008
C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, C2-6alkenyloxy, C2.6alkynyloxy,
Figure imgf000065_0009
Ci-6alkanoyloxy, N-(Ci-6alkyl)amino, N1N-(C i -6alkyl)2amino, C i -6alkanoylamino, N-(C i _6alkyl)carbamoyl, N,N-(Ci.6alkyl)2carbamoyl, N'-(Ci-6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido, N,N',N'-(Ci-6alkyl)3ureido, Ci-6alkylS(O)a wherein a is 0 to 2, Ci-6alkoxycarbonyl, N-(C|.6alkyl)sulfamoyl, N,N-(Ci.6alkyl)2Sulfamoyl, Ci.6alkylsulfonylamino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R16 may optionally bear a
Figure imgf000066_0001
group;
R17 and R19 are independently selected from Ci-βalkyl, Ci-6alkanoyl,
Figure imgf000066_0002
Ci-βalkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R17 may be optionally substituted on carbon by one or more R20;
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)q-, -SO2N(R24)- or -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or Ci-4alkyl and q is 0-2; R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000066_0003
Ci-βalkanoyl, Ci-6alkanoyloxy, N-(Ci-6alkyl)amino, N,N-(Ci-6alkyl)2amino, Ci.6alkanoylamino, N-(Ci-6alkyl)carbamoyl, N N-(C i^alky ^carbamoyl, C i-6alky IS(O)3 wherein a is 0 to 2, Ci_6alkoxycarbonyl, N-(Ci-6alkyl)sulfamoyl, NN-(Ci.6alkyl)2Sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; R26 is selected from
Figure imgf000066_0004
Ci_6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl,
Figure imgf000066_0005
benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl,
N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl,
N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof.
In this embodiment particular values for R6 include, for example any of those described in paragraphs (62) to (74), (86) and (87) described hereinbefore.
In one embodiment there is provided a compound of the formula I, IA or IB, wherein A is CR10R11 and R10 is hydrogen, which is a compound selected from a compound of the formula I*, IA* and IB*, or a pharmaceutically acceptable salt or an Ν- oxide thereof:
Figure imgf000067_0001
I* IA* IB* wherein R1, R2, R3, R4, R5, R6, R7, R11 and p are as hereinbefore in relation to compounds of the formulae I, IA and IB respectively. Particular compounds of the formula I, IA or IB are those wherein R11 is hydrogen or Ci-4alkyl (particularly R11 is Ci- 4alkyl).
In another embodiment are compounds of the formula I*, IA* or IB* wherein R7 is chloro. For example those compounds wherein R7 is chloro and R1 ' is hydrogen or Ci- 4alkyl, wherein R11 is optionally substituted on carbon by one or more R13 selected from halo, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000067_0002
Figure imgf000067_0003
N,N-(Ci-4alkyl)2carbamoyl, Ci-4alkoxycarbonyl, C i-4alky IS(O)3 wherein a is 0 to 2, N-(Ci-6alkyl)sulfamoyl, N,N-(Ci-4alkyl)2Sulfamoyl,
Figure imgf000067_0004
phenyl, pyridyl or pyrimidinyl. More particularly those compounds wherein R7 is chloro and R1 ' is selected from hydrogen and
Figure imgf000068_0001
(for example R1 1 is
Figure imgf000068_0002
In another embodiment of the invention there is provided a compound of the formula I, formula IA or formula IB as hereinbefore defined wherein: R4 and R5 are independently H or Ci-4alkyl or R4 and R5 together form oxo (for example
R4 is H, R5 is Ci-4alkyl such as methyl, or R4 and R5 together form oxo);
A in the compound of the formula I is CR10R1 ';
R10 in the compounds of the formulae I, IA and IB is H;
R11 in the compounds of the formulae I, IA and IB is H or Ci-4alkyl, wherein R11 is optionally substituted on carbon by one or more R13 selected from halo, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_4alkoxy, N-(Ci_4alkyl)amino,
N,N-(Ci-4alkyl)2amino, CMalkanoylamino, N-(Ci-4alkyl)carbamoyl,
NN-(Ci-4alkyl)2carbamoyl, Ci_4alkoxycarbonyl, Chalky IS(O)3 wherein a is 0 to 2,
N-(Ci_6alkyl)sulfamoyl, N,N-(Ci-4alkyl)2Sulfamoyl, Ci-4alkylsulfonylamino, phenyl, pyridyl or pyrimidinyl (particularly R11 is H or
Figure imgf000068_0003
R6 is selected from H, Ci^alkyl, C2-4alkenyl, Ci-4alkanoyl, Ci_4alkylsulfonyl,
Ci-4alkoxycarbonyl, carbamoyl, N-(Ci-4alkyl)carbamoyl and N,N-(Ci_4alkyl)2carbamoyl
(for example R6 is H or Ci^alkyl); and
R7 is selected from H, halo and
Figure imgf000068_0004
(for example R7 is selected from H, halo, hydroxy,
Figure imgf000068_0005
particularly R7 is selected from H, halo, methyl, ethyl, and methoxy, more particularly R7 is selected from H, chloro and bromo); or a pharmaceutically acceptable salt thereof.
In another embodiment of the invention there is provided a compound of the formula I, formula IA or formula IB as hereinbefore defined wherein when A is CR10R11, R10 and R1 ' together do not form an oxo group.
In an embodiment of the invention there is provided a compound of the formula I which is of the formula IC:
Figure imgf000069_0001
1C wherein:
R1, R2 and R3 are independently selected from halo, cyano, nitro or a group of the formula:
-X1 -R8, wherein X1 is a direct bond, O or S and R8 is Ci-4alkyl, p is 1 or 2;
Figure imgf000069_0002
1; R4 and R10 are independently selected from H and
R5 is selected from H, cyano, carboxy, carbamoyl,
Figure imgf000069_0003
C2-4alkenyl, C2-4alkynyl, Ci.4alkanoyl and
Figure imgf000069_0004
R11 is selected from H, cyano, carboxy, carbamoyl, Chalky!, C2-6alkenyl, C2-6alkynyl, Ci-βalkanoyl, N-(Ci-6alkyi)carbamoyl, NN-(C i.6alkyl)2carbamoyl, N-(C i -4alkoxy)carbamoyl, N-(C i -4alkyl)-N-(C i .4alkoxy)carbamoyl, C i -βalkoxycarbonyl, Ci-oalkylsulfonylaminocarbonyl, carbocyc IyI-X2-, heterocyc IyI-X3- or heteroaryl-X4-, wherein R1 ' is optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R may optionally bear 1 or 2 oxo or thioxo substituents; or R4 and R5 together form oxo (=0); or R10 and R11 together form oxo (=0); R6 is selected from H, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkanoyl, Ci.6alkylsulfonyl, Ci_6alkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl, NN-(C i.6alkyl)2carbamoyl, carbocyclyl-X5-, heterocyclyl-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-, -Ν(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or C^alkyl, and wherein R is optionally substituted on carbon by one or more R ; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 or 2 oxo or thioxo substituents;
R7 is selected from H, halo, Ci-4alkyl and Ci-4alkylS(O)a wherein a is 0,
R13 and R16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Ci-βalkanoyl, Q-όalkanoyloxy, N-(C].6alkyl)amino, NN-(Ci.6alkyl)2amino, C i -βalkanoylamino, N-(C i-6alkyl)carbamoyl, NN-(C i -6alkyl)2carbamoyl, N'-(C1-6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido, N,N',N'-(C,.6alkyl)3ureido, C,-6alkylS(O)a wherein a is 0 to 2,
Figure imgf000070_0001
N-(Ci.6alkyl)sulfamoyl, NN-(Ci-6alkyl)2sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13 and R16 may be optionally substituted on carbon by one or more
R 18 and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 and R16 may optionally bear 1 or 2 oxo or thioxo substituents;
R14, R17 and R19 are independently selected from
Figure imgf000070_0002
Ci_6alkylsulfonyl, Ci-6alkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14, R17 and R19 independently of each other may be optionally substituted on carbon by one or more R20;
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or Ci-4alkyl; X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O),-, -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000071_0001
and q is 0-2; R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000071_0002
Ci-βalkanoyl, Ci_6alkanoyloxy, N-(Ci-6alkyl)amino,
Figure imgf000071_0003
Ci-6alkanoylamino, N-(Ci.6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2, Ci-βalkoxycarbonyl,
Figure imgf000071_0004
Ci-6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R1 may optionally bear 1 or 2 oxo or thioxo substituents; R26 is selected from Chalky.,
Figure imgf000071_0005
Ci-βalkylsulfonyl,
Figure imgf000071_0006
carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and
R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, NN-dimethylsulfamoyl, NN-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof.
In particular, in the compounds of formula IC, R1, R2 and R3 are independently selected from bromo, cyano, nitro, methyl, methoxy and methylthio. More particularly, in the compounds of formula IC, R1, R2 and R3 are independently selected from methyl and methoxy and p is 1. In particular, in the compounds of formula IC, R4 and R5 are both H or R4 and R5 together form oxo (=O).
In particular, in the compounds of formula IC, R7 is selected from H, chloro, methyl and methylthio, more particularly H and chloro, and even more particularly R7 is chloro.
In one embodiment there is provided a compound of the formula IC of the formula IC*, or a pharmaceutically acceptable salt or an N-oxide thereof:
Figure imgf000072_0001
IC* wherein R1, R2, R3, R6, R7, R1 ' and p are as hereinbefore defined in relation to a compound of the formula lC.
Particular compounds of the formula IC* are those wherein R1 1 is H or Ci^alkyl, wherein R1 1 is optionally substituted on carbon by one or more R13 selected from halo, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000072_0002
N-(Ci-4alkyl)amino, NN-(Ci _4alkyl)2amino,
Figure imgf000072_0003
NN-(Ci-4alkyl)2carbamoyl, Ci_4alkoxycarbonyl,
Figure imgf000072_0004
wherein a is 0 to 2, N-(Ci.6alkyl)sulfamoyl, NN-(Ci-4alkyl)2sulfamoyl, CMalkylsulfonylamino, phenyl, pyridyl or pyrimidinyl. More particularly R1 1 is selected from H and Ci.4alkyl. Other particular compounds of the formula IC* are those wherein R7 is chloro. For example compounds of the formula IC * wherein R7 is chloro and R11 is selected from H and (For example R1 1 is methyl. Alternatively R11 is hydrogen).
In an embodiment of the invention there is provided a compound of the formula I which is of the formula ID:
Figure imgf000073_0001
ID wherein:
R3 is selected from halo, cyano, nitro or i i group of the formula:
-X '-R8, wherein X1 is a direct bond, O or S and R8 is Ci-4alkyl, p is 1 or 2;
Figure imgf000073_0002
1;
R4 and R5 are both H, or R4 and R5 together form oxo (=0); R10 is H;
R11 is selected from H, cyano, carboxy, carbamoyl, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000073_0003
N-(Ci_6alkyl)carbamoyl, NN-(Ci-6alkyl)2carbamoyl, N-(C i -4alkoxy)carbamoyl, N-(C i ^alky I)-N-(C i -4alkoxy)carbamoyl, C i .βalkoxycarbonyl, Ci-oalkylsulfonylaminocarbonyl, carbocyc IyI-X2-, heterocyc IyI-X3- or heteroaryl-X4-, wherein R1 ' is optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R1 ' may optionally bear a
Figure imgf000073_0004
group;
R6 is selected from H, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkanoyl, Ci-6alkylsulfonyl, Ci-6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, N,N-(Ci.6alkyl)2carbamoyl, carbocyc IyI-X5-, heterocyclyl-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-, -N(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or CMalkyl, and wherein R6 is optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R6 may optionally bear a
Figure imgf000074_0001
group R7 is selected from H, halo,
Figure imgf000074_0002
and
Figure imgf000074_0003
wherein a is 1,
R13 and R16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, C].6alkyl, C2.6alkenyl, C2-6alkynyl, Ci-6alkoxy, C2-6alkenyloxy, C2-6alkynyloxy,
Figure imgf000074_0004
N-(Ci_6alkyl)amino, N,N-(Ci-6alkyl)2amino, Ci-βalkanoylamino, N-(Ci_6alkyl)carbamoyl, N,N-(Ci_6alkyl)2carbamoyl,
N'-(Ci-6alkyl)ureido, N',N'-(Ci.6alkyl)2ureido, N,N',N'-(Ci-6alkyl)3ureido, Ci-6alkylS(O)a wherein a is 0 to 2, Ci-βalkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl, N,N-(Ci.6alkyl)2Sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13 and R16 may be optionally substituted on carbon by one or more
R 18 and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 and R16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R13 and R16 may optionally bear a Ci-3alkylenedioxy group;
R14, R17 and R19 are independently selected from
Figure imgf000074_0005
Ci_6alkanoyl, Ci-6alkylsulfonyl, Ci-όalkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14, R17 and R19 independently of each other may be optionally substituted on carbon by one or more R20; X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -N(R22)C(O)-; wherein R22 is hydrogen or CMalkyl;
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)q-, -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or C]-4alkyl and q is 0-2;
R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci_6alkyl, C2_6alkenyl, C2-6alkynyl, C!-6alkoxy, Ci-6alkanoyl, Ci.6alkanoyloxy, N-(Ci.6alkyl)amino, N1N-(C i.6alkyl)2amino, Ci_6alkanoylamino, N-(Ci-6alkyl)carbamoyl, NN-(Ci-6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2, Ci.6alkoxycarbonyl, N-(Ci-6alkyl)sulfamoyl, N,N-(Ci-6alkyl)2sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R18 may optionally bear a
Figure imgf000075_0001
group;
R26 is selected from Ci-ealkyl,
Figure imgf000075_0002
Ci-βalkylsulfonyl, Ci_6alkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, NN-(C i.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and
R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof. In particular, in the compounds of formula ID, R3 is -X'-R8 wherein X is O and R8 is Ci-4alkyl (more particularly R3 is methoxy) and p is 1.
In particular, in the compounds of formula ID, R7 is selected from H, chloro, methyl and methylthio. Particularly R7 is chloro.
In one embodiment there is provided a compound of the formula ID of the formula ID*, or a pharmaceutically acceptable salt or an N-oxide thereof:
Figure imgf000076_0001
ID* wherein R3, R6, R7, R1 ' and p are as hereinbefore defined in relation to a compound of the formula ID.
Particular compounds of the formula ID* are those wherein R1 1 is selected from H and wherein R11 is optionally substituted on carbon by one or more R13 selected from halo, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000076_0002
Ci_4alkanoyl,
Figure imgf000076_0003
NN-(C i-4alkyl)2amino, Ci-4alkanoylamino, N-(Ci-4alkyl)carbamoyl, NN-(Ci-4alkyl)2carbamoyl, Ci-4alkylS(0)a wherein a is 0 to 2, CMalkoxycarbonyl, N-(Ci_4alkyl)sulfamoyl, NN-(C i-4alkyl)2sulfamoyl, CMalkylsulfonylamino, phenyl, pyridyl and pyrimidinyl. Particularly R11 is selected from hydrogen and
Figure imgf000076_0004
Other particular compounds of the formula ID* are those wherein R7 is chloro. For example compounds of the formula ID* wherein R7 is chloro and R1 ' is selected from H and Ci-4alkyl (For example R1 1 is methyl. Alternatively R1 1 is H).
In an embodiment of the invention there is provided a compound of the formula I which is of the formula IE:
Figure imgf000077_0001
IE wherein:
A Is CR10R1 1; R4 and R5 are both H, or R4 and R5 together form oxo (=0);
R10 Is H;
R11 is selected from H, cyano, carboxy, carbamoyl,
Figure imgf000077_0002
C2-6alkenyl, C2-6alkynyl, Ci.6alkanoyl, N-(Ci.6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, N-(C i -4alkoxy)carbamoy 1, N-(C i ^alky I)-N-(C i -4alkoxy)carbamoyl, C i _6alkoxycarbonyl, Ci-βalkylsulfonylaminocarbonyl, carbocyclyl-X2-, heterocyclyl-X3- or heteroaryl-X4-, wherein R1 ' is optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R1 ' may optionally bear a
Figure imgf000077_0003
group;
R6 is selected from H,
Figure imgf000077_0004
C2-6alkenyl, C2-6alkynyl,
Figure imgf000077_0005
Ci-6alkylsulfonyl, Ci-βalkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl, NN-(Ci.6alkyl)2carbamoyl, carbocyclyl-X5-, heterocyclyl-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-, -Ν(RI2)C(O)- and -SO2-; wherein R12 is selected from hydrogen or CMalkyl, and wherein R6 is optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R6 may optionally bear a
Figure imgf000078_0001
group R7 is selected from H, chloro, methyl and methylthio;
R13 and R16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000078_0002
C2-6alkenyloxy, C2-6alkynyloxy, Ci-6alkanoyl, Ci-βalkanoyloxy, N-(Ci.6alkyl)amino, N,N-(Ci-6alkyl)2amino, Ci.6alkanoylamino, N-(Ci_6alkyl)carbamoyl, N1N-(C i.6alkyl)2carbamoyl,
N'-(C,.6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido, N,N',N'-(Ci-6alkyl)3ureido, C1-6alkylS(O)a wherein a is 0 to 2, Ci-βalkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl, NN-(C ].6alkyl)2sulfamoyl,
Figure imgf000078_0003
carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13 and R16 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 and R16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R13 and R16 may optionally bear a
Figure imgf000078_0004
group;
R14, R17 and R19 are independently selected from
Figure imgf000078_0005
Ci_6alkanoyl,
Figure imgf000078_0006
Ci.6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14, R17 and R19 independently of each other may be optionally substituted on carbon by one or more R20;
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or C1-4alkyl;
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O)q-, -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000078_0007
and q is 0-2; R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000079_0001
C2-6alkenyl, C2-6alkynyl,
Figure imgf000079_0002
Ci-6alkanoyl, Ci-βalkanoyloxy, N-(Ci.6alkyl)amino, N,N-(Ci_6alkyl)2amino, Ci-6alkanoylamino, N-(Ci_6alkyl)carbamoyl, N,N-(Ci.6alkyl)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, Ci.6alkoxycarbonyl, N-(C]_6alkyl)sulfamoyl, N,N-(Ci.6alkyl)2Sulfamoyl, Ci.6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R18 may optionally bear a C^alkylenedioxy group;
R26 is selected from
Figure imgf000079_0003
carbamoyl, N-(Ci-6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and
R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfϊnyl, ethylsulfϊnyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof.
In one embodiment there is provided a compound of the formula IE of the formula IE*, or a pharmaceutically acceptable salt or an Ν-oxide thereof:
Figure imgf000080_0001
IE*
Particular compounds of the formula IE* are those wherein R1 1 is selected from H and wherein R1 1 is optionally substituted on carbon by one or more R13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000080_0002
N-(Ci_4alkyl)amino, N1N-(C i_4alkyl)2amino,
Figure imgf000080_0003
NN-(Ci-4alkyl)2carbamoyl, Ci_4alkylS(0)a wherein a is 0 to 2, Ci-4alkoxycarbonyl, N-(Ci- 4alkyl)sulfamoyl, N N-(C i-4alky I)2 sulfamoyl, Ci-4alkylsulfonylamino, phenyl, pyridyl and pyrimidinyl. Particularly R1 ' is selected from H and
Figure imgf000080_0004
Other particular compounds of the formula IE* are those wherein R7 is chloro. For example compounds of the formula IE* wherein R is chloro and R is selected from H and Ci-4alkyl (For example R1 1 is methyl. Alternatively R11 is H).
In an embodiment of the invention there is provided a compound of the formula I which is of the formula IF:
Figure imgf000080_0005
IF wherein: A Is CR10R1 1;
R4 and R5 are both H, or R4 and R5 together form oxo (=0);
R10 Is H;
R11 is selected from H, cyano, carboxy, carbamoyl,
Figure imgf000081_0001
C2-6alkenyl, C2-6alkynyl,
Figure imgf000081_0002
N-(Ci_6alkyl)carbamoyl, N(N-(C].6alkyl)2carbamoyl,
N-(Ci -4alkoxy)carbamoyl, N-(C i ^alky I)-N-(C i _4alkoxy)carbamoy 1, C i -βalkoxycarbony 1, Ci-ealkylsulfonylaminocarbonyl, carbocyclyl-X2-, heterocyclyl-X3- or heteroaryl-X4-, wherein R1 ' is optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R1 ' may optionally bear a
Figure imgf000081_0003
group; R6 is selected from H, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-όalkanoyl,
Ci-6alkylsulfonyl,
Figure imgf000081_0004
carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(Ci-6alkyl)2carbamoyl, carbocyclyl-X5-, heterocyclyl-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-, -Ν(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or
Figure imgf000081_0005
and wherein R6 is optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R6 may optionally bear a
Figure imgf000081_0006
group
R13 and R16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000081_0007
C2-6alkenyloxy, C2-6alkynyloxy, Ci_6alkanoyl, Ci-βalkanoyloxy, N-(Ci.6alkyl)amino, NN-(Ci.6alkyl)2amino, C i _6alkanoylamino, N-(C i .6alkyl)carbamoyl, NN-(C i -6alky ^carbamoyl, N'-(C,-6alkyl)ureido, N'(N'-(Ci-6alkyl)2ureido, N,N',N'-(Ci.6alkyl)3ureido, Ci.6alkylS(O)a wherein a is 0 to 2,
Figure imgf000082_0001
N-(Ci-6alkyl)sulfamoyl, N,N-(C|.6alkyl)2sulfamoyl, Ci.6alkylsulfonylamino, carbocyclyl-X8-, he terocyc IyI-X9- or heteroaryl-X10-, and wherein R13 and R16 may be optionally substituted on carbon by one or more
R 18 and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 and R16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R13 and R16 may optionally bear a
Figure imgf000082_0002
group;
R14, R17 and R19 are independently selected from Ci-6alkyl, d.6alkanoyl, Ci.6alkylsulfonyl, d-βalkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl, NN-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14, R17 and R19 independently of each other may be optionally substituted on carbon by one or more R20;
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or Ci-4alkyl;
X , X and X are independently selected from a direct bond, -O-, -N(R )-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O),-, -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or Ci-4alkyl and q is 0-2;
R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci-βalkyl, C2.6alkenyl, C2-6alkynyl, Ci-βalkoxy, Ci-όalkanoyl,
Figure imgf000082_0003
N-(Ci-6alkyl)amino, N,N-(Ci-6alkyl)2amino, Ci_6alkanoylamino, N-(Ci_6alkyl)carbamoyl, NN-(C i.6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2,
Figure imgf000082_0004
N-(Ci-6alkyl)sulfamoyl, NN-(C] .6alkyl)2sulfamoyl, Ci-6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R18 may optionally bear a Ci_3alkylenedioxy group;
R26 is selected from Ci-6alkyl, Ci-6alkanoyl, Ci.6alkylsulfonyl, Ci-6alkoxycarbonyl, carbamoyl, N-(Ci-6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and
R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, NN-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof.
In one embodiment there is provided a compound of the formula IF of the formula IF*, or a pharmaceutically acceptable salt or an Ν-oxide thereof:
Figure imgf000083_0001
IF* wherein R6 and R1 ' are as hereinbefore defined in relation to a compound of the formula IF.
Particular compounds of the formula IF* are those wherein R1 ' is selected from H and Ci-4alkyl, wherein R11 is optionally substituted on carbon by one or more R13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci-4alkox N-(Ci.4alkyl)amino, NN-(Ci -4alkyl)2amino,
Figure imgf000084_0001
NN-(Ci-4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2, Ci-4alkoxycarbonyl, N-(Ci- 4alkyl)sulfamoyl, NN-(C
Figure imgf000084_0002
phenyl, pyridyl and pyrimidinyl. Particularly R1 1 is selected from H and
Figure imgf000084_0003
In one aspect of the compounds of formula IC, ID, IE and/or IF, R10 is H and R1 1 is selected from H or
Figure imgf000084_0004
wherein R1 1 may be optionally substituted on carbon by one or more R13; R13 is selected from nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000084_0005
C2-4alkenyl, C2-4alkynyl,
Figure imgf000084_0006
NN-(Ci-4alkyl)2amino,
Figure imgf000084_0007
wherein a is 0 to 2, CMalkoxycarbonyl, N-(CMalkyl)sulfamoyl, NN-(C i-4alkyl)2sulfamoyl, C3-7cycloalkyl-X8-, phenyl-X8-, pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9- or piperidinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R18 is selected from halo, hydroxy, amino, trifluoromethoxy,
Figure imgf000084_0008
(which Ci. 4alkyl is optionally substituted by fluoro), Ci-4alkoxy, N-(C]-4alkyl)amino, NN-(Ci-4alkyl)2amino, CMalkylS(O)a wherein a is 0 to 2,
Figure imgf000084_0009
NN-(Ci-4alkyl)2carbamoyl, piperazinyl-, pyrrolidinyl-, piperidinyl- and morpholinyl-,and R19 is selected from
Figure imgf000084_0010
CMalkanoyl,
Figure imgf000084_0011
Figure imgf000084_0012
and NN-(Ci-4alkyl)2carbamoyl.
In another aspect of the compounds of formula IC, ID, IE and/or IF, R10 is H and R1 1 is selected from H, Ci^alkyl, C3-7cycloalkyl-X2-, phenyl-X2-, heterocyc IyI-X3- or heteroaryl-X4-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, raoφholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein said C3-7cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -N(R22)C(O)-, wherein R22 is hydrogen or CMalkyl; wherein R11 may be optionally substituted on carbon by one or more R13; R13 is selected from nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, C].4alkyl, C2-4alkenyl, C2-4alkynyl, Ci.4alkoxy, Ci-4alkanoyl, C|.4alkanoyloxy, N-(Ci-4alkyl)amino, NN-(Ci_4alkyl)2amino, Ci-4alkanoylamino, N-(Ci-4alkyl)carbamoyl, NN-(C i-4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2, Ci-4alkoxycarbonyl, N-(Ci_4alkyl)sulfamoyl, NN-(C i_4alkyl)2sulfamoyl, C3-7cycloalkyl-X8-, phenyl-X8-, pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9- or piperidinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; R18 is selected from halo, hydroxy, amino, trifluoromethoxy,
Figure imgf000085_0001
(which Ci.
4alkyl is optionally substituted by fluoro), Ci_4alkoxy, N-(Ci-4alkyl)amino, NN-(Ci-4alkyi)2amino, Ci-4alkylS(O)a wherein a is 0 to 2, N-(Ci_4alkyl)carbamoyl, NN-(Ci-4alkyl)2carbamoyl, piperazinyl-, pyrrolidinyl-, piperidinyl- and morpholinyl-, and
R19 is selected from
Figure imgf000085_0002
N-(Ci-4alkyl)carbamoyl and NN-(Ci-4alkyl)2carbamoyl.
In particular, in the compounds of formula IC, ID, IE and/or IF, R10 is H and R1 1 is selected from H and
Figure imgf000085_0003
wherein R1 ' is optionally substituted on carbon by one or more R13 wherein R13 is selected from carboxy, carbamoyl, N-(Ci_6alkyl)carbamoyl, Ci_6alkoxycarbonyl and carbocyclyl-X8- (such as phenyl-X8-), wherein X8 represents a direct bond and wherein R13 is optionally substituted on carbon by NN-(Ci_6alkyl)2amino. In one aspect of the compounds of formula IC, ID, IE, IF, 1C*, ID*, IE* and/or IF*, R6 has any of the values defined hereinbefore, for example as defined in any of (62) to (74) above.
In one aspect of the compounds of formula IC, ID, IE, IF, IC*, ID*, IE* and/or 5 IF*, R6 is selected from H,
Figure imgf000086_0001
and C2-6alkynyl (particularly H and Ci^alkyl), and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; wherein R is selected from fluoro, cyano, hydroxy, trifluoromethoxy, amino, io carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000086_0002
C2-4alkynyl,
Figure imgf000086_0003
N-(Ci_4alkyl)amino, N,N-(Ci-4alkyi)2amino, Ci-4alkanoylamino, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, C].4alkylS(O)a wherein a is 0 to 2,
Figure imgf000086_0004
N-(C1-4alkyl)sulfamoyl, NN-(C Malkyl)2sulfamoyl, C3-7cycloalkyl-X8-, phenyl-X8-, i5 pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9-, piperidinyl-X9- and moφholinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R16 is optionally substituted with one or more R18; wherein R18 is selected from halo, hydroxy, amino, trifluoromethoxy, Ci-4alkyl 2o (which Ci-4alkyl is optionally substituted by fluoro),
Figure imgf000086_0005
N-(Ci-4alkyl)amino and NN-(Ci-4alkyl)2amino; and wherein R17 is selected from Ci-4alkyl,
Figure imgf000086_0006
N-(Ci-4alkyl)carbamoyl and NN-(C i-4alkyl)2carbamoyl.
In another aspect of the compounds of formula IC, ID, IE, IF, IC*, ID*, IE* 25 and/or IF*, R6 is selected from H,
Figure imgf000086_0007
C3-7cycloalkyl-X5- , phenyl-X5-, heterocyclyl- X6- and heteroaryl-X7-, wherein said heterocyclyl is a monocyclic 5 or 6-membered heterocyclyl ring containing 1, 2 or 3 (suitably 1 or 2) heteroatoms selected from O, S and Ν, and wherein said heteroaryl is a monocyclic 5, 6 or 7-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν,
30 and wherein X5, X6 and X7 are each independently selected from a direct bond or -
Ν(R12)C(O)-, wherein R12 is hydrogen or C)-4alky, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; wherein R16 is selected from fluoro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000087_0001
C2-4alkenyl, C2-4alkynyl,
Figure imgf000087_0002
Ci_4alkanoyl,
Figure imgf000087_0003
N-(Ci.4alkyl)amino, N,N-(Ci-4alkyl)2amino, Ci-4alkanoylamino, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2, Ci.4alkoxycarbonyl, N-(Ci-4alkyl)sulfamoyl, NN-(C Malkyl)2sulfamoyl, Cs.ycycloalkyl-X8-, phenyl-X8-, pyridinyl-X10-, pyrimidinyl-X10-, thiazolyl-X10-, imidazolyl-X10-, pyrazolyl-X10-, piperazinyl-X9-, pyrrolidinyl-X9-, piperidinyl-X9- and morpholinyl-X9-, wherein X8, X9 and X10 each represent a direct bond; and wherein R16 is optionally substituted with one or more R18; wherein R18 is selected from halo, hydroxy, amino, trifluoromethoxy, Ci.4alkyl (which is optionally substituted by fluoro), Ci-4alkoxy,
Figure imgf000087_0004
and NN-(Ci-4alkyl)2amino; and
R17 is selected from Ci-4alkyl,
Figure imgf000087_0005
N-(Ci-4alkyl)carbamoyl and NN-(Ci.4alkyl)2carbamoyl.
In particular, in the compounds of formula IC, ID, IE, IF, IC*, ID*, IE* and/or IF*, R6 is selected from H and Ci-βalkyl, wherein R6 is optionally substituted on carbon by one or more R16, wherein R16 is selected from fluoro, Ci^aUcoxy, NN-(Ci.6alkyl)2amino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, wherein X8, X9 and X10 each represents a direct bond and wherein any heterocyclyl group within R16 optionally bears 1 or 2 oxo substituents. In another aspect of the compounds of formula IC, ID, IE, IF, IC*, ID*, IE* and/or IF*, R6 has any of the values defined hereinbefore, for example as defined in any of (62) to (74) above; and R11 is selected from H and
Figure imgf000087_0006
wherein R11 is optionally substituted on carbon by one or more R13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci-4alkoxy, Ci-4alkanoyl,
Figure imgf000087_0007
N-(CMalkyl)amino, NN-(Ci.4alkyl)2amino, Ci_4alkanoylamino, N-(C].4alkyl)carbamoyl, NN-(C i-4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2,
Figure imgf000087_0008
N-(C].4alkyl)sulfamoyl, NN^Ci^alkyl^sulfamoyl, Ci-4alkylsulfonylamino, phenyl, pyridyl and pyrimidinyl (particularly R11 is selected from
H and CMalkyl).
In another embodiment of the invention there is provided a compound of the formula I selected from: (7S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one;
(7S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-propyl-7,8- dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7,8-dihydropteridin-6(5H)-one;
(75)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin-
2-amine;
(75)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-7,8- dihydropteridin-6(5H)-one;
(7S)-2-amino-5-ethyl-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one;
(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-7,8- dihydropteridin-6(5H)-one; 2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-methyl-7,8-dihydropteridin-
6(5H)-one;
(75)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8- tetrahydropteridin-2-amine;
(7/?)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin- 2-amine; and
(7/?)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8- tetrahydropteridin-2-amine; or a pharmaceutically acceptable salt thereof.
In another embodiment of the invention there is provided a compound of the formula I selected from:
(7S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5 Η)-one; (7S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-propyl-7,8- dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one; 2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7,8-dihydropteridin-6(5H)-one;
(75)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-7,8- dihydropteridin-6(5H)-one;
(75)-2-amino-5-ethyl-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one; (7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-7,8- dihydropteridin-6(5H)-one;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-methyl-7,8-dihydropteridin-
6(5H)-one;
(75)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin- 2-amine;
(75)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8- tetrahydropteridin-2-amine;
(7/?)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin-
2-amine; (7Λ)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8- tetrahydropteridin-2-amine;
8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-methyl-5,6,7,8-tetrahydropteridin-2- amine;
(7R)-2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-7-(2-methylpropyl)-7,8- dihydropteridin-6(5H)-one;
(7R)-2-amino-7-benzyl-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-7,8- dihydropteridin-6(5H)-one; methyl {(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl} acetate; (7R)-2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-7-propyl-7,8- dihydropteridin-6(5H)-one; 2-amino-4-chloro-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-5,7-dihydropteridin-6- one;
2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-4-methylsulfanyl-5,7- dihydropteridin-6-one; 5 (7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methoxypropyl)-7- methyl-7,8-dihydropteridin-6(5H)-one;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methoxypropyl)-7,8- dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2- i o pheny lethy l)-7 , 8 -dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-piperazin-l- ylethyl)-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-5-(2,2-difluoroethyl)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7- methyl-7,8-dihydropteridin-6(5H)-one; is 2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methylbutyl)-7,8- dihydropteridin-6(5H)-one;
2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methylbutyl)-7,8- dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(3- 20 methylbutyl)-7,8-dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-propyl-7,8- dihydropteridin-6(5H)-one;
(7/?)-2-amino-5-benzyl-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one; 25 (7Λ)-2-amino-5-(cyclopropylmethyl)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7- methyl-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-pyrrolidin- l-ylethyl)-7,8-dihydropteridin-6(5H)-one;
(7Λ)-2-amino-5-[2-(dimethylamino)-2-methylpropyl]-8-[(4-methoxy-3,5-dimethylpyridin- 30 2-yl)methyl]-7-methyl-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-5-[3-(dimethylamino)propyl]-8-[(4-methoxy-3,5-dimethylpyridin-2- yl)methyl]-7-methyl-7,8-dihydropteridin-6(5H)-one; (7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-moφholin-
4-ylethyl)-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-pyridin-4- ylethyl)-7,8-dihydropteridin-6(5H)-one; (7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-pyridin-3- ylethyl)-7,8-dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(3-pyridin-3- ylpropyl)-7,8-dihydropteridin-6(5H)-one;
2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(2-pyridin-3- ylethyl)-7,8-dihydropteridin-6(5H)-one;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-propyl-7,8-dihydropteridin-
6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-[2-(2- oxoimidazolidin- 1 -yl)ethyl]-7,8-dihydropteridin-6(5H)-one; (7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-[2-(2- oxopyrrolidin- 1 -yl)ethyl]-7,8-dihydropteridin-6(5H)-one;
2-amino-5-benzyl-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7,8- dihydropteridin-6(5H)-one;
2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-propyl-7,8- dihydropteridin-6(5H)-one;
2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(2-phenylethyl)-7,8- dihydropteridin-6(5H)-one;
{(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl} acetic acid; 2-{(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl}acetamide;
2-{(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl}-N-[3-(dimethylamino)propyl]acetamide;
2-{(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl}-N-[2-(dimethylamino)ethyl]acetamide;
2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-4-methyl-5,7-dihydropteridin-
6-one; or an N-oxide thereof; or a pharmaceutically acceptable salt thereof.
Synthesis
The compounds of the present invention can be prepared in a number of ways using methods analogous to well known methods of organic synthesis. More specifically, the novel compounds of this invention may be prepared using the reactions and techniques described herein. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are not compatible with the reaction conditions, will be apparent to one skilled in the art and alternate methods must then be used. It will be appreciated that during certain of the following processes certain substituents may require protection to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and later removed.
For examples of protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley Interscience (1991). Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a ^-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium- on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a 7-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. Resins may also be used as a protecting group.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
Compounds of the formula I, or pharmaceutically-acceptable salts or prodrugs thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds and intermediates, for example as described in WO 04/076454, WO 03/020722, WO 04/076454 and WO 03/020722. Such processes, when used to prepare a compound of the formula I, or a pharmaceutically-acceptable salt or prodrug thereof, are provided as a further feature of the invention and are illustrated by the following representative examples. Necessary starting materials may be obtained by standard procedures of organic chemistry (see, for example, Advanced Organic Chemistry (Wiley-Interscience), Jerry March). The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
The present invention also provides that compounds of the formula I, or pharmaceutically acceptable salts or prodrugs thereof, can be prepared by a process (a) to (g) as follows (wherein the variables are as defined above unless otherwise stated):
Process (a): For the preparation of compounds of the formula I wherein A is CR10R1 ' and R4 and R5 together form oxo, the reduction and cyclisation in the presence of a suitable reducing agent of the compound of the formula II:
Figure imgf000094_0001
II wherein R1, R2, R3, R7, R10, R1 ' and p are as hereinbefore defined, except any functional group is protected if necessary; and Pgi is a suitable carboxy protecting group; or
Process (b) for the preparation of those compounds of the formula I wherein R6 is optionally substituted
Figure imgf000095_0001
C2-6alkenyl, C2-6alkynyl, heterocyclyl, carbocyclyl or heteroaryl, the coupling of a compound of the formula I wherein R6 is H, with an alcohol of the formula R6-OH; or
Process (c) for the preparation of those compounds of the formula I wherein R4 and R5 are both hydrogen, the reduction of a compound of the formula I of the formula I':
Figure imgf000095_0002
r wherein R1, R2, R3, R6, R7, A and p are as hereinbefore defined, except any functional group is protected if necessary; or
Process (d) for the preparation of those compounds of the formula I wherein A in the compound of formula I is CHR11 and R11 is optionally substituted Ci^alkyl, C2-6alkenyl, C2-6alkynyl, C3-7CyC loalkyl, or an optionally substituted carbon-linked heterocyclyl, the deprotonation and alkylation of a compound of the formula I" with a compound of the formula III:
Figure imgf000096_0001
III
wherein R1, R2, R3, R6, R7, R11 and p are as hereinbefore defined, except any functional group is protected if necessary and Lg3 is a displaceable group; or
Process (e) the amination of a compound of the formula IV:
Figure imgf000096_0002
IV wherein R1, R2, R3, R4, R5, R6, R7, A and p are as hereinbefore defined, except any functional group is protected if necessary and Lg4 is a displaceable group; or
Process (f) for the preparation of those compounds of the formula I wherein A in the compound of formula I is CHR11 and R11 is a Ci-βalkyl group substituted by a carboxy group, the hydrolysis of a compound of the formula I'":
Figure imgf000097_0001
wherein R1, R2, R3, R6, R7 and p are as hereinbefore defined, except any functional group is protected if necessary and R28 is a Ci^alkyl group; or Process (g) for the preparation of those compounds of the formula I wherein A in the compound of formula I is CHR11 and R11 is a Ci^alkyl group substituted by a carbamoyl, N-(Ci-6alkyi)carbamoyl or
Figure imgf000097_0002
group, the coupling of a compound of the formula 1"" (or a suitable salt thereof) with ammonia or a N-(Ci_6alkyl)amino or N5N-(C i.6alkyl)2amino group:
Figure imgf000097_0003
wherein R1, R2, R3, R6, R7 and p are as hereinbefore defined, except any functional group is protected if necessary; and thereafter, if necessary (in any order):
(i) converting a compound of the formula I into another compound of the formula I; (ii) removing any protecting groups; and (iii) forming a pharmaceutically acceptable salt of the compound of formula 1. Specific conditions for the above reactions are as follows.
Reaction Conditions for Process fa):
Pgi is a suitable carboxy protecting group such as Ci-βalkyl, for example methyl. The reduction of the nitro group in the compound of formula II is conveniently carried out in the presence of a suitable reducing agent such as a transitions metal, for example iron in the presence of a suitable acid. Suitable acids include mineral acids such as hydrochloric acid or sulfuric acid or organic acids such as acetic acid or formic acid. Other suitable reducing agents that may be used under neutral pH conditions include zinc, samarium-di-iodide and trivalent titanium. Conveniently the reaction is carried out in the presence of an inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one, dimethylsulfoxide or acetonitrile. The above reaction is conveniently carried out at a temperature in the range, for example, 00C to 1800C, conveniently in the range ambient temperature to 800C or preferably, at or near the reflux temperature of the solvent when used.
The above reaction conveniently gives the in-situ cyclisation of the resulting amino derivative of the compound of formula II, thereby providing the compound of formula I. Preparation of starting materials for Process (a)
The compound of formula II may be prepared using conventional methods, for example as illustrated in Reaction Scheme 1:
Figure imgf000099_0001
He amination
NH3 (aq) THF
Il
Reaction Scheme 1 wherein R1, R2, R3, R7, R10, R1 1 and p are as hereinbefore defined, except any functional group is protected if necessary; Pg 1 is a suitable carboxy protecting group such as Ci-βalkyl (for example methyl) or benzyl; and Lg, Lg1 and Lg2 are suitable displaceable groups.
Lg is for example halo, such as chloro. Suitable displaceable groups represented by Lg1 and Lg2 include, for example halo (particularly chloro), aryloxy, mercapto, alkylthio, alkylsulfonyl, arylsulfonyl, alkylsulfonyloxy or arylsulfonyloxy methanesuflonyloxy or toluene-4-sulfonyloxy group. A particular displaceable group for Lg and Lg is chloro.
Suitable reaction conditions for Reaction Scheme 1 are well known for the preparation of similar compounds and are illustrated by the examples described herein.
The starting materials of the formulae Ha and Hb are commercially available or can be prepared using conventional methods. Reaction Conditions for Process (b):
The coupling reaction is suitably carried out under Mitsunobu conditions as described in Hughes, D. L. et.al. Org. Prep. (1996), 28, 127-164. For example, the reaction is conveniently carried out in the presence of a suitable electrophilic activating agents, for example, diisopropyl azodicarboxylate (DIAD) or l,l'-(azodicarbonly)dipiperidine (ADDP) or 4,7-dimethyl-3,5,7-hexahydro-l,2,4,7-tetrazocin-3,8-dione (DHTD) in combination with a nucleophilic activating agent such as for example phosphorous based activating agent such as for example tributylphosphine, triphenylphosphine , or cyanomethylenetributylphosphorane. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran or an aromatic solvent such as for example benzene or toluene or an non polar solvent such as acetonitirle. The reaction is conveniently carried out at temperatures in a range, for example, from below room temperature to elevated temperatures such as boiling point of solvent, conveniently at or near ambient temperature.
The phosphine coupling reagent is optionally immobilised on a solid support. Reaction Conditions for Process (c):
The reduction is carried out in the presence of a suitable reducing agent such as a borane-THF complex. The reaction is suitably carried out in a solvent such as an ether, for example tetrahydrofuran. The reaction is conveniently performed at elevated temperature, for example, under reflux conditions. Reaction Conditions for Process (d)
Suitable displaceable groups represented by Lg3 include for example halo such as bromo or iodo.
The deprotonation of the compound of formula I" may be achieved by formation of the alkali metal enolate of the compound of formula I" for example the lithium or potassium enolate.
The reaction is conveniently performed in the presence of a suitable base, for example, an alkali metal hydride such as sodium hydride, an alkali metal disalazide such as sodium hexamethyldisalazide or an organolitium reagent such as N-butyl-lithium or methyl-lithium. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran or 1,4-dioxane, an aromatic solvent such a s toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N- dimethylacetamide, N-methylpyrrolidin-2-one, or dimethylsulfoxide.
The reaction is suitably carried out at a temperature of from -800C to 3O0C, conveniently at temperatures of-78°C. Suitable reaction conditions for the deprotonation and reaction with R11 -Lg3 are known in the literature, for example as described in Bull et.al., Tetrahedron (2006), 62(33), 7911-25; or Viso et.al., Journal of Organic Chemistry (2006), 71(4), 1442-48.
Reaction Conditions for Process (e): s Lg4 is a suitable displaceable group, for example, a halo (particularly chloro), aryloxy, mercapto, alkylthio, alkylsulfonyl, arylsulfonyl, alkylsulfonyloxy or arylsulfonyloxy or groups for example chloro, bromo, fluoro, methoxy, phenoxy, pentafluorophenoxy, methylthio, methanesulfonyl, methanesulfonyloxy or toluene-4- sulfonyloxy group. A particular displaceable group Lg4 is chloro. o The reaction is conveniently carried out in the presence of base, acid or transition metal catalyst, particular conditions are the displacement of Lg4 in the presence of base.
The amination reaction is conveniently performed in an inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, ans ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N- methylpyrrolidin-2-one, dimethylsulfoxide or acetonitrile. Particular solvents are ethers such as tetrahydrofuran or 1,4-dioxane.
The reaction is conveniently carried out at a temperature in the range, for example,Ό 00C to 1800C, particularly in the range ambient temperature to 8O0C or more particularly, at or near the reflux temperature of the solvent when used.
Conveniently the amination reaction is carried out with ammonia, or a latent form of ammonia such a benzylamine or hydrazine derivative. Conveniently amination may be carried out using a latent source of ammonia in the presence of a suitable transition metal5 catalyst. For example benzophenonimine might be used as a latent source of ammonia in the presence of a palladium catalyst. If latent sources of ammonia are used, the amino group is liberated after the displacement reaction, for example with acids such as trifluorosulfonic acid, hydrochloric acid or sulfuric acid. It will be appreciated by those skilled in the art that in the liberation of latent amino functionalities might require the0 utility of aqueous acid. Suitable aqueous acids include, for example hydrochloric acid, or and organic acid such as acetic acid a buffer may also be used to maintain pH at the desired level during the reaction. Particularly, the amination uses of ammonia, which may be conveniently dissolved in a suitable solvent such as for water or methanol.
Reaction Conditions for Process (f):
The hydrolysis reaction is conveniently carried out in the presence of a suitable aqueous base or suitable aqueous acid. Suitable aqueous bases include aqueous sodium hydroxide and potassium hydroxide. Suitable aqueous acids include aqueous sulphuric acid.
Conveniently the hydrolysis reaction is carried out in the presence of an inert solvent or diluent, for example water, an ester or an ether such as tetrahydrofuran or 1 ,4- dioxan. For example, a suitable solvent may be a mixture of water and tetrahydrofuran.
The reaction is conveniently carried out at a temperature in the range, for example, 00C to
1000C, conveniently at ambient temperature.
Reaction Conditions for Process (g):
For the coupling of the compound of formula I"" with a N-(Ci_6alkyl)amino or N,N-(Ci-6alkyl)2amino group, the reaction is conveniently conducted using analogous conditions to those defined above for Process (b).
For the coupling of the compound of formula I"" with ammonia, the reaction is conveniently carried out in the presence of a suitable coupling agent. A suitable coupling agent is, for example, a suitable peptide coupling agent, such as O-(7-azabenzotriazol-l-
Figure imgf000102_0001
hexafluoro-phosphate (HATU) or a carbodiimide such as dicyclohexylcarbodiimide or l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI). The reaction may conveniently be carried out in the presence of a suitable base. A suitable base is, for example, an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, di-isopropylethylamine, Ν-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or an alkali or alkaline earth metal carbonate, such as sodium carbonate, potassium carbonate, caesium carbonate or calcium carbonate.
The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ester such as ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or
1 ,4-dioxan, an aromatic solvent such as toluene, an alcohol such as methanol or ethanol, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide. The reaction is conveniently carried out at a temperature in the range, for example, from 0 to 1200C, particularly at or near ambient temperature. Conveniently, this reaction may also be performed by heating the reactants in a sealed vessel using a suitable heating apparatus such as a microwave heater.
It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulfinyl or alkylsulfonyl.
When a pharmaceutically acceptable salt of a compound of the formula I is required, for example an acid or base addition salt, it may be obtained by, for example, reaction of the compound of formula I with a suitable acid or base using a conventional procedure. Methods for the preparation of pharmaceutically acceptable salts are well known in the art. For example, following reaction of a compound of the formula I with an acid or base the required salt may be precipitated from solution by supersaturating the solution containing the compound of the formula I. Super saturation may be achieved using well-known techniques, for example by cooling the solution, by removing solvent by evaporation or by the addition of a suitable anti-solvent to precipitate the salt.
To facilitate isolation of a compound of the formula I during its preparation, the compound may be prepared in the form of a salt that is not a pharmaceutically acceptable salt. The resulting salt can then be modified by conventional techniques to give a pharmaceutically acceptable salt of the compound. Such salt modification techniques are well known and include, for example ion exchange techniques or re-precipitation of the compound from solution in the presence of a pharmaceutically acceptable counter ion as described above, for example by re-precipitation in the presence of a suitable pharmaceutically acceptable acid to give the required pharmaceutically acceptable acid addition salt of a compound of the formula I.
Stereoisomers of compounds of formula I may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The enantiomers may be isolated by separation of a racemate for example by fractional crystallisation, resolution or HPLC. The diastereoisomers may be isolated by separation by virtue of the different physical properties of the diastereoisomers, for example, by fractional crystallisation, HPLC or flash chromatography. Alternatively particular stereoisomers may be made by chiral synthesis from chiral starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, with a chiral reagent. When a specific stereoisomer is isolated it is suitably isolated substantially free from other stereoisomers, for example containing less than 20%, particularly less than 10% and more particularly less than 5% by weight of other stereoisomers.
In the synthesis section above and hereafter, the expression "inert solvent" refers to a solvent which does not react with the starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative and in some occasions, more convenient manner, the individual process steps mentioned hereinbefore may be performed in different order, and/or the individual reactions may be performed at different stage in the overall route (i.e. chemical transformations may be performed upon different intermediates to those associated hereinbefore with a particular reaction). Biological Activity
The following assays can be used to measure the effects of the compounds of the present invention as HSP90 inhibitors.
Test (a) In vitro Binding Assay Test (a) measures the ability of a compound to bind to the ATP pocket of HSP90α. 6His tagged HSP90α protein (amino acids 2- 732) expressed in E.coli was purified and stored at -8O0C in aliquots. Assay measurements were performed in assay buffer comprising 2OmM HEPES pH 7.4, 5OmM KCl, 2OmM NaHMoO4, 0.01% Nonidet P40, 2mM DTT and 0. lmg/ml BSA. Following resuspension in DMSO, the FP probe 3-[[5-(5- ethyl-2,4-dihydroxy-phenyl)-4-(4-methoxyphenyl)2H-pyrazole-3-carbonyl]amino]propyl- Cy3B-amide; 14-(2-{[3-({[3-(5-ethyl-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-lH- pyrazol-5-yl]carbonyl} amino)propyl] amino} -2-oxoethyl)- 16,16,18,18-tetramethyl-2-sulfo- 6,7,7a,8a,9, 10,16,18-octahydrobenzo[2",3"]indolizino [8",7":5',6']pyrano[3',2':3,4]pyrido[l,2-a]indol-5-ium) was diluted to a final concentration of 5nM in assay buffer. Test compounds were prepared by dilution in 100% DMSO to give the appropriate dose range and dispensed into a 384 well assay plate as a 6X concentrate. Upon addition of recombinant HSP90α to a final assay concentration of lμg/ml, FP probe was added and plates incubated at room temperature for 1 to 4 hours. Final DMSO concentration was 1% in a total assay volume of 18μl. Fluorescence Polarisation measurements were made using a Tecan Ultra plate reader using an excitation wavelength of 530nm and an emission wavelength of 590nm. Millipolarisation (mP) values were estimated using Xfluor software. Assay Probe The 3-[[5-(5-ethyl-2,4-dihydroxy-phenyl)-4-(4-methoxyphenyl)2H-pyrazole-3- carbonyi]amino]propyl-Cy3B-amide; 14-(2-{[3-({[3-(5-ethyl-2,4-dihydroxyphenyl)-4-(4- methoxyphenyl)-lH-pyrazol-5-yl]carbonyl}amino)propyl]amino}-2-oxoethyi)- 16,16,18,18-tetramethyl-2-sulfo-6,7,7a,8a,9, 10, 16, 18-octahydrobenzo[2",3"]indolizino [8",7":5',6']pyrano[3',2':3,4]pyrido[l,2-a]indol-5-ium used as the assay probe in Test (a) was prepared as follows:
Figure imgf000105_0001
Assay Probe
A cold solution (00C) of pyrano[3",2":3,4;5",6":3',4']dipyrido[l,2-a:l',2'-a']diindol-5- ium, 2-[2-[(2,5-dioxo-l-pyrrolidinyl)oxy]-2-oxoethyl]-6,7,9,10,16,l8-hexahydro- 16,16,18,18-tetramethyl-14-sulfo-, inner salt [(9CI) CAS No: 228272-52-4 (also known as Cy 3B NHS Ester)] (5mg) in ImI dry DMF was added to a solution of N-(3-aminopropyl)- 5-(5-ethyl-2,4-dihydroxy-phenyl)-4-(4-methoxyphenyl)-2H-pyrazole-3-carboxamide (4mgs) and dry N,N-diisopropylethylamine (7μL) in 2ml of dry DMF. The reaction mixture was stirred at 00C for 1 hour before then warmed up slowly to room temperature. The reaction mixture was then stirred for an additional 14 hours at room temperature. The product was isolated directly from the reaction mixture without prior workup by reverse phase HPLC. The fractions containing the desired product were combined and evaporated under reduced pressure at a temperature not exceeding 300C. Purification Conditions: Waters XTerra® C18 50x 10mm HPLC Column, 5 micron particle size, flow rate 3.5ml/min, gradient 30%-55%B 10 minutes (A=10% NH3/H2O; B=100% CH3CN). Mass Spectrum: (M+H^ 953 Retention time 1.89 minutes. (For alternative conditions see Moulick et.al. Bioorganic & Medicinal Chemistry Letters (2006), 16, 4515-18).
The N-(3-aminopropyl)-5-(5-ethyl-2,4-dihydroxy-phenyl)-4-(4-methoxyphenyl)- 2H-pyrazole-3-carboxamide starting material was prepared as follows:
Preparation of 1 -(5-ethyl-2,4-dihvdroxy-phenvi)-2-(4-methoxyphenyl)ethanone: 4-Ethylbenzene-l,3-diol (17.5g, 159mmol) and 4-methoxyphenylacitic acid (26.4g,
159mmol) was heated with boron trifuoride dietherate solution (100.7ml, 795mmol) to 900C for 3 hours. The mixture was then cooled to 500C before it was added to a stirred solution of 10% aqueous sodium acetate (11). The resulting mixture was stirred at room temperature over night at room temperature. The resulting solid was filtered off dissolved in a minimum volume of methanol and pre-absorbed onto silica gel. For the initial purification the crude material was chromatographed, eluting with an increasingly polar mixture of methylene chloride/methanol (95/5 to 90/10). The fractions containing product were grouped into two groups, evaporated under vacuum to give a solid which was triturated with diethyl ether in a further purification step. The title compound was obtained in three portions of varying purity as an off white solid from combined purest fractions (10.78g, 26.2%) the less pure fractions (7.56g, 18.4%) and from the combined, evaporated mother liquors after renewed trituration with iso-hexane/diethylether to give the title product (6.32g, 15.4%). 1H NMR Spectrum f purest solid): δH(300 MHz, CDCl3) 1.22 (3H t, J= 7.5 Hz), 1.63 (IH, s), 2.57 (2H q, J= 7.5 Hz), 3.79 (3H, s), 4.16 (2H d, J= 3.0 Hz), 5.52 (IH, s), 6.30 (IH, s), 6.85 - 6.90 (2H, m), 7.16 - 7.21 (2H, m), 7.59 (IH, s), 12.51 (IH, s); Mass Spectrum: (M+H") 258.20. Preparation of Methyl 6-ethyl-7-hvdroxy-3-(4-methoxyphenyl)-4-oxo-chromene-2- carboxylate: l-(2,4-Dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone (18.16g, 63.42mmol) was dissolved in anhydrous pyridine (100ml). The solution was cooled to 00C in an ice bath. Then methyl chlorooxacetate (17.5ml, 190.27mmol) was added drop wise over a period of 15 minutes to the vigorously stirred solution. A precipitate formed immediately. The resulting suspension was stirred at 00C for a further 4 hours before it was place in a refrigerator over night. Then the reaction mixture was warmed to room temperature before all volatile components were removed in vacuum. The residue was suspended with DCM and washed with IN aqueous hydrochloric acid solution, brine. The organic phase was dried over magnesium sulfate and evaporated to dryness. LC/MS analysis indicted that the condensation reaction had only completed partially. To complete the condensation reaction the crude material was dissolved in methanol (400ml) and 2N hydrochloric acid was added (100ml) and subsequently heated to reflux for 2 hours. Then the reaction mixture was filtered whilst hot to give the title product as a white solid (13.6g) which was used without further purification. Mass Spectrum: (M+H+) 355.28, (M+H") 353.08.
Preparation of 6-ethyl-7-hvdroxy-3-(4-methoxyphenyl)-4-oxo-chromene-2- carboxylic acid:
Methyl 6-ethyl-7-hydroxy-3-(4-methoxyphenyl)-4-oxo-chromene-2-carboxylate (13.6g, 41.73mmol) was dissolved in acetone (200ml). Then a 2N aqueous solution of Sodium hydroxide (62.59ml, 125.19mmol) was added at room temperature. The resulting mixture was stirred at room temperature over night. After the reaction was complete the mixture was acidified under cooling with concentrated hydrochloric acid to pH 2.5. A solid precipitated from the solution. The solid was filtered off, washed with water and diethyl ether and dried at 400C under vacuum to yield the title product as an off white solid (11.2g quantitative). The material was used directly without further purification in the next step. Mass Spectrum: (M+H+) 341.25, (M+H ) 339.19. Preparation of 5-(^-ethyl-2,4-dihvdroxy-phenv0-4-(4-methoxyphenyl)-2H-pyrazole- 3-carboxylic acid:
6-Ethyl-7-hydroxy-3-(4-methoxyphenyl)-4-oxo-chromene-2-carboxylic acid (13.6g, 41.73mmol) and hydrazine monohydrate (6.1ml, 125.19mmol) were suspended in ethanol
5 (200ml) at room temperature. The mixture was then heated slowly to 7O0C and stirred at this temperature for 4 hours. The mixture was cooled to room temperature and all volatile components were removed in vacuum. The residue was partitioned between water (11) and Ethyl acetate (1.41). Then the aqueous phase was separated. The organic phase yielded some product. The remainder of the product was extracted from the aqueous phase witho Ethyl acetate (4 x 500ml). The combined organic extracts were dried over Magnesium sulfate and evaporated to dryness under vacuum resulting in a further quantity of the desired product. The combined isolated product portions yielded 6.99g (51%) of a light brown solid. 1H NMR Spectrum: δH(400 MHz, DMSO-6d) 0.84 (3H t, J= 7.5 Hz), 2.23 (2H q, J= 7.5 Hz), 3.38 (IH s, br), 3.74 (3H, s), 6.36 (IH, s), 6.56 (IH, s), 6.85 (2H d, J=s 8.7 Hz), 7.13 (2H d, J= 8.7 Hz), 9.3 (IH s, br), 9.4 (IH s, br), 12.8 (IH s, br); Mass Spectrum: (M+H+) 355.04, (M+H") 353.09.
Preparation of tert-butyl N-[3-Fr5-(5-ethyl-2.4-dihvdroxy-phenyl)-4-(4- methoxyphenyl)2H-pyrazole-3-carbonyllamino1propyllcarbamate:
HOBT (572mg, 4.2mmol), NMM (1.55ml, H.lmmol) and EDACHCl (820mg,o 4.3mmol) were added at 00C consecutively to a solution of 5-(5-ethyl-2,4-dihydroxy- phenyl)-4-(4-methoxyphenyl)-2H-pyrazole-3-carboxylic acid (500mg, 1.4mmol) in 40ml of dry DCM. The resulting mixture was stirred at O0C for 15 minutes. Then a solution of N-BOC- 1,3-diaminopropane (740mg, 4.3mmol) in 5ml of dry DCM was added. The resulting mixture was stirred at O0C for one our and at room temperature for 2.5hours. The5 reaction mixture was washed with 50ml of 10% w/v aqueous citric acid solution, 50ml 20% aqueous KHCO3 solution and 50ml of distilled water. The organic extracts were dried over MgSO4 and evaporated under reduced pressure. The crude material was purified by automated column chromatography on a 4Og RediSep™ normal phase silica cartridge using an ISCO Companion™ eluting with a mixture of 5% methanol in DCM0 was used. The fractions containing the desired product were combined and evaporated under reduced pressure go give the title compound as a white solid (450mg, 63%); ^H NMR Spectrum: δH(400 MHz, DMSO-d6) 0.90 (3H t, J= 7.5 Hz), 1.38 (9H, s), 1.56 (2H t, J= 6.9 Hz), 2.28 (2H q, J= 7.4 Hz), 2.95 (2H d, J= 6.1 Hz), 3.15 - 3.20 (2H, m), 3.72 (3H, s), 6.41 (IH, s), 6.57 (2H, s), 6.72 (IH, s br), 6.78 (2H d, J= 7.3 Hz), 7.12 - 7.14 (2H, m), 7.92-8.02 (IH, m br), 9.28-9.35 (2H, m), 12.89 (IH, s, br); Mass Spectrum: (M+H+) 511.12; (M-H+) 509.2, (M-1Bu) 455.08, (M-BOC) 411.09. Preparation of N-(3-aminopropylV5-(5-ethyl-2,4-dihvdroxy-phenyl)-4-(4- methoxyphenyl)-2H-pyrazole-3-carboxamide
Tert-butyl N-[3-[[5-(5-ethyl-2,4-dihydroxy-phenyl)-4-(4-methoxyphenyl)2H- pyrazole-3-carbonyl]amino]propyl]carbamate (350mg) was added as a solution in 15 ml dry methanol at room temperature to a solution of 4M HCl in dioxin (15 ml). The resulting solution was warmed to 5O0C for 2 hours. The mixture was cooled to room temperature before it was evaporated to dryness under reduced pressure. The residue was dissolved in methanol and loaded onto a 20 g SCX-2 cartridge. The cartridge was washed with methanol before the product was eluted with a mixture of methanol and 7N ammonia. The fractions containing the desired product were combined and evaporated under vacuum to give a light brown solid (326 mg). The material was subsequently suspended with dry di- ethylether (50 mg) and stirred over night. The resulting material was filtered off and dried and was identified as the title compound as a light brown solid (274 mg, 83%); 1H NMR Spectrum: (400.132 MHz, d6-DMSO) δ 0.89 (3H, t, J= 8.0 Hz), 1.77 (2H, m), 2.27 (q, J = 6.8 Hz, 2H), 2.79 (2H, m), 3.26 (2H, q, J= 6.2 Hz), 3.72 (3H, s), 6.46 (IH, s), 6.55 (IH, s), 6.79 (2H, d, J= 8.8 Hz,), 7.13 (2H, d, J= 8.8 Hz), 7.90 (2H, s br), 8.20 (IH, t, J= 5.8 Hz), 9.40 (IH, s br); Mass Spectrum: (M+H*) 411.30; (M-H+) 409.27. Test (b) Cellular Assay
HSP90 mediated regulation of both Her2 and Androgen Receptor is well documented and assays to measure HSP90 inhibition are described in the literature. Her2 down regulation in SKBr3 breast cell line can be monitored using an antibody in ELISA or Western blot analysis after exposure to an HSP90 inhibitor (Huezo et al, Chemistry and Biology, 2003, 10, 629-634). Alternatively a fluorescently labelled antibody can be used to detect Her2 levels using a plate reader. Reduction of Androgen Receptor levels by HSP90 inhibitors, as measured by antibody detection, in prostate cell lines eg LNCaP, CWR22, can also be used to measure cellular activity (Solit et al, Clin. Can. Res., 2002, 8, 986-993). Although the pharmacological properties of the compounds of the formula I vary with structural change as expected, in general activity possessed by compounds of the formula I, may be demonstrated at the following concentrations or doses in one or more of the above tests (a) or (b) of for example: -
Test (a):- IC50 of less than 200μM, generally in the range of, for example, 1OnM to 150μM (for example 1OnM to lOOμM). Preferred compounds are those with an IC50 of less that 5μM, more preferably less than lμM.
Test (b):- IC50 in the range, for example, 0.InM to 10 μM. By way of example, activity for the following compounds was observed in Test (a):
Figure imgf000110_0001
The data in the above table was generated in an assay substantially as described above in relation to in-vitro Binding Assay (a). Some of the compounds shown in the table were tested more than once in the assay. For those compounds the IC50 value shown is the geometric mean of the measured IC50 values. Therefore, as will be understood, the IC50 values quoted above are not absolute and further measurements of the IC50 values may result in a different mean IC50 value.
The compounds of examples 5 and 6.1 exhibited low activity in the enzyme assay, test (a). Acordingly these compounds are not preferred compounds. Accordingly, in one embodiment the compounds of examples 5 and 6.1 are excluded ((75)-8-[(4-methoxy-3,5- dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin-2-amine and (75)-8-[(4- methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8-tetrahydropteridin-2- amine). Pharmaceutical Compositions
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof, as defined hereinbefore in association with a pharmaceutically acceptable diluent or carrier.
The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents. An effective amount of a compound of the present invention for use in therapy of infection is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of infection, to slow the progression of infection, or to reduce in patients with symptoms of infection the risk of getting worse.
The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. The size of the dose for therapeutic or prophylactic purposes of a compound of the formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
In using a compound of the formula 1 for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.
The compounds of the present invention are expected to possess, amongst others, anti-angiogenic properties such as anti-cancer properties that are believed to arise from their HSP90 inhibitory properties.
Accordingly, the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by HSP90, i.e. the compounds may be used to produce an HSP90 inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention provide a method for the treatment of malignant cells characterised by inhibition of HSP90. Particularly the compounds of the invention may be used to produce an anti-tumour effect by means of anti-angiogenic and/or an anti-proliferative and/or anti-invasive effect and/or apoptotic and/or cell cycle arrest effect mediated alone or in part by the inhibition of HSP90. Particularly, the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours that are sensitive to inhibition of HSP90 that are involved in for example, angiogenesis, proliferation, cell cycle regulation, invasion and the signal transduction steps associated therewith. Accordingly the compounds of the present invention may be useful in the treatment of hyperproliferative disorders including psoriasis, benign prostatic hyperplasia (BPH) and cancer by providing an anti-proliferative effect and/or anti-invasive and/or anti-angiogenic effect and/or a pro-apoptotic effect, particularly in the treatment of HSP90 sensitive cancers. Such benign or malignant tumours may affect any tissue and include non-solid tumours such as leukaemia, multiple myeloma or lymphoma, and also solid tumours, for example, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, endometrial cancer, uterine cancer, vulval cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, bile duct cancer, bone cancer, neuronal cancer, testicular cancer, particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and lung cancer - NSCLC and SCLC.
The compounds of the invention may also be useful in the treatment of pathogenic angiogenesis, for example in the treatment of cancers as hereinbefore described and other diseases in which inappropriate, or pathogenic angiogenesis occurs, for example diabetic retinopathy. The compounds of the invention may also be useful in the treatment or prophylaxis of other conditions in which HSP90 is implicated, for example inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases, such as multiple sclerosis, lupus, rheumatoid arthritis and irritable bowel syndrome CJD, Huntington's disease and Alzheimer's disease. The compounds may also be useful for the protection of normal cells against chemotherapy induced toxicity,
In another aspect of the present invention there is provided a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof, as defined hereinbefore for use as a medicament. In another embodiment the present invention provides the use of a compound of formula I or a pharmaceutically acceptable or salt N-oxide or prodrug thereof in the preparation of a medicament.
In another embodiment the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the treatment or prophylaxis of a cancer, for example a cancer involving a solid tumour.
In another embodiment the present invention provides a compound of formula 1 or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the treatment or prophylaxis of neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer), colon, rectum, prostate, bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, pancreas, skin, testes, thyroid, uterus, cervix, vulva or other tissues, as well as leukemias and lymphomas including CLL and CML, tumors of the central and peripheral nervous system, and other tumor types such as melanoma, multiple myeloma, fibrosarcoma and osteosarcoma, and malignant brain tumors.
In still another embodiment the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the treatment or prophylaxis of pathologically angiogenic diseases, inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases.
In another embodiment the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use in the inhibition of HSP90 activity.
In another embodiment the present invention provides a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof for use as an antiangiogenic agent in the treatment of a solid tumour.
In another embodiment the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for the treatment or prophylaxis of a cancer, for example a cancer involving a solid tumour.
In another embodiment the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for the treatment or prophylaxis of neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer), colon, rectum, prostate, bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, pancreas, skin, testes, thyroid, uterus, cervix, vulva or other tissues, as well as leukemias and lymphomas including CLL and CML, tumors of the central and peripheral nervous system, and other tumor types such as melanoma, multiple myeloma, fibrosarcoma and osteosarcoma, and malignant brain tumors.
In still another embodiment the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for the treatment or prophylaxis of pathologically angiogenic diseases, inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases .
In another embodiment the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the preparation of a medicament for use in the inhibition of HSP90 activity.
In another embodiment the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof in the manufacture of a medicament for use as an antiangiogenic agent in the treatment of a solid tumour.
In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the production of an HSP90 inhibitory effect in a warm-blooded animal such as man.
In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically acceptable diluent or carrier for use in the production of an anti-cancer effect in a warm-blooded animal such as man.
In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically acceptable diluent or carrier for use as an antiangiogenic agent in the treatment of a solid tumour.
In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide or prodrug thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment or prophylaxis of pathologically angiogenic diseases, inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders and metabolic diseases.
In another embodiment the present invention provides a method of inhibiting pathogenic angiogenesis in a human or animal comprising administering to said human or animal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof. In a further embodiment the present invention provides a method of inhibiting
HSP90 comprising administering to an animal or human in need of said inhibiting a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
In a further embodiment the present invention provides a method of prophylaxis or treatment of a disease mediated in part or alone by HSP90 comprising administering to an animal or human in need of said inhibiting a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
In another embodiment the present invention provides a method of treatment of a human or animal suffering from a cancer comprising administering to said human or animal a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
In further embodiment the present invention provides a method of prophylaxis or treatment of cancer comprising administering to a human or animal in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof. In another embodiment the present invention provides a method of treatment of a human or animal suffering from a neoplastic disease such as carcinoma of the breast, ovary, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer), colon, rectum, prostate, bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, pancreas, skin, testes, thyroid, uterus, cervix, vulva or other tissues, as well as leukemias and lymphomas including CLL and CML, tumors of the central and peripheral nervous system, and other tumor types such as melanoma, multiple myeloma, fibrosarcoma and osteosarcoma, and malignant brain tumors comprising administering to a human or animal in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide or prodrug thereof.
In another embodiment the present invention provides a method of treatment of a human or animal suffering from a pathologically angiogenic disease comprising administering to said human or animal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or N-oxide or prodrug thereof. Combination Therapies
The anti-cancer treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:-
(i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin- C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinase inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin); (ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5α-reductase such as finasteride; (iii) anti-invasion agents [for example c-Src kinase family inhibitors like 4-(6-chloro-2,3- methylenedioxyanilino)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-tetrahydropyran-4- yloxyquinazoline (AZD0530; International Patent Application WO 01/94341), N-(2- chloro-6-methylphenyl)-2- {6-[4-(2-hydroxyethyl)piperazin- 1 -yl]-2-methylpyrimidin-4- ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem.. 2004, 47, 6658- 6661) and bosutinib (SKJ-606), and metalloproteinase inhibitors like marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase]; (iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbBl antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern et al. Critical reviews in oncology/haematology, 2005, Vol. 54, pp 11-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-moφholinopropoxy)quinazolin-4-amine (gefitinib, ZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3- morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AMΝ107); inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006), tipifarnib (Rl 15777) and lonafarnib (SCH66336)), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-IR kinase inhibitors, IGF receptor (insulin- like growth factor) kinase inhibitors; aurora kinase inhibitors (for example AZDl 152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 AND AX39459) and cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors; (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and for example, a VEGF receptor tyrosine kinase inhibitor such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SUl 1248), axitinib (AG-013736), pazopanib (GW 786034) and 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3- pyrrolidin-l-ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), compounds such as those disclosed in International Patent Applications WO97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin αvβ3 function and angiostatin)]; (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;
(vii) an endothelin receptor antagonist, for example zibotentan (ZD4054) or atrasentan; (viii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense; (ix) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRC A2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and (x) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
According to a further aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula I as defined hereinbefore and an additional anti-tumour agent as defined hereinbefore for the conjoint treatment of cancer.
According to a further aspect of the invention there is provided a method of treatment of a human or animal suffering from a cancer comprising administering to said human or animal a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or prodrug or N-oxide thereof simultaneously, sequentially or separately with an additional anti-tumour agent as defined hereinbefore. According to a further aspect of the invention there is provided a compound of formula I, or a pharmaceutically acceptable salt or prodrug or N-oxide thereof for use simultaneously, sequentially or separately with an additional anti-tumour agent as defined hereinbefore, in the treatment of a cancer. Although the compounds of the formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects HSP90. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
Examples
The invention will now be illustrated in the following Examples in which, generally: (i) operations were carried out at ambient temperature, i.e. in the range 17 to
250C and under an atmosphere of an inert gas such as nitrogen or argon unless otherwise stated;
(ii) in general, the course of reactions was followed by thin layer chromatography
(TLC) and/or analytical high pressure liquid chromatography (HPLC); the reaction times that are given are not necessarily the minimum attainable;
(iii) when necessary, organic solutions were dried over anhydrous magnesium sulfate, work-up procedures were carried out using traditional layer separating techniques, evaporations were carried out either by rotary evaporation in vacuo or in a Genevac HT-4 /
EZ-2. (iv) yields, where present, are not necessarily the maximum attainable, and when necessary, reactions were repeated if a larger amount of the reaction product was required;
(v) in general, the structures of the end-products of the formula I were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; electrospray mass spectral data were obtained using a Waters ZMD or Waters ZQ LC/mass spectrometer acquiring both positive and negative ion data, generally, only ions relating to the parent structure are reported; proton NMR chemical shift values were measured on the delta scale using a Bruker DPX-400. The following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; (vi) unless stated otherwise compounds containing an asymmetric carbon and/or sulfur atom were not resolved;
(vii) intermediates were not necessarily fully purified but their structures and purity were assessed by TLC, analytical LCMS and/or NMR analysis;
(viii) unless otherwise stated, column chromatography (by the flash procedure) was performed on Merck Kieselgel silica (Art. 9385); medium pressure liquid chromatography (MPLC) used Silicycle® Isco™ compatible 40-63 μm 60 A silica packed cartridges; Ion exchange chromatography was carried out with Isolute® strong cation exchange (SCX) cartridges.
(ix) the following analytical HPLC methods were used; in general, reversed- phase silica was used with a flow rate of about 1 ml per minute and detection was by Electrospray Mass Spectrometry and by UV absorbance at a wavelength of 254 nm;
(x) the following abbreviations have been used:-
DCM: Dichloromethane
DMF: N,N-Dimethylformamide THF: Tetrahydrofuran
DIAD: Diisopropyl azodicarboxylate
DMSO: Dimethylsulfoxide
DMA: N,N-dimethylacetamide
MeOH: Methanol HATU: O-(7-Azabenzotriazol-l-yl)-NrNr/V,N'-Tetramethyluronium Hexafluoro-
Phosphate Example 1
(7S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one
Figure imgf000122_0001
Methyl (2S)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl]amino]propanoate (Intermediate 1) (500 mg, 1.28 mmol) was dissolved in acetic acid (4 mL) and heated to 7O0C, then iron powder (144 mg, 2.58 mmol) was added. The mixture was stirred at 7O0C for 1 hour, then 100 0C for 30 minutes. The dark mixture was filtered through celite®, and the filter media was washed with DCM. The filtrate was concentrated under reduced pressure, then purified by column chromatography (eluting with 5-20% methanol in DCM) to yield the title product as a cream foam (354 mg, 84%); 1H NMR spectrum (400 MHz, DMSO-d6) δl.30 (3H, d), 2.18 (3H, s), 2.20 (3H, s), 3.73 (3H, s), 3.88 (IH, q), 4.15 (IH, d), 5.51 (IH, d), 5.83 (2H, s), 7.40 (IH, s), 8.18 (IH, s), 10.18 (IH, s); Mass spectrum: (M+H)+ 329.
The methyl (2S)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl]amino]propanoate (Intermediate 1) used as the starting material was prepared as follows:
Intermediate 2
Methyl (2S)-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yI)methylamino]propanoate
Figure imgf000123_0001
A suspension of alanine methyl ester hydrochloride (22.6 g, 162 mmol) in DMF (215 mL) was treated with diisopropylethylamine (56 mL, 0.32 mol) and stirred for 5 minutes until dissolution occurred. 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine,
5 hydrochloride (12 g, 54 mmol) was added portionwise and the resulting solution was stirred overnight at room temperature. The mixture was heated to 500C for 1.5 hours. The mixture was partitioned between ethyl acetate and saturated sodium bicarbonate. The organics were washed twice with water and brine, then dried with magnesium sulfate and concentrated under reduced pressure. The residue was purified by MPLC on silica usingo gradient elution (3% methanol/DCM to 10% methanol/DCM). Intermediate 2 was obtained as a yellow oil (9.76 g); 1H NMR spectrum (400 MHz, CDCl3) δl.38 (3H, d), 2.21 (3H, s), 2.23 (3H, s), 3.50 (IH, q), 3.71 (3H, s), 3.74 (3H, s), 3.78 (IH, d), 3.84 (IH, d), 8.20 (IH, s); Mass spectrum: (M+H)+ 253. s Intermediate 3
Methyl (2S)-2-[(2-chloro-5-nitro-pyrimidin-4-yI)-[(4-methoxy-3,5-dimethyl-pyridin-2- y l)methyl| amino] propanoate
Figure imgf000123_0002
Methyl (2S)-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylamino]propanoateo (Intermediate 2) (2.9 g, 11.5 mmol) in acetone (15 mL) was added to a mixture of 2,4- dichloro-5-nitro-pyrimidine (2.23 g, 11.5 mmol) and potassium carbonate (1.64 g, 11.90 mmol) in acetone (10 mL). The mixture was stirred for 30 minutes at room temperature then partitioned between ethyl acetate and water. The organics were dried with magnesium sulfate and concentrated under reduced pressure. The residue was purified by MPLC on silica using gradient elution (15% ethyl acetate/isohexane to 50% ethyl acetate/isohexane)to give Intermediate 3 as a yellow gum (2.29 g, 49%). 1H NMR spectrum (400 MHz, CDCl3) δl.63 (3H, d), 2.14 (3H, s), 2.21 (3H, s), 3.74 (3H, s), 3.76 (3H, s), 4.50 (IH, d), 4.81 (IH, d), 5.27 (IH, q), 8.02 (IH, s), 8.50 (IH, s); Mass spectrum: (M+H)+ 410,412.
Intermediate 1 Methyl (2S)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methy 1| amino] propanoate
Figure imgf000124_0001
A solution of methyl (2S)-2-[(2-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5- dimethyl-pyridin-2-yl)methyl]amino]propanoate (Intermediate 3) (l.Og, 2.44 mmol) in THF (30 niL) was treated with ammonia (28% in water, 3 mL). The reaction mixture was stirred at room temperature for 2.5 hours, then partitioned between DCM and water. The organic solution was dried with magnesium sulfate and concentrated under reduced pressure. The residue was purified by MPLC on silica using gradient elution (30% ethyl acetate/isohexane to 100% ethyl acetate). Intermediate 1 was obtained as a yellow foam (770 mg, 81%); 1H NMR spectrum: (400 MHz CDCl3) δl .63 (3H, d), 2.10 (3H, s), 2.22 (3H, s), 3.65 (3H, s), 3.74 (3H, s), 4.44 (IH, d), 4.64 - 4.72 (2H, m), 5.24 (2H, s), 8.14 (IH, s), 8.66 (IH, s); Mass spectrum: (M+H)+ 391.
Example 2 Using a similar procedure to that described in Example 1, the compounds shown in
Table 1 were prepared by cyclising the appropriate nitropyrimidine starting materials shown as "SM" in Table 1. Table 1
Figure imgf000125_0001
Notes for Table 1
The products gave the characterising data shown below:
[1] 1H NMR spectrum: (400 MHz, OMSO-d6) 50.85 (3 H, t), 1.18 - 1.30 (2H, m), 1.71
1.79 (2H, m), 2.18 (3H, s), 2.20 (3H, s), 3.73 (3H, s), 3.85 - 3.87 (IH, m), 4.12 (IH, d),
5.57 (IH, d), 5.81 (2H, s), 7.36 (IH, s), 8.17 (IH, s), 10.22 (IH, s); Mass spectrum:
(M+H)+ 359. [2] 1H NMR spectrum (400 MHz, DMSO-J6) δl.30 (3H, d), 2.19 (4H, s), 2.20 (3H, s), 3.73 (3H, s), 3.88 (IH, q), 4.15 (IH, d), 5.51 (IH, d), 5.83 (2H, s), 7.40 (IH, s), 8.18 (IH, s), 10.18 (IH, s); Mass spectrum: (M+H)+ 329.
[3] 1H NMR spectrum: (400 MHz, DMSO-J6) 52.19 (3H, s), 2.20 (3H, s), 3.73 (3H, s), 4.00 (2H, s), 4.76 (2H, s), 5.73 (2H, s), 7.35 (IH, s), 8.15 (IH, s), 10.24 (IH, s); Mass spectrum: (M+H)+ 315.
The Intermediate 4 used as the starting material was benzyl (2S)-2-[(2-amino-5-nitro- pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]pentanoate and was prepared as follows:
Intermediate 7
Benzyl (2S)-2- [(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylamino] pentanoate
Figure imgf000126_0001
Intermediate 7 was prepared using an analogous method to that used for the preparation of Intermediate 2, except commercially available L-norvaline benzyl ester, 4- toluenesulfonate was used in place of L-alanine methyl ester, hydrochloride to give Intermediate 7 as yellow oil (11.15 g); 1H NMR spectrum (400 MHz, CDCl3)δ0.88 (3H, t), 1.35 - 1.43 (2H, m), 1.62 (IH, s), 1.64 - 1.75 (IH, m), 1.67 - 1.73 (2H, m), 2.16 (3H, s), 2.22 (3H, s), 3.41 (IH, t), 3.73 (3H, s), 3.74-3.83 (2H, m), 5.16 (2H, s), 7.29 - 7.36 (5H, m), 8.18 (IH, s): Mass spectrum: (M+H)+ 357.
Intermediate 8
Benzyl (2S)-2-[(2-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl] amino] pentanoate
Figure imgf000127_0001
Intermediate 8 was prepared using an analogous method to that used for the preparation of Intermediate 3, except Intermediate 7 was used in place of Intermediate
2 to give Intermediate 8 as a yellow gum (7.44 g); 1H NMR spectrum (400 MHz, CDCI3) δθ.96 (3H, t), 1.50 - 1.57 (2H, m), 1.85-2.15 (5H, m), 2.17 (3H, s), 3.69 (3H, s), 4.49 (IH, d), 4.68 (IH, d), 5.06 (IH, d), 5.19 (IH, d), 5.49 - 5.53 (IH, m), 7.29 - 7.36 (5H, m), 7.91 (IH, s), 8.46 (IH, s); Mass spectrum: (M+H)+ 514,516.
Intermediate 4 Benzyl (2S)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl] amino] pentanoate
Figure imgf000127_0002
Intermediate 4 was prepared using an analogous method to that used for the preparation of Intermediate 1, except Intermediate 8 was aminated in place of Intermediate 3 to give Intermediate 4 (4.49 g); 1H NMR spectrum (400 MHz, CDCl3) δθ.96 (3H, t), 1.50 - 1.58 (2H, m), 1.98 (3H, s), 2.00 - 2.14 (2H, m), 2.19 (3H, s), 3.66 (3H, s), 4.47 (IH, d), 4.54 (IH, d), 4.74 - 4.77 (IH, m), 4.87-4.97 (3H, m), 5.04 (IH, d), 7.19 - 7.21 (2H, m), 7.28 - 7.33 (3H, m), 8.07 (IH, s), 8.63 (IH, s); Mass spectrum: (M+H)+ 495. The Intermediate 5 used as the starting material was methyl (2R)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]propanoate and was prepared as follows:
Intermediate 9
Methyl (2R)-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylaminojpropanoate
Figure imgf000128_0001
Intermediate 9 was prepared using an analogous method to that used for the preparation of Intermediate 2, except commercially available D-alanine methyl ester,o hydrochloride was used in place of L-alanine methyl ester, hydrochloride to give
Intermediate 9 as a yellow oil (12.8 g); 1H NMR spectrum: (400 MHz, DMSO-J6) δl.23 (d, 3H), 3.41 (q, IH), 3.63 (s, 3H), 3.72 (s, 3H), 8.16 (s, IH); Mass spectrum: (M+H)+ 253. s Intermediate 5
Methyl (2R)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl] amino] propanoate
Figure imgf000128_0002
Intermediate 9 (11.61 g, 46 mmol) in acetone (15 mL) was added to a mixture of 2,4-o dichloro-5-nitro-pyrimidine (8.93 g, 46 mmol) and potassium carbonate (6.91 g, 50 mmol) in acetone (100 mL). The mixture was stirred for 30 minutes at room temperature and then the reaction mixture was filtered to remove unwanted salts. The filtrate was evaporated under reduced pressure and the residue was purified by flash column chromatography on silica eluting with a gradient of 10% to 100% ethyl acetate/isohexane to afford a yellow oil (3.5 g); Mass spectrum: (M+H)+ 410, 412. This material was treated with concentrated aqueous ammonia (20 mL) in THF (70 mL). The mixture was vigorously stirred for 2 hours before being partitioned between DCM and water. The organics were dried with magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica using gradient elution (30% ethyl acetate/isohexane to 100% ethyl acetate). Intermediate 5 was obtained as a yellow crystalline solid (1.73 g, 53%); 1H NMR spectrum (400 MHz, CDCl3) δl.63 (3H, d), 2.10 (3H, s), 2.22 (3H, s), 3.65 (3H, s), 3.74 (3H, s), 4.44 (IH, s), 4.62-4.73 (2H, m), 5.23 (2H, s), 8.14 (IH, s), 8.66 (IH, s); Mass spectrum: (M+H)+ 391.
The Intermediate 6 used as the starting material was methyl 2-[(2-amino-5-nitro- pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]acetate and was prepared as follows:
Intermediate 10
Methyl 2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyIamino]acetate
Figure imgf000129_0001
Intermediate 10 was prepared using an analogous method to that used for the preparation of Intermediate 2, except commercially available glycine methyl ester, hydrochloride was used in place of L-alanine methyl ester, hydrochloride to give
Intermediate 10 as a yellow oil (9.96g); 1H NMR spectrum: (400 MHz, CDCl3) δl.87 (2H, s), 2.20 (3H, s), 2.24 (3H, s), 3.75 (3H, s), 3.92 - 3.93 (2H, m), 8.21 (IH, s); Mass spectrum: (M+H)+ 239.
Intermediate 11
Methyl 2-[(2-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl] amino] acetate
Figure imgf000130_0001
lntermediate 11 was prepared using an analogous method to that used for the preparation of Intermediate 3, except Intermediate 10 was used in place of Intermediate
2 to give Intermediate 1 1 as a brown oil (6.28 g); 1H NMR spectrum: (500 MHz, DMSO- de) 52.15 (3H, s), 2.18 (4H, s), 3.70 (3H, s), 3.73 (3H, s), 4.46 (2H, s), 4.85 (2H, s), 8.09 (IH, s), 8.83 (IH, s); Mass spectrum: (M+H)+ 396, 398.
Intermediate 6
Methyl 2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl|amino]acetate
Figure imgf000130_0002
Intermediate 6 was prepared using an analogous method to that used for the preparation of Intermediate 1, except Intermediate 11 was used in place of Intermediate
3 to give Intermediate 6 as a yellow solid (2.87 g); 1H NMR spectrum (300 MHz, DMSO- d6) 52.10 (3H, s), 2.18 (3H, s), 3.64 (3H, s), 3.71 (3H, s), 4.23 (2H, s), 4.71 (2H, s), 7.28 (IH, s), 7.42 (IH, s), 8.10 (IH, s), 8.66 (IH, s) Mass spectrum: (M+H)+ 377.
Example 3
(7-S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylj-5,7-dimethyl-7,8- dihydropteridin-6(5//)-one
Figure imgf000131_0001
(75)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one (Example 1) (164 mg, 0.5 mmol) was stirred in anhydrous THF (1 niL) and triphenylphosphine (400 nig, 1.53 mmol) and methanol (0.2 rnL, 4.94 mmol) were added. DIAD (0.3 niL, 1.52 mmol) was added dropwise and the mixture was stirred at room temperature overnight. The reaction mixture was loaded onto a SCX cartridge and washed with THF and methanol, then eluting with methanolic ammonia (7M). The crude product was further purified by MPLC eluting with 0-15% methanol/DCM. The title compound was isolated as a colourless foam after trituration and re-concentration from ether (113 mg, 66%); 1H NMR spectrum (400 MHz, CDCl3) δl.39 (3H, d), 2.17 (3H, s), 2.25 (3H, s), 3.26 (3H, s), 3.75 (3H, s), 4.03-4.15 (2H, m), 4.66 (2H, s), 5.71 (IH, d), 7.57 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 343.
Example 4 Using a similar procedure to that used for the synthesis of Example 3, the compounds shown in Table 2 were prepared from the appropriate 7,8-dihydropteridin-6-one (SM in Table 2) and appropriate alcohol (ROH in Table 2).
Table 2
Figure imgf000131_0002
Figure imgf000132_0001
Notes for Table 2
The products gave the characterising data shown below: [1] 1H NMR spectrum (400 MHz, CDCl3) δl.22 (3H, t), 1.36 (3H, d), 2.17 (3H, s), 2.25 (3H, s), 3.70-3.81 (4H, m), 3.91 - 3.98 (IH, m), 4.03 (IH, q), 4.09 (IH, d), 4.66 (2H, s), 5.70 (IH, d), 7.60 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 356. [2] 1H NMR spectrum (400 MHz, CDCl3) δl.39 (3H, d), 2.17 (3H, s), 2.25 (3H, s), 3.26 5 (3H, s), 3.75 (3H, s), 4.04-4.15 (2H, m), 4.65 (2H, s), 5.71 (IH, d), 7.57 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 343.
[3] 1H NMR spectrum: (400 MHz, DMSO-c/6) 62.18 (3H, s), 2.20 (3H, s), 3.18 (3H, s), 3.73 (3H, s), 4.11 (2H, s), 4.78 (2H, s), 5.83 (2H, s), 7.57 (IH, s), 8.14 (IH, s); Mass spectrum: (M+H)+ 329.
!0
Example 5
(7£)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8- tetrahydropteridin-2-amine
Figure imgf000133_0001
is (75)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one (Example 1) (164 mg, 0.50 mmol) was stirred in THF (3 mL) and borane-THF complex (IM in THF, 2 mL, 2 mmol) was added slowly. The mixture was stirred at room temperature for 1 hour, then heated at reflux for 30 minutes. The mixture was slowly treated with hydrochloric acid (2M, 5 mL). The solution was loaded onto a
20 SCX column and washed with methanol. The product was eluted with methanolic ammonia (7M) and the volatiles were removed under reduced pressure. Further purification was achieved by MPLC eluting with 5-30% methanol/ DCM to give the title compound as a cream foam (115 mg, 73%); 1H NMR spectrum (400 MHz, CDCl3) δl.22 (3H, d), 2.24 (6H, s), 2.94 - 2.97 (IH, m), 3.13 - 3.17 (IH, m), 3.20 (IH, s), 3.57 - 3.62
25 (IH, m), 3.75 (3H, s), 4.32 (IH, d), 4.36 (2H, s), 5.59 (IH, d), 7.33 (IH, s), 8.17 (IH, s); Mass spectrum: (M+H)+ 315. Example 6
Using a similar procedure to that used for the synthesis of Example 5, the compounds shown in Table 3 were prepared by reducing the appropriate 7,8-dihydropteridin-6-one (SM in Table 3).
Table 3
Figure imgf000134_0001
No. Compound SM and Note
[3] (7/?)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]- Example 4[2] 5,7-dimethyl-5,6,7,8-tetrahydropteridin-2-amine (47 mg)
Figure imgf000135_0001
[4] 8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5- Example 4[3] methyl-5,6,7,8-tetrahydropteridin-2-amine
Figure imgf000135_0002
The products gave the characterising data shown below:
[1] 1H NMR spectrum: (400 MHz, CDCl3) δ 1.25 (3H, d), 2.22 (3H, s), 2.23 (3H, s), 2.72
2.74 (4H, m), 2.93 - 2.97 (IH, m), 3.59 - 3.64 (IH, m), 3.74 (3H, s), 4.32 (3H, d), 5.60
(IH, d), 7.18 (IH, s), 8.16 (IH, s): Mass spectrum: (M+H)+329.
[2] 1H NMR spectrum: (400 MHz, CDCl3) δl.22 (3 H, d), 2.24 (6H, s), 2.94 - 2.97 (IH, m), 3.13 - 3.17 (IH, m), 3.25 (IH, s), 3.57 - 3.61 (IH, m), 3.75 (3H, s), 4.32 (IH, d),
4.37 (2H, s), 5.59 (IH, d), 7.34 (IH, s), 8.17 (IH, s); Mass spectrum: (M+H)+315. [3] 1H NMR spectrum: (400 MHz, CDCl3) δ 1.25 (3H, d), 2.22 (3H, s), 2.23 (3H, s), 2.72 - 2.74 (4H, m), 2.96 (IH, dd), 3.59 - 3.64 (IH, m), 3.74 (3H, s), 4.28-4.39 (3H, m), 5.60 (IH, d), 7.18 (IH, s), 8.16 (IH, s); Mass spectrum: (M+H)+ 329. [4] 1H NMR spectrum (300 MHz, CDCl3) δ 2.15 (3H, s), 2.16 (3H, s), 2.63 (3H, s), 2.88 (2H, t), 3.38 (2H, t), 3.65 - 3.69 (3H, m), 4.34 (2H, s), 4.85 (2H, s), 7.10 (IH, s), 8.09 (IH, s); Mass spectrum: (M+H)+ 315.
Example 7
Using a similar procedure to that described in Example 1, the compounds shown in Table 4 were prepared by cyclising the appropriate nitropyrimidine starting materials shown as "SM" in Table 4.
Table 4
Figure imgf000136_0001
Figure imgf000137_0001
Notes for Table 1
The products gave the characterising data shown below:
[1] 1H NMR spectrum (400 MHz, CDCl3) δθ.91 - 0.93 (6H, m), 1.65-75 (3H, m), 2.16
(3H, s), 2.24 (3H, s), 3.75 (3H, s), 4.00 (IH, t), 4.12 (IH, d), 5.69 - 5.76 (3H, m), 7.42 (IH, s), 8.18 (IH, s), 11.50 (IH, br); Mass spectrum: (M+H)+.
[2] 1H NMR spectrum (400 MHz, CDCl3) δ 2.13 (3H, s), 2.26 (3H, s), 3.08 - 3.13 (IH, m), 3.30 - 3.34 (IH, m), 3.76 (3H, s), 4.16 (IH, d), 4.35 (IH, t), 5.72 (2H, s), 5.77 (IH, d),
6.93 (IH, s), 7.07-7.19 (5H, m), 8.20 (IH, s): Mass spectrum: 405 (M+H)+.
[3] 1H NMR spectrum (400 MHz, DMSO-(I6) δ 2.19 (6H, s), 2.72 -2.92 (2H, m), 3.51
(3H, s), 3.73 (3 H, s), 4.23 (IH, d), 4.29 (IH, t), 5.45 (IH, d), 5.76 (2H, s), 7.37 (IH, s),
8.14 (IH, s), 10.33 (IH, s); Mass spectrum: 387 (M+H)+.
[4] 1H NMR spectrum (400 MHz, DMSO-d6) δ 0.85 (3 H, t), 1.12-1.35 (2H, m), 1.65-
1.81 (2H, m), 2.17 (3H, s), 2.20 (3H, s), 3.73 (3H, s), 3.81 - 3.88 (IH, m), 4.11 (IH, d), 5.56 (IH, d), 5.80 (2H, s), 7.36 (IH, s), 8.17 (IH, s), 10.22 (IH, s); Mass spectrum: 357 (M+H)+.
The Intermediate 12 used as the starting material was methyl (2R)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]-4-methyl- pentanoate and was prepared as follows:
Intermediate 16
Methyl (2R)-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylamino]-4-methyl- pentanoate
Figure imgf000138_0001
Intermediate 16 was prepared using an analogous method to that used for the preparation of Intermediate 2, except commercially available D-leucine methyl ester, hydrochloride was used in place of L-alanine methyl ester, hydrochloride to give Intermediate 16 as a yellow oil; 1H NMR spectrum (400 MHz, CDCl3) δθ.86 - 0.93 (6H, dd), 1.53 - 1.57 (2H, t), 1.73 - 1.80 (IH, m), 2.22 (3H, s), 2.23 (3H, s), 3.40 (IH, t), 3.71 (3H, s), 3.74 (3H, s), 3.74 - 3.84 (2H, m), 8.19 (IH, s): Mass spectrum: (M+H)+ 295.
Intermediate 17 Methyl (2R)-2-[(2-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyI]amino]-4-methyl-pentanoate
Figure imgf000139_0001
Intermediate 17 was prepared using an analogous method to that used for the preparation of Intermediate 3, except Intermediate 16 was used in place of Intermediate
2 to give Intermediate 17 as a yellow gum; 1H NMR spectrum (500 MHz, DMSOd6) 50.93 (3H, d), 1.03 (3H, d), 1.81 - 1.91 (3H, m), 2.12 (3H, s), 2.19 (3H, s), 3.70 (3H, s), 3.72 (3H, s), 4.57 (IH, d), 4.78 (IH, d), 5.70 - 5.73 (IH, m), 7.96 (IH, s), 8.44 (IH, s); Mass spectrum: (M+H)+ 452, 454.
Intermediate 12 Methyl (2R)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl]amino]-4-methyl-pentanoate
Figure imgf000139_0002
Intermediate 12 was prepared using an analogous method to that used for the preparation of Intermediate 1, except Intermediate 17 was used in place of Intermediate 3 to give Intermediate 12 as a yellow solid; 1H NMR spectrum (300 MHz, DMSO-J6) δθ.88 (3H, d), 0.96 (3H, d), 1.77 - 1.85 (2H, m), 1.90-1.97 (IH, m), 2.04 (3H, s), 2.16 (3H, s), 3.51 (3H, s), 3.68 (3H, s), 4.48 (IH, d), 4.63 (IH, d), 5.15 - 5.18 (IH, m), 7.03 - 7.49 (2H, br), 8.05 (IH, s), 8.53 (IH, s); Mass spectrum: (M+H)+ 433.
The Intermediate 13 used as the starting material was benzyl (2R)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]-3-phenyl- propanoate and was prepared as follows: lntermediate 18
Benzyl (2R)-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylamino)-3-phenyI- propanoate
Figure imgf000140_0001
Intermediate 18 was prepared using an analogous method to that used for the preparation of Intermediate 2, except commercially available D-phenylalanine benzyl ester, 4-toluenesulfonate was used in place of L-alanine methyl ester, hydrochloride to give Intermediate 18 as a yellow oil; 1H NMR spectrum (400 MHz, CDCl3) δ 2.09 (3H, s), 2.21 (3H, s), 3.02 - 3.04 (2H, m), 3.68 (IH, t), 3.71 (3H, s), 3.74-3.84 (2H, m), 5.02 - 5.09 (2H, m), 7.13 - 7.37 (1OH, m), 8.14 (IH, s); Mass spectrum: (M+H)+ 405.
Intermediate 19
Benzyl (2R)-2-[(2-chloro-5-nitro-pyrimidin-4-yI)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl]amino]-3-phenyl-propanoate
Figure imgf000140_0002
Intermediate 19 was prepared using an analogous method to that used for the preparation of Intermediate 3, except Intermediate 18 was used in place of Intermediate
2 to give Intermediate 19 as a yellow gum; 1H NMR spectrum (400 MHz, CDCl3) δl.98 (3H, s), 2.17 (3H, s), 3.33 - 3.46 (2H, m), 3.69 (3H, s), 4.41 (IH, d), 4.60 (IH, d), 5.00 (IH, d), 5.17 (IH, d), 5.54 (IH, t), 7.19 - 7.36 (1OH, m), 7.93 (IH, s), 8.48 (IH, s); Mass spectrum: (M+H)+ 562, 564.
Intermediate 13 Benzyl (2R)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)tnethyl]amino]-3-phenyl-propanoate
Figure imgf000141_0001
Intermediate 13 was prepared using an analogous method to that used for the preparation of Intermediate 1, except Intermediate 19 was used in place of Intermediate 3 to give Intermediate 13 as a yellow solid; 1H NMR spectrum (400 MHz, CDCl3) δl.97 (3H, s), 2.19 (3H, s), 3.38 (IH, dd), 3.55 (IH, dd), 3.67 (3H, s), 4.28 (IH, d), 4.53 (IH, d), 4.89 - 4.99 (4H, m), 5.05 (IH, d), 7.16 - 7.32 (1OH, m), 8.08 (IH, s), 8.63 (IH, s); Mass spectrum: (M+H)+ 543.
The Intermediate 14 used as the starting material was dimethyl (2Λ)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]butanedioate and was prepared as follows:
Intermediate 20 Dimethyl (2R)-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylamino]butanedioate
Figure imgf000142_0001
Intermediate 20 was prepared using an analogous method to that used for the preparation of Intermediate 2, except commercially available D-aspartic acid dimethyl ester, hydrochloride was used in place of L-alanine methyl ester, hydrochloride to give Intermediate 20 as a yellow oil; 1H NMR spectrum (400 MHz, CDCl3) δ 2.21 (3H, s), 2.23 (3H, s), 2.70 - 2.76 (IH, m), 2.77 - 2.84 (IH, m), 3.68 (3H, s), 3.73 (3H, s), 3.75 (3H, s), 3.77 - 3.81 (IH, m), 3.84 (IH, d), 3.91 (IH, d), 8.18 (IH, s); Mass spectrum: (M+H)+ 311.
Intermediate 21
Dimethyl (2R)-2-[(2-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl] amino] butanedioate
Figure imgf000142_0002
Intermediate 21 was prepared using an analogous method to that used for the preparation of Intermediate 3, except Intermediate 20 was used in place of Intermediate
2 to give Intermediate 21 as a yellow gum; 1H NMR spectrum (400 MHz, CDCl3) δ 2.13 (3H, s), 2.20 (3H, s), 3.23 (IH, dd), 3.44 (IH, dd), 3.66 (3H, s), 3.74 (6H, s), 4.70 (IH, d), 4.77 (IH, d), 5.11 - 5.19 (IH, m), 8.00 (IH, s), 8.52 (IH, s); Mass spectrum: (M+H)+ 468, 470. Intermediate 14
Dimethyl (2/?)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-diinethyl-pyridin-
2-y l)methyl] amino] butanedioate
Figure imgf000143_0001
Intermediate 14 was prepared using an analogous method to that used for the preparation of Intermediate 1, except Intermediate 21 was used in place of Intermediate
3 to give Intermediate 14 as a yellow solid; 1H NMR spectrum (400 MHz, CDCl3) 52.10 (3H, s), 2.21 (3H, s), 3.20 - 3.26 (IH, m), 3.44 - 3.50 (IH, m), 3.65 (3H, s), 3.70 (3H, s), 3.74 (3H, s), 4.55 (IH, d), 4.68 (IH, d), 4.87 - 4.90 (IH, m), 5.25 (2H, s), 8.10 (IH, s), 8.65 (IH, s); Mass spectrum: (M+H)+ 449.
The Intermediate 15 used as the starting material was benzyl (2R)-2-[(2-amino-5- nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]pentanoate and was prepared as follows:
Intermediate 22
Benzyl (2R)-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylamino]pentanoate
Figure imgf000143_0002
Intermediate 22 was prepared using an analogous method to that used for the preparation of Intermediate 2, except commercially available D-norvaline benzyl ester 4- toluenesulfonate was used in place of L-alanine methyl ester, hydrochloride to give Intermediate 22 as a yellow oil; 1H NMR spectrum (400 MHz, CDCl3) 50.88 (3H, t), 1.36 - 1.42 (2H, m), 1.62 - 1.75 (2H, m), 2.16 (3H, s), 2.22 (3H, s), 3.41 (IH, t), 3.73 (3H, s), 3.74 - 3.82 (2H, m), 5.16 (2H, s), 7.29 - 7.37 (5H, m), 8.18 (IH, s); Mass spectrum: (M+H)+ 357.
Intermediate 23
Benzyl (2R)-2-[(2-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl-pyridin-2- yl)methyl I amino] pentanoate
Figure imgf000144_0001
Intermediate 23 was prepared using an analogous method to that used for the preparation of Intermediate 3, except Intermediate 22 was used in place of Intermediate
2 to give Intermediate 23 as a yellow gum; 1H NMR spectrum (400 MHz, CDCl3) δ 0.95 (3H, t), 1.48 -1.60 (2H, m), 1.91 - 1.99 (IH, m), 2.02 (3H, s), 2.04 - 2.15 (IH, m), 2.17 (3H, s), 3.69 (3H, s), 4.48 (IH, d), 4.68 (IH, d), 5.06 (IH, d), 5.19 (IH, d), 5.49 - 5.53 (IH, m), 7.29 - 7.37 (5H, m), 7.91 (IH, s), 8.46 (IH, s): Mass spectrum: (M+H)+ 514, 516.
Intermediate 15
Benzyl (2R)-2-[(2-amino-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyI-pyridin-2- yl)methyl] amino] pentanoate
Figure imgf000144_0002
Intermediate 15 was prepared using an analogous method to that used for the preparation of Intermediate 1, except Intermediate 23 was used in place of Intermediate 3 to give Intermediate 15 as a yellow solid; ' H NMR spectrum (400 MHz, CDCl3) δθ.96 (3H, t), 1.50 - 1.61 (2H, m), 1.99 (3H, s), 2.01 - 2.16 (2H, m), 2.19 (3H, s), 3.66 (3H, s), 4.47 (IH, d), 4.54 (IH, d), 4.74 - 4.78 (IH, m), 4.85 - 4.98 (3H, m), 5.04 (IH, d), 7.19 - 7.22 (2H, m), 7.28 - 7.33 (3H, m), 8.07 (IH, s), 8.63 (IH, s); Mass spectrum: (M+H)+ 495.
Example 8
2-Amino-4-chloro-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-5,7- dihydropteridin-6-one
Figure imgf000145_0001
Methyl 2-[(2-amino-6-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl] amino]acetate (Intermediate 25) (2.0 g) was dissolved in acetic acid (120 mL) and warmed to 650C. Iron powder (5 g) was added and the mix heated at 85°C for 40 minutes. The reaction mixture allowed to cool, filtered and the filtrate was evaporated to dryness. The residue was purified by flash chromatography on silica, eluting with increasingly polar mixtures of methanol DCM (1/99-10/90) to give crude product. The crude product was triturated with methanol (3 mL) and the resulting solid filtered off then redissolved in 5N aqueous HCl (5 mL) and heated at 8O0C for 30 minutes. The reaction mixture was cooled, evaporated to dryness and the residue triturated with aqueous ammonia solution (d=0.880). The resulting solid was filtered off to give the title compound (129 mg) as a beige coloured solid; 1H NMR spectrum (400 MHz, DMSO) 2.20 (6H, s), 3.74 (3H, s), 4.05 (2H, s), 4.79 (2H, s), 6.17 (2H, s), 8.15 (IH, s), 9.92 (IH, s); Mass spectrum: (M+H)+ 349.37, 351.33
The methyl 2-[(2-amino-6-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5- dimethyl-pyridin-2-yl)methyl] amino]acetate (Intermediate 25) used as starting material was made as follows:
Intermediate 24 MethyI-2-[(2-amino-6-hydroxy-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl] amino] acetate, DMF adduct
Figure imgf000146_0001
To a mixture of N,N-diisopropylethylamine (3.86 mL) and methyl 2-[(4-methoxy- 3,5-dimethyl-pyridin-2-yl)methylamino]acetate (Intermediate 10) (2.38 g) in DMF (50 mL) was added solid 2-amino-4-chloro-5-nitro-6-hydroxypyrimidine (1.9 g) (prepared as described in Justus Leibigs Annalen der Chemie (1964), 677, 113-126). The yellow solution was stirred at ambient temperature for 2 hours. The reaction mixture was evaporated to dryness and the residue partitioned between DCM and saturated aqueous sodium bicarbonate solution. The organic layer was separated, dried over magnesium sulphate, filtered and the filtrate evaporated to dryness to give Intermediate 24 as a yellow solid (3.65 g). NMR shows the presence of 1 equivalent of DMF; 1H NMR spectrum (400 MHz, DMSOd6) δ 2.09 (3H, s), 2.19 (3H, s), 2.75 (3H, s), 2.90 (3H, s), 3.62 (3H, s), 3.72 (3H, s), 4.15 (2H, s), 4.63 (2H, s), 6.79 - 7.13 (2H, br), 7.97 (IH, s), 8.14 (IH, s), 10.77 (IH, s): Mass spectrum: (M+H)+ 393.35.
Intermediate 25
Methyl 2-[(2-amino-6-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl] amino] acetate
Figure imgf000146_0002
Methyl-2-[(2-amino-6-hydroxy-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl]amino]acetate, DMF adduct (Intermediate 24) (2 g) was dissolved in toluene and the solution evaporated to dryness. This procedure was repeated twice again to give methyl-2-[(2-amino-6-hydroxy-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl]amino]acetate, free of DMF, as a pale brown solid. All of this material was added to stirred phosphorus oxychloride (40 rnL) and heated to 900C for 20 minutes. The mixture was evaporated to dryness and azeotroped with toluene to give Intermediate 25 (1.9 g) as a brown gum; 1H NMR spectrum (400 MHz, CDCl3) 2.14 (3H, s), 2.24 (3H, s), 3.73 (3H, s), 3.76 (3H, s), 4.33 (2H, s), 4.65 (2H, s), 5.07 (2H, s), 8.17 (IH, s); Mass spectrum: (M+H)+41 1.33.
Example 9
2-Amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-4-methyIsuIfanyl-5,7- dihydropteridin-6-one
Figure imgf000147_0001
To a solution of methyl 2-[(2-amino-6-methylsulfanyl-5-nitro-pyrimidin-4-yi)-[(4- methoxy-3,5-dimethyl-pyridin-2-yl)methyl]amino]acetate (Intermediate 26) (212 mg) in glacial acetic acid (5 mL) stirred at 70 C was added iron powder (120 mg). The reaction mixture was heated at 700C for 30 minutes then allowed to cool to room temperature. The reaction mixture was filtered, the filtrate evaporated to dryness and azeotroped with toluene to give a brown gum. This material was stirred with 5% methanol in DCM (10 mL) and then filtered to remove iron residues. The filtrate was purified by flash chromatography on silica eluting with an increasingly polar gradient of methanol/DCM (0/100 to 5/95) to give the title compound (52 mg) as a beige solid. 1H NMR spectrum (400 MHz, DMSO-de) 2.11 (6H, s), 2.37 (3H, s), 3.66 (3H, s), 3.88 (2H, s), 4.68 (2H, s), 5.80 (2H, s), 8.07 (IH, s), 9.34 (IH, s); Mass spectrum: (M+H)+ 361.44.
The 2-[(2-amino-6-methylsulfanyl-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl]amino]acetate (Intermediate 26) used as starting material was made as follows:
Intermediate 26
2-[(2-Amino-6-methylsulfanyl-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl] amino] acetate
Figure imgf000148_0001
Methyl 2-[(2-amino-6-chloro-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl] amino] acetate (Intermediate 25) (250 mg) was dissolved in DMA (3 niL) and sodium methanethiolate (43 mg) added. The reaction was stirred at room temperature for 1 hour. The reaction was monitored by LC/MS during the addition of additional portions of sodium methanethiolate, until all starting material was consumed. The reaction mixture was evaporated to dryness and the residue partitioned between ethyl acetate and water. The organic layer was dried with MgSO4, filtered and the filtrate evaporated to dryness. The residue was purified by flash chromatography on silica, eluting with an increasingly polar gradient of ethylacetate/DCM (0/100 to 20/80) to give
Intermediate 26 as a yellow foam (218 mg). 1H NMR spectrum (400 MHz, CDCl3) 2.06 (3H, s), 2.16 (3H, s), 2.34 (3H, s), 3.63 (3H, s), 3.68 (3H, s), 4.21 (2H, s), 4.58 (2H, s), 4.99 (2H, s), 8.09 (IH, s); Mass spectrum: (M+H)+423.13.
Example 10
(7/?)-2-Amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methoxypropyl)- 7-methyl-7,8-dihydropteridin-6(5//)-one
Figure imgf000148_0002
(7i?)-2-Amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one (Example 2[2J) (60 mg, 0.18 mmol) was suspended in TΗF (10 mL) and the 3-methoxy-l-propanol (70 μL, 0.73 mmol) was added, followed by triphenylphosphine (192 mg, 0.73 mmol) and DIAD (144 μL, 0.73 mmol). The mixture was stirred at room temperature for 2 hours. A further quantitiy of triphenylphosphine (192 mg, 0.73 mmol) and DIAD (144 μL, 0.73 mmol) were added and stirring continued for 2 hours. A further quantitiy of triphenylphosphine (192 mg, 0.73 mmol) and DIAD (144 μL, 0.73 mmol) were added and stirring continued overnight. TLC and LCMS analysis showed complete reaction; the mixture was diluted with methanol (5 niL) and loaded onto an SCX-2 column which had been equilibrated with 30% methanol in DCM. The column was eluted with 30% methanol in DCM to remove impurites, then with 30% (3M NH3 in methanol) in DCM to elute the product. The appropriate fractions were concentrated in vacuo; the residue (about 40 mg) was found to be a mixture of N- and O- alkylated products. The sample was dissolved in methanol (5 mL) and 6N HCl (2 mL) was added. The mixture was stirred at room temperature for 2 hours. LCMS showed complete hydrolysis of the O-alkylated material; the desired N-alkylated material was unchanged. The mixture was concentrated in vacuo and the residue was purified by chromatography, eluting with 0 to 5% (10: 1 methanol/concentrated NH3 (aqUeous)) in DCM. The appropriate fractions were concentrated under reduced pressure to give the title compound as a pale yellow gum (20 mg, 27%); 1H NMR spectrum (400 MHz, CDCl3) δ 1.36 (3H, d), 1.89 (2H, ddt), 2.17 (3H, s), 2.25 (3H, s), 3.39 (2H, td), 3.75 (3H, s), 3.81 (IH, dd), 3.97 (IH, dd), 4.03 (IH, q), 4.09 (IH, d), 4.67 (2H, s), 5.70 (IH, d), 7.70 (IH, s), 8.18 (IH, s); Mass spectrum: (M+HV" 401.
Example 11
Using a similar procedure to that used for the synthesis of Example 3, the compounds shown in Table 5 were prepared from the appropriate 7,8-dihydropteridin-6-one (SM in Table 5) and appropriate alcohol (ROH in Table 5). Either THF or DCM could be used as solvent, as indicated in Table 5. Additional quantities of triphenylphosphine and DIAD were added (typically 4 equivalents of each added every 2 hours) until most of the starting materials were consumed. In all cases excess of these reagents were removed during the SCX purification step (as described for Example 10). Where indicated, to facilitate purification of the required N-alkylated compounds, O-alkylated isomers were hydrolysed at ambient temperature with hydrochloric acid and methanol (as described for Example 10), prior to purification by MPLC or preparative reverse phase HPLC. Purification, in some instances, could also be achieved by fractional crystallisation. The choice of purification method was determined based on ease of separation, as judged from TLC and LCMS analysis.
Table 5
No. Compound ROH Solvent SM and Note
[1] 2-amino-8-[(4-methoxy-3,5- MeO(CH2)3OH THF Example 2 [3] dimethylpyridin-2-yl)methyl]-5-(3- methoxypropyl)-7,8-dihydropteridin- 6(5i/)-one
Figure imgf000150_0001
[2] (7Λ)-2-amino-8-[(4-methoxy-3,5- PhCH2CH2OH THF Example 2 [2] dimethylpy ridin-2-y 1) methyl] -7- methyl-5-(2-phenylethyl)-7,8- dihydropteridin-6(5//)-one
Figure imgf000150_0002
[3] (7/?)-2-amino-8-[(4-methoxy-3,5- TΗF Example 2[2] dimethylpyridin-2-yl)methyl]-7- methyl-5-(2-piperazin-l-yIethyl)-7,8- dihydropteridin-6(5H)-one
Figure imgf000150_0003
Figure imgf000150_0004
[4] (7Λ)-2-amino-5-(2,2-difluoroethyl)-8- CHF2CH2OH THF Example 2 [2] [(4-methoxy-3,5-dimethylpyridin-2- yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Notes for Table 5
Following SCX purification the products were further purified as follows, and gave the characterising data shown below:
[1] Purification was achieved by MPLC on silica eluting with 2% to 10% methanol in
DCM; 1H NMR spectrum (400 MHz, DMSO-d6) δ 1.74 - 1.80 (2H, m), 2.19 (3H, s), 2.21
(3H, s), 3.24 (3H, s), 3.37 (2H, t), 3.74 (3H, s), 3.85 (2H, t), 4.11 (2H, s), 4.78 (2H, s), 5.86
(2H, s), 7.62 (IH, s), 8.15 (IH, s): Mass spectrum: (M+H)+ 387.
[2] The crude product was stirred in 6N HCl/methanol for 2 hours, concentrated under reduced pressure and then purified by MPLC on silica eluting with 0% to 10% methanol in
DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 1.33 (3H, d), 2.16 (3H, s), 2.25 (3 H, s),
2.92 (2H, m), 3.75 (3H, s), 3.84 - 3.94 (IH, m), 3.99 - 4.15 (3H, m), 4.68 (2H, s), 5.69 (IH, d), 7.16 - 7.32 (5H, m), 7.56 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+433.
[3] The crude product was stirred in concentrated HCl (37%) (1 mL) and methanol (5 mL) for 2 hours, then concentrated under reduced pressure and purified by MPLC on silica eluting with 2% to 20% methanol in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 1.36 (3H, d), 2.17 (3H, s), 2.25 (3H, s), 2.40 - 2.48 (2H, m), 2.53 - 2.60 (4H, m), 2.84 - 2.89 (4H, m), 3.75 (3H, s), 3.80 - 3.85 (IH, m), 4.00 - 4.14 (3H, m), 4.67 (2H, s), 5.70 (IH, d), 7.69 (IH, s), 8.18 (IH, s): Mass spectrum: fM+H)+441. [4] The crude product was stirred in 6N HCl/methanol for 2 hours, concentrated under reduced pressure and then purified by MPLC on silica eluting with 0% to 10% methanol in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 1.38 (3 H, d), 2.18 (3H, s), 2.25 (3H, s), 3.76 (3H, s), 3.86 - 3.95 (IH, m), 4.08 - 4.16 (2H, m), 4.31 - 4.40 (IH, m), 4.72 (2H, s), 5.69 (IH, d), 5.85 - 6.16 (IH, m), 7.74 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+393. [5] Purification was achieved by MPLC on silica eluting with 0% to 3% [10: 1 methanol/concentrated NH3 (aqueous)] in ethyl acetate. The resulting material was recrystallised twice from ethyl acetate/isohexane; 1H NMR spectrum (400 MHz, CDCl3) δ 0.96 (3H, s), 0.98 (3H, s), 1.51 (2H, m), 1.66 (IH, m), 2.23 (3H, s), 2.24 (3H, s), 3.77 (3H, s), 3.82 (2H, m), 4.14 (2H, s), 4.83 (2H, s), 5.09 (2H, s), 7.46 (IH, s), 8.17 (IH, s); Mass 5 spectrum: (M+H)+ 385.
[6] Purification was achieved by MPLC on silica eluting with 50% to 60% ethyl acetate/isohexane. The resulting material was recrystallised from ethyl acetate/isohexane; 1H NMR spectrum (400 MHz, CDCl3) δ 0.87 (6H, d), 1.39 (2H, ddd), 1.49 (2H, ddd), 2.20 (3H, s), 2.24 (3H, s), 3.76 (3H, s), 3.93 (2H, s), 4.12 (2H, ddd), 4.72 (2H, s), 4.77 (2H, s),0 8.14 ( IH. s): Mass spectrum: (M+H)+419. 421.
[7] Purification was achieved by MPLC on silica eluting with 0% to 3% [10: 1 methanol/concentrated NH3 (aqueous)] in ethyl acetate. The resulting material was stirred in 6N HCl/methanol for 2 hours, then concentrated under reduced pressure and purified by MPLC on silica eluting with 0% to 3% [10: 1 methanol/concentrated NH3 (aqueous)] in5 ethyl acetate; 1H NMR spectrum (400 MHz, CDCl3) δ 0.95 (6H, d), 1.36 (3H, d), 1.48 (2H, dddd), 1.64 (IH, m), 2.16 (3H, s), 2.25 (3H, s), 3.74 (IH, ddd), 3.86 (IH, ddd), 4.03 (IH, q), 4.10 (IH, d), 4.86 (2H, s), 5.70 (IH, d), 7.55 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 399. [8] Purification was achieved by MPLC on silica eluting with 0% to 3% [10: 1 o methanol/concentrated NH3 (aqueous)] in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 0.93 (3H, t), 1.37 (3H, d), 1.65 (2H, tq), 2.16 (3H, s), 2.25 (3H, s), 3.70 (IH, ddd), 3.75 (3H, s), 3.84 (IH, ddd), 4.03 (IH, q), 4.09 (IH, d), 4.75 (2H, s), 5.71 (IH, d), 7.57 (IH, s), 8.18 (IH, s); Mass spectrum: (M+Hf 371.
[9] The crude product was stirred in 6N HCl/methanol for 16 hours, concentrated under reduced pressure and then purified by MPLC on silica eluting with 0% to 7% [10: 1 methanol/concentrated NH3 (aqueous)] in ethyl acetate. The resulting material was recrystallised from ethyl acetate/isohexane; 1H NMR spectrum (400 MHz, CDCl3) δ 1.51 (3H, d), 2.19 (3H, s), 2.26 (3H, s), 3.77 (3H, s), 4.16 (IH, d), 4.24 (IH, q), 4.75 (IH, d),
5.00 (2H, s), 5.30 (IH, d), 5.71 (IH, d), 7.18 (2H, d), 7.25 (IH, dd), 7.32 (2H, dd), 7.39 (IH, s), 8.20 (IH, s); Mass spectrum: (M+H)+419. [10] The crude product was stirred in 6N HCl/methanol for 16 hours, concentrated under reduced pressure and then purified by MPLC on silica eluting with 0% to 7% [10:1 methanol/concentrated NH3 (aqueous)] in ethyl acetate; 1H NMR spectrum (400 MHz, CDCl3) δ 0.36 (IH, m), 0.41 (IH, m), 0.50 (2H, m), 1.11 (IH, m), 1.38 (3H, d), 2.17 (3H, s), 2.25 (3H, s), 3.63 (IH, dd), 3.75 (3H, s), 3.85 (IH, dd), 4.03 (IH, q), 4.11 (IH, d), 4.78 (2H, s), 5.72 (IH, d), 7.69 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+383.
[11] The crude product was stirred in 6N HCl/methanol for 16 hours, concentrated under reduced pressure and then purified by MPLC on silica eluting with 0% to 5% [10:1 methanol/concentrated NH3 (aqueous)] in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 1.36 (3 H, d), 1.77 (4H, m), 2.16 (3H, s), 2.25 (3H, s), 2.58 (4H, m), 2.68 (2H, ddd), 3.75 (3H, s), 3.86 (IH, ddd), 4.03 (IH, q), 4.04 (IH, ddd), 4.08 (IH, d), 4.63 (2H, s), 5.70 (IH, d), 7.70 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 426.
[12] The crude product was purified by MPLC on silica eluting with 0% to 7% [10:1 methanol/concentrated NH3 (aqueous)] in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ
1.01 (6H, s), 1.33 (3H, d), 2.16 (3H, s), 2.25 (3H, s), 2.30 (6H, s), 3.74 (3H, s), 3.90 (2H, br.s), 3.99 (IH, q), 4.08 (IH, d), 4.62 (2H, s), 5.69 (IH, d), 8.03 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 428.
[13] The crude product was stirred in 6N HCl/methanol for 2 hours, then concentrated under reduced pressure and purified by MPLC on silica eluting with 0% to 5% [10: 1 methanol/concentrated NH3 (aqueous)] in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 1.36 (3H, d), 1.80 (2H, ddt), 2.17 (3H, s), 2.23 (6H, s), 2.25 (3H, s), 2.33 (2H, td), 3.75 (3H, s), 3.79 (IH, dt), 3.93 (IH, dt), 4.03 (IH, q), 4.09 (2H, d), 4.65 (2H, s), 5.70 (IH, d), 7.70 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 414. [14] The crude product was stirred in 6N HCl/methanol for 16 hours, then concentrated under reduced pressure and purified by MPLC on silica eluting with 0% to 5% [10: 1 methanol/concentrated NH3 (aqueous)] in DCM. Further purification was by preparative reverse-phase HPLC, eluting with 20% to 40% acetonitrile in water containing 1% aqueous ammonia (d = 0.88) solution; 1H NMR spectrum (400 MHz, CDCl3) δ 1.37 (3H, d), 2.17 (3H, s), 2.25 (3H, s), 2.51 (4H, m), 2.56 (2H, dd), 3.66 (4H, m), 3.76 (3H, s), 3.84 (IH, m), 4.04 (IH, m), 4.04 (IH, q), 4.10 (IH, d), 4.64 (2H, s), 5.70 (IH, d), 7.67 (IH, s), 8.18 (IH, s); Mass spectrum: (M+H)+ 442. [15] Purification was achieved by MPLC on silica eluting with 0% to 6% [10: 1 methanol/concentrated NH3 (aqueous)] in ethyl acetate; 1H NMR spectrum (400 MHz, CDCl3) δl.32 (3H, d), 2.16 (3H, s), 2.25 (3H, s), 2.92 (2H, t), 3.76 (3H, s), 4.03 (IH, q), 4.05 (IH, dd), 4.08 (IH, d), 4.12 (IH, dd), 4.65 (2H, s), 5.68 (IH, d), 7.14 (2H, dd), 7.60 (IH, s), 8.18 (IH, s), 8.50 (2H, dd); Mass spectrum: (M+H)+ 434. [16] The crude product was stirred in 6N HCl/methanol for 5 hours then concentrated under reduced pressure and purified by MPLC on silica eluting with 0% to 6% [10: 1 methanol/concentrated NH3 (aqueous)] in ethyl acetate. Further purification was carried out by MPLC on silica eluting with 0% to 5% [10: 1 methanol/concentrated NH3 (aqueous)] in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 1.31 (3H, d), 2.16 (3H, s), 2.25 (3H, s), 2.94 (2H, t), 3.76 (3H, s), 3.96 (IH, dd), 4.01 (IH, q), 4.08 (IH, d), 4.14 (IH, dd), 4.66 (2H, s), 5.68 (IH, d), 7.20 (IH, ddd), 7.57 (IH, ddd), 7.59 (IH, s), 8.18 (IH, s), 8.45 (IH, d), 8.47 (IH, dd); Mass spectrum: (M+H)+ 434.
[17] The crude product was stirred in 6N HCl/methanol for 5 hours, then concentrated under reduced pressure and purified by MPLC on silica eluting with 0% to 6% [10:1 methanol/concentrated NH3 (aqueous)] in ethyl acetate. Further purification was carried out by MPLC on silica eluting with 0% to 5% [10: 1 methanol/concentrated NH3
(aqueous)] in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 1.37 (3H, d), 1.95 (2H, m), 2.16 (3H, s), 2.24 (3H, s), 2.67 (2H, t), 3.74 (3H, s), 3.81 (IH, ddd), 3.91 (IH, ddd), 4.06 (IH, q), 4.09 (IH, d), 4.64 (2H, s), 5.69 (IH, d), 7.21 (IH, ddd), 7.50 (IH, s), 7.51 (IH, ddd), 8.17 (IH, s), 8.45 (IH, s), 8.45 (2H, dd); Mass spectrum: (M+H)+448. [18] The crude product was purified by MPLC on silica eluting with 0% to 2% [10:1 methanol/concentrated NH3 (aqueous)] in ethyl acetate. Further purification was carried out by MPLC on silica eluting with 0% to 2% [10:1 methanol/concentrated NH3 (aqueous)] in DCM 1H NMR spectrum (400 MHz, CDCl3) δ 2.20 (3H, s), 2.24 (3H, s), 2.91 (2H, t), 3.77 (3H, s), 3.97 (2H, s), 4.33 (2H, t), 4.72 (2H, s), 4.74 (2H, s), 7.17 (IH, dd), 7.50 (IH, dd), 8.13 (IH, s), 8.37 (IH, d), 8.44 (IH, dd); Mass spectrum: (M+H)+454, 456. [19] The crude product was purified by MPLC on silica eluting with 0% to 3% [10: 1 methanol/concentrated NH3 (aqueous)] in ethyl acetate. The resulting material was recrystallised from ethyl acetate/isohexane; 1H NMR spectrum (400 MHz, DMSOd6) δ 0.89 (3 H, t), 1.56 (2H, tq), 2.19 (3H, s), 2.20 (3H, s), 3.74 (3H, s), 3.77 (2H, t), 4.10 (2H, s), 4.78 (2H, s), 5.84 (2H, s), 7.62 (IH, s), 8.15 (IH, s); Mass spectrum: (M+H)+357. [20] Purified by preparative reverse-phase HPLC, eluting with 20% to 40% acetonitrile in water containing 1% aqueous ammonia (d = 0.88); 1H NMR spectrum (400 MHz, CDCl3) δ 1.29 (3H, d), 2.11 (3H, s), 2.18 (3H, s), 3.22 - 3.35 (3H, m), 3.36 - 3.53 (2H, m), 3.69 (3H, s), 3.69 - 3.77 (IH, m), 3.95 - 4.15 (4H, m), 4.57 (2H, s), 5.63 (IH, d), 7.70 (IH, s), 8.10 (IH, s); Mass spectrum: (M+H)+ 441.50. [21] The crude product was stirred in methanol/6N HCl for 16 hours, then concentrated under reduced pressure and purified by preparative reverse-phase HPLC, eluting with 20% to 40% acetonitrile in water containing 1% aqueous ammonia (d = 0.88); 1H NMR spectrum (400 MHz, DMSOd6) δ 1.68 - 1.75 (2H, m), 1.98 (2H, t), 1.15 (3H, d), 2.09 (3H, s), 2.12 (3H, s), 3.18 - 3.36 (3H, m), 3.38 - 3.46 (IH, m), 3.69 - 3.78 (IH, m), 3.83 (IH, q), 4.01 (IH, d), 5.47 (IH, d), 5.89 (2H, s), 7.67 (IH, s), 8.09 (IH, s); Mass spectrum: (M+H)+ 440.52
[22] Purification was achieved by preparative reverse-phase HPLC, eluting with 20% to 40% acetonitrile in water containing 1% aqueous ammonia (d = 0.88); 1H NMR spectrum (400 MHz, DMSO-(I6) δ 2.16 (3H, s), 2.21 (4H, s), 3.75 (3H, s), 4.09 (2H, s), 4.80 (2H, s), 5.27 (2H, s), 6.40 (2H, s), 7.09 - 7.14 (2H, m), 7.18 - 7.29 (m, 3H), 8.18 (IH, s); Mass spectrum: (M+H)+ 439.43
[23] The crude product was stirred in methanol/6N HCl for 16 hours, then concentrated under reduced pressure and purified by MPLC on silica eluting with 0% to 10% methanol in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 0.74 (3H, t), 2.14 (3H, s), 2.17 (3H, s), 3.69 (3H, s), 3.88 (2H, s), 3.99 (2H, t), 4.65 (2H, s), 4.71 (2H, s), 8.07 (IH, s); Mass spectrum: (M+H)+ 391.39 [24] The crude product was stirred in methanol/6N HCl for 16 hours, then concentrated under reduced pressure and purified by MPLC on silica eluting with 0% to 10% methanol in DCM; 1H NMR spectrum (400 MHz, CDCl3) δ 2.12 (3H, s), 2.17 (3H, s), 2.80 (2H, t), 3.69 (3H, s), 3.86 (2H, s), 4.26 (2H, t), 4.65 (4H, s), 7.05 - 7.18 (5H, m), 8.07 (IH, s); Mass spectrum: (M+H)+ 453.15
Example 12 {(7/?)-2-amino-8-[(4-methoxy-3,5-dimethyIpyridin-2-yl)methyll-6-oxo-5,6,7,8- tetrahydropteridin-7-yl} acetic acid
Sodium hydroxide (1 mL, 2M, 2 mmol) was added to a solution of methyl {(7/?)-2- amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8-tetrahydropteridin- 7-yl}acetate (272 mg, 0.26 mmol) (Example 7[3]) in methanol (1 mL) and THF (3 mL). The mixture was stirred for 2 hours and then concentrated under reduced pressure. The solution was diluted with water (1 mL) and made acidic by the addition of acetic acid. This solution was loaded onto an SCX column, washed with water and then methanol and the product was eluted with 2M ammonia in methanol. Thus, the title compound was obtained as a cream solid (169 mg, 65%); 1H NMR spectrum (400 MHz, DMSOd6) δ 2.18 (6H, s), 2.29 (IH, d), 2.38 (IH, d), 3.72 (3H, s), 4.13 - 4.15 (IH, m), 4.41 (IH, d), 5.49 (IH, d), 5.55 (2H, s), 7.27 (IH, s), 8.13 (IH, s), 9.91 (IH, s); Mass spectrum: (M+H)+ 373.
Example 13
2-{(7R)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl}acetamide
Figure imgf000163_0001
HATU (128 mg, 0.34 mmol) was added to a mixture of 2-{(7Λ)-2-amino-8-[(4- methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8-tetrahydropteridin-7- yl}acetamide (106 mg, 0.28 mmol) (Example 12) and diisopropylethylamine (0.1 mL) in
5 DMF (2 mL). The mixture was stirred for 5 minutes and concentrated aqueous ammonia (0.2 mL) was then added. The reaction mixture was stirred for 16 hours at room temperature. The mixture was partitioned between DCM and water. The organic solution was dried with magnesium sulfate and concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC (acetonitrile/water/0.1% ammonia). The
I0 title compound was obtained as a colourless solid (17 mg, 16%); 1H NMR spectrum (400 MHz, DMSO-d6) δ 2.17 (3H, s), 2.19 (3H, s), 3.73 (3H, s), 4.03 - 4.18 (2H, m), 5.44 - 5.60 (3H, m), 6.82 (IH, s), 7.27 (IH, s), 7.79 (IH, br), 8.15 (IH, s); Mass spectrum: (M+H)+ 372.
is Example 14
Using a similar procedure to that described in Example 10, the compounds shown in Table 4 were prepared by coupling Example 12 with the amines shown as "SM" in Table 4.
20 Table 4
Figure imgf000164_0001
Notes for Table 4
The products gave the characterising data shown below:
[1] 1H NMR spectrum (400 MHz, DMSO-d6) δ 1.42 - 1.49 (2H, m), 2.10 (6H, s), 2.12-
2.22 (8H, m), 2.55 - 2.68 (2H, m), 3.00 (2H, q), 3.73 (3H, s), 4.16 (IH, d), 4.22 (IH, t),
5.52 (IH, d), 5.70 (2H, s), 7.34 (IH, s), 8.01 (IH, t), 8.15 (IH, s), 10.16 (IH, s); Mass spectrum: (M+H)+457.
[2] 1H NMR spectrum (400 MHz, CDCl3) δ 2.19 (9H, s), 2.23 (3H, s), 2.32 (2H, t), 2.82
2.94 (2H, m), 3.22 - 3.25 (2H, m), 3.76 (3H, s), 4.33 - 4.37 (2H, m), 5.52-5.65 (3H, m),
6.92 (IH, s), 7.43 (IH, s), 8.15 (IH, s); Mass spectrum: (M+H)+443. Example 15 2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-4-methyl-5,7- dihydropteridin-6-one
Figure imgf000165_0001
Methyl 2-[(2-amino-6-methyl-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl] amino] acetate (Intermediate 27) (190mg, 0.49mmol) was heated to 700C in acetic acid (10 mL) and iron powder (55 mg, 0.97 mmol) was added and the mixture stirred at 7O0C for 1.5 hours. The mixture was poured through celite®, washing with DCM (200 mL) and the filtrate concentrated in vacuo. NaHCO3 (saturated aqueous, 200 mL) was added and extracted with DCM (3 x 100 mL). The organics were combined and concentrated and purified by column chromatography (eluting with 0 to 10% 2M methanolic ammonia in DCM) and appropriate fractions combined to the title compound as a yellow solid (87 mg, 54%); 1H NMR spectrum (400 MHz, DMSO-d6) 52.12 (3H, s), 2.20 (6H, s), 3.74 (3H, s), 3.98 (2H, s), 4.76 (2H, s), 5.67 (2H, s), 8.15 (IH, s), 9.81 (IH, s); Mass spectrum: (M+H)+ 329.
The methyl 2-[(2-amino-6-methyl-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5- dimethyl-pyridin-2-yl)methyl]amino]acetate (Intermediate 27) used as a starting material was made as follows:
Intermediate 28
Methyl iV-(2-chloro-6-methyl-5-nitropyrimidin-4-yl)-7V-[(4-methoxy-3,5- dimethylpyridin-2-yl)methyl]glycinate
Figure imgf000166_0001
Methyl 2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylamino]acetate (Intermediate 10) (1.15g, 4.81mmol) in acetone (10 mL) was added to a stirred mixture of 2,4-dichloro-6-methyl-5-nitro-pyrimidine (1 g, 4.81 mmol) and potassium carbonate (731 mg, 5.29 mmol) in acetone (20 mL) and the mixture stirred at room temperature for 4 hours. The mixture was concentrated in vacuo and water (200 mL) added and extracted with ethyl acetate (3 x 100 mL). The organics were combined and concentrated in vacuo and the residue was purified by column chromatography (eluting with 0 to 100% ethyl acetate in isohexane) and appropriate fractions combined to yield Intermediate 28 as an orange oil (958 mg, 49%); 1H NMR spectrum (400 MHz, CDCl3) 52.19 (3H, s), 2.24 (3H, s), 2.37 (3H, s), 3.76 (6H, s), 4.41 (2H, s), 4.71 (2H, s), 8.14 (IH, s); Mass spectrum: (M+H)+ 410.
Intermediate 27 Methyl iV-(2-amino-6-methyl-5-nitropyrimidin-4-yl)-iV-[(4-methoxy-3,5- dimethylpyridin-2-yl)methyIjglycinate
Figure imgf000166_0002
Methyl 2-[(2-chloro-6-methyl-5-nitro-pyrimidin-4-yl)-[(4-methoxy-3,5-dimethyl- pyridin-2-yl)methyl]amino]acetate (Intermediate 28) (465 mg, 1.13 mmol) was stirred in THF (50 niL) and ammonia (28% in water, 10 mL) was added and the mixture stirred at room temperature overnight. The mixtures were concentrated in vacuo and water (200 mL) was added and extracted with DCM (3 x 100 mL) and concentration in vacuo yielded Intermediate 27 an orange solid (437 mg, 99%); 1H NMR spectrum (400 MHz, DMSO- d6) δ 2.21 (9H, m), 3.63 (3H, d), 3.73 (3 H, s), 4.39 (2H, d), 4.98 (2H, d), 7.90 (2H, s), 8.14 (IH, s); Mass spectrum: (M+H)+ 391.

Claims

1. A compound of formula I:
Figure imgf000168_0001
I wherein:
R1, R2 and R3 are independently selected from H, halo, cyano, nitro or a group of the formula:
-X1 -R8, wherein X1 is a direct bond, O, S or NR8a, wherein R8a is H or Ci_6alkyl, and R8 is selected from H,
Figure imgf000168_0002
C2-6alkenyl, C3-7Cycloalkyl and C2.6alkynyl, and wherein R1, R2 and R3 may independently of each other be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, N-(Ci-6alkyl)amino, NN-(C i.6alkyl)2amino,
Figure imgf000168_0003
C3-7CyClOaIlCyI, carbamoyl, N-(Ci.6alkyl)carbamoyl and NN-(Ci-6alkyl)2carbamoyl; p is 1 or 2; A is NR9 or CR10R1 1;
R4 and R10 are independently selected from H, C].6alkyl, C2-6alkenyl and C2-6alkynyl, wherein R4 and R10 may, independently of each other, be optionally substituted on carbon by halo, hydroxy, amino, Ci^alkoxy, N-(Ci_6alkyl)amino and N,N-(Ci-6alkyl)2amino;
R5 and R11 are independently selected from H, cyano, carboxy, carbamoyl, C2-6alkenyl, C2-6alkynyl,
Figure imgf000168_0004
N-(Ci.6alkyl)carbamoyl, N, N-(C i -βalky l)2carbamoy 1, N-(C i _4alkoxy)carbamoy 1, N-(C i .4alkyl)-N-(C i -4alkoxy)carbamoyl, C i -6alkoxycarbonyl, Ci-βalkylsulfonylaminocarbonyl, carbocyc IyI-X2-, heterocyc IyI-X3- or heteroaryl-X4-, wherein R5 and R1 ' may independently of each other be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R5 and R1 ' may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R5 and R1 1 may optionally bear a
Figure imgf000169_0001
group; or R4 and R5 together form oxo (=0); or R10 and R11 together form oxo (=0); or one of the following pairs of substituents (i) R4 and R6, (ii) R4 and R10 or (iii) R4 and R9 together form a bond;
R6 and R9 are independently selected from H,
Figure imgf000169_0002
C2-6alkenyl, C2-6alkynyl, Ci -όalkanoyl, C i -6alkylsulfonyl, C i -βalkoxycarbonyl, carbamoyl, N-(C i _6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, carbocyclyl-X5-, heterocyclyl-X6- or heteroaryl-X7-, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)-, -Ν(R12)C(O)- and -SO2-; wherein R12 is selected from hydrogen or
Figure imgf000169_0003
and wherein R6 and R9 may, independently of each other, be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 and R9 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R6 and R9 may optionally bear a
Figure imgf000169_0004
group;
R7 is selected from H, halo, hydroxy, trifluoromethoxy, mercapto, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, C|.6alkoxy,
Figure imgf000169_0005
a is 0 to 2, wherein R7 may be optionally substituted on carbon by one or more R15; R13, R15 and R16 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, ureido, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, C2-6alkenyloxy, C2.6alkynyloxy, Ci-6alkanoyl, Ci-6alkanoyloxy, N-(Ci.6alkyl)amino, NN-(C i.6alkyl)2amino, C i _6alkanoylamino, N-(C i -6alkyl)carbamoyl, NN-(C i .6alkyl)2carbamoyl, N'-(Ci-6alkyl)ureido, N',N'-(Ci-6alkyl)2ureido, N,N',N'-(Ci-6alkyl)3ureido, C,.6alkylS(O)a wherein a is 0 to 2, Ci-βalkoxycarbonyl, N-(Ci-6alkyl)sulfamoyl, NN-(C i.6alkyl)2sulfamoyl, Ci-όalkylsulfonylamino, carbocyclyl-X8-, heterocyclyl-X9- or heteroaryl-X10-, and wherein R13, R15 and R16 may be optionally substituted on carbon by one or more R18, and wherein if said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13, R15 and R16 may optionally bear 1 or 2 oxo or thioxo substituents and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R13, R15 and R16 may optionally bear a Ci-3alkylenedioxy group;
R14, R17 and R19 are independently selected from Ci-βalkyl,
Figure imgf000170_0001
Ci -βalky lsulfonyl, C i .όalkoxycarbonyl, carbamoyl, N-(C i .6alkyl)carbamoyl,
NN-(C i-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R14, R17 and R19 independently of each other may be optionally substituted on carbon by one or more R20;
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-; wherein R22 is hydrogen or CMalkyl;
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, -N(R22)C(O)-, -C(O)N(R23)-, -S(O),-, -SO2N(R24)- and -N(R25)SO2-; wherein R21, R22, R23, R24 and R25 are independently selected from hydrogen or
Figure imgf000170_0002
and q is 0-2;
R18 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000170_0003
Ci_6alkanoyl, Ci-βalkanoyloxy, N-(Ci.6alkyl)amino, NN-(Ci-6alkyl)2amino,
Figure imgf000170_0004
Ci-6alkylS(O)a wherein a is 0 to 2, Ci-βalkoxycarbonyl, N-(Ci_6alkyl)sulfamoyl, NN-(C i.6alkyl)2sulfamoyl, Ci.6alkylsulfonylamino, carbocyclyl, heterocyclyl or heteroaryl; wherein R18 may be optionally substituted on carbon by one or more R25; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R26; and wherein any heterocyclyl group within R18 may optionally bear 1 or 2 oxo or thioxo substituents; and wherein any carbocyclyl, heterocyclyl or heteroaryl group within R may optionally bear a
Figure imgf000171_0001
group; R26 is selected from
Figure imgf000171_0002
Ci-βalkylsulfonyl, Ci_6alkoxycarbonyl, carbamoyl, N-(Ci_6alkyl)carbamoyl,
Figure imgf000171_0003
benzyl, benzyloxycarbonyl, benzoyl and phenylsulfonyl; wherein R26 may be optionally substituted on carbon by one or more R27; and
R20, R25 and R27 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfϊnyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl or N-methyl-N-ethylsulfamoyl; or an Ν-oxide thereof; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, or a pharmaceutically acceptable salt or Ν-oxide thereof, wherein A is CR10R1 1 wherein R10 and R1 1 are as defined in claim 1.
3. A compound according to claim 1, or a pharmaceutically acceptable salt or Ν- oxide thereof, wherein: A is CR'V 1;
R10 is H; and
R11 is selected from H,
Figure imgf000171_0004
C3-7cycloalkyl-X2-, phenyl-X2, heterocyclyl-X3- or heteroaryl-X4-, wherein said heteroaryl is a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and said heterocyclyl is a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1 or 2 heteroatoms selected from O, S and Ν, wherein R1 1 may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 oxo substituent, and wherein any phenyl or heteroaryl group within R1 ' may optionally bear a C1- 3alkylenedioxy group;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000172_0001
C]_4alkanoyl, Ci-4alkanoyloxy, N-(Ci.4alkyl)amino,
Figure imgf000172_0002
CMalkanoylamino, N-(Ci-4alkyl)carbamoyl, N,N-(Ci_4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2,
Figure imgf000172_0003
C3-7cycloalkyl, phenyl-, a monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, S and Ν, and a monocyclic 5, 6 or 7-membered heterocyclyl ring containing 1 or 2 heteroatoms selected from O, S and Ν, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent;
R14 and R19 are independently selected from Ci-4alkyl, C]-4alkanoyl, Ci-4alkylsulfonyl,
Figure imgf000172_0004
carbamoyl, N-(Ci-6alkyl)carbamoyl, NN-(C i.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000172_0005
N-(Ci. 4alkyl)amino and N N-(C i ^alky l)2amino ; and
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-, wherein R22 is selected from hydrogen or CMalkyl.
4. A compound according to claim 1, or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
A iS CR10R"; R10 is H; R11 is selected from H, Ci-βalkyl, Ca.γcycloalkyl-X2-, phenyl-X2, heterocyclyl-X3- and heteroaryl-X4-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, moφholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein said C3_7cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and wherein R1 ' may be optionally substituted on carbon by one or more R13; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R14, and wherein any heterocyclyl group within R1 ' may optionally bear 1 oxo substituent;
R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl,
Figure imgf000173_0001
C2-4alkenyl, C2-4alkynyl,
Figure imgf000173_0002
Ci_4alkanoyl,
Figure imgf000173_0003
N-(Ci_4alkyl)amino, NN-(Ci-4alkyl)2amino,
Figure imgf000173_0004
N-(Ci-4alkyl)carbamoyl, NN-(C].4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2, Ci^alkoxycarbonyl, N^CMalkytysulfamoyl, N,N-(Ci-4alkyl)2Sulfamoyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, a heteroaryl selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and a heterocyclyl selected from azetidinyl, pyrrolidinyl, moφholinyl, piperidinyl and piperazinyl, and wherein R13 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; and wherein any heterocyclyl group within R13 may optionally bear 1 oxo substituent; R14 and R19 are independently selected from
Figure imgf000174_0001
Ci-4alkylsulfonyl, CMalkoxycarbonyl, carbamoyl, N-(C|.6alkyl)carbamoyl, N,N-(Ci.6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl;
R18 is selected from halo, hydroxy, amino,
Figure imgf000174_0002
N-(Ci- 4alkyl)amino and NN-(C Malkyl^amino; and
X2, X3 and X4 are independently selected from a direct bond, -C(O)- and -Ν(R22)C(O)-, wherein R22 is selected from hydrogen or Ci_4alkyl.
5. A compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
A iS CR10R11; R10 is H; and
R11 is selected from H and
Figure imgf000174_0003
wherein R1 1 is optionally substituted on carbon by one or more R13; R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000174_0004
Ci_4alkanoyl, Ci_4alkanoyloxy,
Figure imgf000174_0005
NN-(Ci_4alkyl)2amino,
Figure imgf000174_0006
N-(Ci-4alkyl)carbamoyl,
Figure imgf000174_0007
Ci-4alkylS(O)a wherein a is 0 to 2, C i ^alkoxycarbonyl, N-(C Malkyl)sulfamoyl, NN-(Ci -4alkyl)2sulfamoyl, Ci-4alkylsulfonylamino, phenyl, pyridyl and pyrimidinyl.
6. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or Ν-oxide thereof, wherein:
R6 is selected from H, Ci-6alkyl, C3-7cycloalkyl-X5-, phenyl-X5-, heterocyclyl-X6- and heteroaryl-X7-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)- and -N(R12)C(O)-, wherein R12 is selected from hydrogen or CMalkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 oxo substituent;
R16 is selected from halo, cyano, hydroxy, amino, mercapto, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000175_0001
N,N-(Ci-4alkyl)2amino,
Figure imgf000175_0002
wherein a is 0 to 2,
Figure imgf000175_0003
cyclopropyl-X8-, cyclobutyl-X8-, cyclopentyl-X8-, cyclohexyl-X8-, phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and heteroaryl-X10-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent;
R17 and R19 are independently selected from
Figure imgf000175_0004
CMalkylsulfonyl, Ci_4alkoxycarbonyl, carbamoyl, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl; R18 is selected from halo, hydroxy, amino, Ci-4alkyl, Ci^alkoxy, N-(Q-
4alkyl)amino and
Figure imgf000175_0005
and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or
Figure imgf000175_0006
and q is 0-2.
7. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or N-oxide thereof, wherein: R6 is selected from H,
Figure imgf000176_0001
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl-Ci-4alkyl, cyclopropyl-Ci-4alkyl,
Figure imgf000176_0002
cyclohexyl-Ci-4alkyl, azetidinyl-Ci-4alkyl, pyrrolidinyl-Ci-4alkyl, moφholinyl-Ci-4alkyl,
Figure imgf000176_0003
imidazolidinyl-Ci-4alkyl, piperazinyl-Ci-4alkyl and pyridinyl-C). 4alkyl, wherein R6 may be optionally substituted on carbon by one or more substituents selected from halo, hydroxy, amino, Ci-4alkyl, Ci-4alkoxy, N-(Ci_4alkyl)amino and NN-(Ci .4alkyl)2amino, and wherein any -NH- in a azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolidinyl, piperidinyl or piperazinyl group in R6 is optionally substituted by C^alkyl, and wherein any azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperidinyl or piperazinyl group in R6 optionally bears 1 oxo substituent.
8. A compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
A i5 CR10R1 1;
R10 is H; and
R11 is selected from H and
Figure imgf000176_0004
wherein R11 is optionally substituted on carbon by one or more R13; R13 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl, Ci-4alkoxy,
Figure imgf000176_0005
Ci-4alkanoyloxy, N-(Ci.4alkyl)amino, N,N-(Ci-4alkyl)2amino, CMalkanoylamino, N-(Ci-4alkyl)carbamoyl, NN-(C i-4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2, C i _4alkoxycarbonyl, N-(C Malkyl)sulfamoyl, NN-(C i -4alkyl)2sulfamoyl, CMalkylsulfonylamino, phenyl, pyridyl and pyrimidinyl; and
R6 is as defined in claim 6
9. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or Ν-oxide thereof, wherein R4 and R5 together form oxo.
10. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or Ν-oxide thereof, wherein R7 is chloro.
1 1. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
R1 is selected from halo and Ci-3alkyl; R2 is selected from halo,
Figure imgf000177_0001
and p is 1 and R3 is in the meta-position to the pyridyl nitrogen, and is selected from H, halo, hydroxy, Ci-4alkyl,
Figure imgf000177_0002
and CMalkylthio.
12. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or N-oxide thereof, wherein the pyridyl group in formula I is of the formula:
Figure imgf000177_0003
is selected from 4-methoxy-3,5-dimethylpyridin-2-yl, 4-chloro-3,5- dimethylpyridin-2-yl, 4-chloro-3,5-dimethyl-l-oxypyridin-2-yl, 4-methoxy-3,5-dimethyl- l-oxypyridin-2-yl, 4-bromo-3,5-dimethylpyridin-2-yl, 4-bromo-3,5-dimethyl-l-oxy- pyridin-2-yl, 4-iodo-3,5-dimethyl-l-oxy-pyridin-2-yl, 4-iodo-3,5-dimethylpyridin-2-yl, 3- bromo-4,5,6-trimethoxypyridin-2-yl, 3-chloro-4,5,6-trimethoxypyridin-2-yl, 3,4,5- trimethylpyridin-2-yl, 3,4,5-trimethyl-l-oxypyridin-2-yl, 3,4,5-trimethoxypyridin-2-yl, 6- chloro-4-methoxy-3,5-dimethylpyridin-2-yl, 6-bromo-4-methoxy-3,5-dimethylpyridin-2- yl, 6-chloro-4-methoxy-3,5-dimethyl- 1 -oxy-pyridin-2-yl, 6-bromo-4-methoxy-3,5- dimethyl- 1 -oxy-pyridin-2-yl, 6,4-dimethoxy-3,5-dimethylpyridin-2-yl, 6,4-dimethoxy-3,5- dimethyl-1 -oxy-pyridin-2-yl, 3-bromo-4,5,6-trimethoxy-l -oxy-pyridin-2-yl and 3-chloro- 4,5,6-trimethoxy- 1 -oxy-pyridin-2-yl.
13. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or N-oxide thereof, wherein the group of the formula:
Figure imgf000178_0001
in formula I is of the formula: wherein ""^ indicates the point of attachment to the nitrogen in formula I.
14. A compound according to claim 1, or a pharmaceutically acceptable salt or N-oxide thereof, wherein the pyridyl group in formula I is of the formula:
Figure imgf000178_0002
is selected from 4-methoxy-3,5-dimethylpyridin-2-yl, 4-chloro-3,5- dimethylpyridin-2-yl, 4-chloro-3,5-dimethyl-l-oxypyridin-2-yl, 4-methoxy-3,5-dimethyl- l-oxypyridin-2-yl, 4-bromo-3,5-dimethylpyridin-2-yl, 4-bromo-3,5-dimethyl-l-oxy- pyridin-2-yl, 4-iodo-3,5-dimethyl-l-oxy-pyridin-2-yl, 4-iodo-3,5-dimethylpyridin-2-yl, 3- bromo-4,5,6-trimethoxypyridin-2-yl, 3-chloro-4,5,6-trimethoxypyridin-2-yl, 3,4,5- trimethylpyridin-2-yl, 3,4,5-trimethyl-l-oxypyridin-2-yl, 3,4,5-trimethoxypyridin-2-yl, 6- chloro-4-methoxy-3,5-dimethylpyridin-2-yl, 6-bromo-4-methoxy-3,5-dimethylpyridin-2- yl, 6-chloro-4-methoxy-3,5-dimethyl-l-oxy-pyridin-2-yl, 6-bromo-4-methoxy-3,5- dimethyl- l-oxy-pyridin-2-yl, 6,4-dimethoxy-3,5-dimethylpyridin-2-yl, 6,4-dimethoxy-3,5- dimethyl-l-oxy-pyridin-2-yl, 3-bromo-4,5,6-trimethoxy-l-oxy-pyridin-2-yl and 3-chloro- 4,5,6-trimethoxy- 1 -oxy-pyridin-2-yl; R7 is chloro; and R4 and R5 together form oxo.
15. A compound according to claim 1, or a pharmaceutically acceptable salt or N-oxide thereof, of the formula IF*:
Figure imgf000179_0001
IF* wherein:
R6 and R11 are as defined in claim 1.
16. A compound according to claim 15, or a pharmaceutically acceptable salt or N- oxide thereof, of the formula IF* wherein R11 is selected from H and Ci-4alkyl, wherein
R1 ' is optionally substituted on carbon by one or more R13 selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carboxyamino, carbamoyl, mercapto, sulfamoyl,
Figure imgf000179_0002
N-(Ci.4alkyi)amino,
Figure imgf000179_0003
N-(Ci_4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, Chalky IS(O)3 wherein a is 0 to 2, CMalkoxycarbonyl, N-(Ci- 4alkyl)sulfamoyl, NN-(C Malkyl)2sulfamoyl, Ci-4alkylsulfonylamino, phenyl, pyridyl and pyrimidinyl.
17. A compound according to claim 15, or a pharmaceutically acceptable salt or Ν- oxide thereof, of the formula IF* wherein R6 is selected from H, Cj-βalkyl, C3_7cycloalkyl- X5-, phenyl-X5-, heterocyclyl-X6- and heteroaryl-X7-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein said heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolinyl, pyrrolidinyl, moφholinyl, piperidinyl, piperazinyl, indolinyl and isoindolinyl, wherein X5, X6 and X7 are independently selected from a direct bond, -C(O)- and -N(R12)C(O)-, wherein R12 is selected from hydrogen or Ci-4alkyl, and wherein R6 may be optionally substituted on carbon by one or more R16; and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17, and wherein any heterocyclyl group within R6 may optionally bear 1 oxo substituent;
R16 is selected from halo, cyano, hydroxy, amino, mercapto,
Figure imgf000180_0001
C2-4alkenyl, C2-4alkynyl,
Figure imgf000180_0002
N-(Ci-4alkyl)amino, NN-(C i-4alkyl)2amino,
Figure imgf000180_0003
wherein a is 0 to 2,
Figure imgf000180_0004
cyclopropyl-X8-, cyclobutyl-X8-, cyclopentyl-X8-, cyclohexyl-X8-, phenyl-X8-, heterocyclyl-X9-, wherein said heterocyclyl is selected from azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, and heteroaryl-X10-, wherein said heteroaryl is selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and wherein R16 may be optionally substituted on carbon by one or more R18, and wherein if any of said heterocyclyl or heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19, and wherein any heterocyclyl group within R16 may optionally bear 1 oxo substituent;
R17 and R19 are independently selected from Ci-4alkyl, Ci-4alkanoyl, CMalkylsulfonyl, CMalkoxycarbonyl, carbamoyl, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, benzyl, benzyloxycarbonyl and benzoyl; R18 is selected from halo, hydroxy, amino, C].4alkyl, Ci-4alkoxy, N-(Ci-
4alkyl)amino and NN-(C i_4alkyl)2amino; and
X8, X9 and X10 are independently selected from a direct bond, -O-, -N(R21)-, -C(O)-, and -S(O)q-, wherein R21 is selected from hydrogen or
Figure imgf000180_0005
and q is 0-2.
18. A compound selected from:
(7S)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one; (75)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-propyl-7,8- dihydropteridin-6(5H)-one;
(7i?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one; 2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7,8-dihydropteridin-6(5H)-one;
(75)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-7,8- dihydropteridin-6(5H)-one;
(7S)-2-amino-5-ethyl-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one; (7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-7,8- dihydropteridin-6(5H)-one;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-methyl-7,8-dihydropteridin-
6(5H)-one;
(7Λ)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5,6,7,8-tetrahydropteridin- 2-amine;
(7/?)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5,7-dimethyl-5,6,7,8- tetrahydropteridin-2-amine;
8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-methyl-5,6,7,8-tetrahydropteridin-2- amine; (7R)-2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-7-(2-methylpropyl)-7,8- dihydropteridin-6(5H)-one;
(7R)-2-amino-7-benzyl-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-7,8- dihydropteridin-6(5H)-one; methyl {(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl}acetate;
(7R)-2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-7-propyl-7,8- dihydropteridin-6(5H)-one;
2-amino-4-chloro-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-5,7-dihydropteridin-6- one; 2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-4-methylsulfanyl-5,7- dihydropteridin-6-one; (7R)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methoxypropyl)-7- me thy 1-7 , 8 -dihydropteridin-6(5H)-one ;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methoxypropyl)-7,8- dihydropteridin-6(5H)-one; (7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2- phenylethyl)-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-piperazin-l- ylethyl)-7,8-dihydropteridin-6(5H)-one;
(7R)-2-amino-5-(2,2-difluoroethyl)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7- methyl-7,8-dihydropteridin-6(5H)-one;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methylbutyl)-7,8- dihydropteridin-6(5H)-one;
2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(3-methylbutyl)-7,8- dihydropteridin-6(5H)-one; (7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(3- methylbutyl)-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-propyl-7,8- dihydropteridin-6(5H)-one;
(7Λ)-2-amino-5-benzyl-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-7,8- dihydropteridin-6(5H)-one;
(7Λ)-2-amino-5-(cyclopropylmethyl)-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7- methyl-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-pyrrolidin- l-ylethyl)-7,8-dihydropteridin-6(5H)-one; (7Λ)-2-amino-5-[2-(dimethylamino)-2-methylpropyl]-8-[(4-methoxy-3,5-dimethylpyridin-
2-yl)methyl]-7-methyl-7,8-dihydropteridin-6(5H)-one;
(7Λ)-2-amino-5-[3-(dimethylamino)propyl]-8-[(4-methoxy-3,5-dimethylpyridin-2- yl)methyl]-7-methyl-7,8-dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-morpholin- 4-ylethyl)-7,8-dihydropteridin-6(5H)-one;
(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-pyridin-4- ylethyl)-7,8-dihydropteridin-6(5H)-one; (7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(2-pyridin-3- ylethyl)-7,8-dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-(3-pyridin-3- ylpropyl)-7,8-dihydropteridin-6(5H)-one; 5 2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(2-pyridin-3- ylethyl)-7,8-dihydropteridin-6(5H)-one;
2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-propyl-7,8-dihydropteridin-
6(5H)-one;
(77?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-[2-(2- i o oxoimidazolidin- 1 -yl)ethyl]-7,8-dihydropteridin-6(5H)-one;
(7Λ)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7-methyl-5-[2-(2- oxopyrrolidin- 1 -yl)ethyl]-7,8-dihydropteridin-6(5H)-one;
2-amino-5-ben2yl-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-7,8- dihydropteridin-6(5H)-one ; is 2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-propyl-7,8- dihydropteridin-6(5H)-one;
2-amino-4-chloro-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-(2-phenylethyl)-7,8- dihydropteridin-6(5H)-one;
{(7i?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- 2G tetrahydropteridin-7-yl} acetic acid;
2-{(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl } acetamide;
2-{(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-y 1 } -N- [3 -(dimethy lamino)propy 1] acetamide; 25 2-{(7/?)-2-amino-8-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-6-oxo-5,6,7,8- tetrahydropteridin-7-yl}-N-[2-(dimethylamino)ethyl]acetamide;
2-amino-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methyl]-4-methyl-5,7-dihydropteridin-
6-one; or an Ν-oxide thereof; 30 or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt or N-oxide, as defined in any one of the preceding claims in association with a pharmaceutically acceptable diluent or carrier.
20. A compound of the formula I, or a pharmaceutically acceptable salt or N-oxide, as defined in any one of claims 1 to 18 for use as a medicament.
21. A compound of the formula I, or a pharmaceutically acceptable salt or N-oxide, as defined in any one of claims 1 to 18 for use as in the treatment of a cancer.
22. Use of a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide, as defined in any one of claims 1 to 18 in the preparation of a medicament for treatment of a cancer
23. Use of a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide, as defined in any one of claims 1 to 18 in the preparation of a medicament for the treatment of a disease mediated in part or alone by HSP90.
24. Use of a compound of the formula I, or a pharmaceutically acceptable salt or N- oxide, as defined in any one of claims 1 to 18 in the preparation of a medicament for the treatment of a cancer simultaneously, sequentially or separately with an additional anti- tumour agent.
25. A method of treatment of a human or animal suffering from a cancer comprising administering to said human or animal a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or N-oxide thereof as defined in any one of claims 1 to 18.
26. A process for preparing a compound of the formula I, or a pharmaceutically acceptable salt or N-oxide thereof as defined in claim 1, which process comprises:
Process (a): for the preparation of compounds of the formula I wherein A is CR10R1 1 and R4 and R5 together form oxo, the reduction and cyclisation in the presence of a suitable reducing agent of the compound of the formula H:
Figure imgf000185_0001
II wherein R1, R2, R3, R7, R10, R1 1 and p are as defined in claim 1, except any functional group is protected if necessary; and Pgi is a suitable carboxy protecting group; or
Process (b) for the preparation of those compounds of the formula 1 wherein R6 is optionally substituted Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, heterocyclyl, carbocyclyl or heteroaryl, the coupling of a compound of the formula I wherein R6 is H, with an alcohol of the formula R6-OH; or
Process (c) for the preparation of those compounds of the formula I wherein R4 and R5 are both hydrogen, the reduction of a compound of the formula I of the formula I':
Figure imgf000185_0002
r wherein R1, R2, R3, R6, R7, A and p are as defined in claim 1, except any functional group is protected if necessary; or
Process (d) for the preparation of those compounds of the formula I wherein A in the compound of formula I is CHR11 and R11 is optionally substituted
Figure imgf000186_0001
C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, or an optionally substituted carbon-linked heterocyclyl, the deprotonation and alkylation of a compound of the formula I" with a compound of the formula III:
Figure imgf000186_0002
III
wherein R1, R2, R3, R6, R7, R1 ' and p are as defined in claim 1, except any functional group is protected if necessary and Lg3 is a displaceable group; or Process (e) the amination of a compound of the formula IV:
Figure imgf000186_0003
IV wherein R1, R2, R3, R4, R5, R6, R7, A and p are as defined in claim 1, except any functional group is protected if necessary and Lg4 is a displaceable group; or
Process (f) for the preparation of those compounds of the formula I wherein A in the compound of formula I is CHR1 1 and R11 is a
Figure imgf000187_0001
group substituted by a carboxy group, the hydrolysis of a compound of the formula I"':
Figure imgf000187_0002
wherein R1, R2, R3, R6, R7 and p are as defined in claim 1, except any functional group is protected if necessary and R28 is a
Figure imgf000187_0003
group; or
Process (s) for the preparation of those compounds of the formula I wherein A in the compound of formula I is CHR1 ' and R1 ' is a
Figure imgf000187_0004
group substituted by a carbamoyl, N-(C i -6alkyl)carbamoyl or N,N-(C i ^alky l)2carbamoyl group, the coupling of a compound of the formula 1"" (or a suitable salt thereof) with ammonia or a N-(Ci_6alkyl)amino or N,N-(Ci-6alkyi)2amino group:
Figure imgf000188_0001
wherein R!, R2, R3, R6, R7 and p are as defined in claim 1, except any functional group is protected if necessary; and thereafter, if necessary (in any order):
(i) converting a compound of the formula I into another compound of the formula I; (ii) removing any protecting groups; and (iii) forming a pharmaceutically acceptable salt of the compound of formula I.
PCT/GB2008/000303 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors WO2008093075A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2009547752A JP2010517989A (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
CN200880010915A CN101652365A (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
DE602008003404T DE602008003404D1 (en) 2007-02-01 2008-01-31 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS
CA002675677A CA2675677A1 (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
EP08701973A EP2109612B1 (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
MX2009008084A MX2009008084A (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors.
AT08701973T ATE487720T1 (en) 2007-02-01 2008-01-31 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS
BRPI0807868-8A BRPI0807868A2 (en) 2007-02-01 2008-01-31 COMPOUND OR PHARMACEUTICALLY ACCEPTABLE OR N-oxide salt thereof, PHARMACEUTICAL COMPOSITION, USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE OR N-oxide salt, METHOD FOR THE TREATMENT OF A HUMAN OR ANIMAL BEING TO PROFER, A CULP A PHARMACEUTICALLY ACCEPTABLE OR N-oxide COMPOUND OR SALT OF THE SAME
KR1020097018333A KR20090104920A (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
AU2008211729A AU2008211729A1 (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88771607P 2007-02-01 2007-02-01
US60/887,716 2007-02-01
US95065407P 2007-07-19 2007-07-19
US60/950,654 2007-07-19

Publications (2)

Publication Number Publication Date
WO2008093075A2 true WO2008093075A2 (en) 2008-08-07
WO2008093075A3 WO2008093075A3 (en) 2008-10-02

Family

ID=39365852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000303 WO2008093075A2 (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors

Country Status (13)

Country Link
US (1) US7799781B2 (en)
EP (1) EP2109612B1 (en)
JP (1) JP2010517989A (en)
KR (1) KR20090104920A (en)
CN (1) CN101652365A (en)
AT (1) ATE487720T1 (en)
AU (1) AU2008211729A1 (en)
BR (1) BRPI0807868A2 (en)
CA (1) CA2675677A1 (en)
DE (1) DE602008003404D1 (en)
MX (1) MX2009008084A (en)
RU (1) RU2009132605A (en)
WO (1) WO2008093075A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010098344A1 (en) 2009-02-25 2010-09-02 第一三共株式会社 Tricyclic pyrazolopyrimidine derivative
WO2011004132A1 (en) 2009-07-10 2011-01-13 Sanofi-Aventis Novel hsp90-inhibiting indole derivatives, compositions containing said derivatives, and use thereof
WO2011027081A2 (en) 2009-09-03 2011-03-10 Sanofi-Aventis Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof
WO2012026433A1 (en) 2010-08-23 2012-03-01 第一三共株式会社 Free crystal of tricyclic pyrazolopyrimidine derivative
WO2012026434A1 (en) 2010-08-23 2012-03-01 第一三共株式会社 Crystal of tricyclic pyrazolopyrimidine derivative
JP2012511520A (en) * 2008-12-09 2012-05-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Quinazolinamide derivatives
JP2013505927A (en) * 2009-09-25 2013-02-21 バーテックス ファーマシューティカルズ インコーポレイテッド Method for preparing pyrimidine derivatives useful as protein kinase inhibitors
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US10617772B2 (en) 2014-09-17 2020-04-14 Memorial Sloan Kettering Cancer Center Hsp9O-targeted inflammation and infection imaging and therapy
US10975056B2 (en) 2016-06-13 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of DNMT1

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2013071217A1 (en) 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
WO2007092496A2 (en) * 2006-02-07 2007-08-16 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177986B (en) 1979-02-23 1982-02-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing 1-acyl-1,2- or -1,4-dihydro-pyrido/3,4-e/-as-triazine derivatives
JP2000154139A (en) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd Condensed ring pyrazine derivative
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1129091B1 (en) 1998-11-12 2002-10-02 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
CN101928288B (en) 2000-11-02 2013-09-11 斯隆-凯特林癌症研究所 Small molecule compositions for binding to HSP90
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP4397691B2 (en) 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Purine analogs having HSP90 inhibitory activity
KR101139314B1 (en) 2003-08-29 2012-04-26 베르날리스(캠브리지)리미티드 Pyrimidothiophene compounds
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
NZ561939A (en) 2005-03-30 2011-03-31 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
EP1879863A1 (en) 2005-05-03 2008-01-23 Pfizer, Inc. Amide resorcinol compounds
DE102005022977A1 (en) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
US20070105874A1 (en) 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
US20050113340A1 (en) * 2003-09-18 2005-05-26 Conforma Therapeutics Corporation 2-Aminopurine analogs having HSP90-inhibiting activity
WO2007092496A2 (en) * 2006-02-07 2007-08-16 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511520A (en) * 2008-12-09 2012-05-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Quinazolinamide derivatives
US8445504B2 (en) 2009-02-25 2013-05-21 Daiichi Sankyo Company, Limited Tricyclic pyrazolopyrimidine derivatives
WO2010098344A1 (en) 2009-02-25 2010-09-02 第一三共株式会社 Tricyclic pyrazolopyrimidine derivative
US8236813B2 (en) 2009-02-25 2012-08-07 Daiichi Sankyo Company, Limited Tricyclic pyrazolopyrimidine derivatives
WO2011004132A1 (en) 2009-07-10 2011-01-13 Sanofi-Aventis Novel hsp90-inhibiting indole derivatives, compositions containing said derivatives, and use thereof
WO2011027081A2 (en) 2009-09-03 2011-03-10 Sanofi-Aventis Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof
JP2013505927A (en) * 2009-09-25 2013-02-21 バーテックス ファーマシューティカルズ インコーポレイテッド Method for preparing pyrimidine derivatives useful as protein kinase inhibitors
WO2012026434A1 (en) 2010-08-23 2012-03-01 第一三共株式会社 Crystal of tricyclic pyrazolopyrimidine derivative
WO2012026433A1 (en) 2010-08-23 2012-03-01 第一三共株式会社 Free crystal of tricyclic pyrazolopyrimidine derivative
US8815880B2 (en) 2010-08-23 2014-08-26 Daiichi Sankyo Company, Limited Crystal of tricyclic pyrazolopyrimidine derivative
US8846703B2 (en) 2010-08-23 2014-09-30 Daiichi Sankyo Company, Limited Crystal of a free tricyclic pyrazolopyrimidine derivative
EP2810945A1 (en) 2010-08-23 2014-12-10 Daiichi Sankyo Company, Limited Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US10617772B2 (en) 2014-09-17 2020-04-14 Memorial Sloan Kettering Cancer Center Hsp9O-targeted inflammation and infection imaging and therapy
US11065350B2 (en) 2014-09-17 2021-07-20 Memorial Sloan Kettering Cancer Center HSP90-targeted inflammation and infection imaging and therapy
US10975056B2 (en) 2016-06-13 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of DNMT1

Also Published As

Publication number Publication date
US20080194572A1 (en) 2008-08-14
JP2010517989A (en) 2010-05-27
BRPI0807868A2 (en) 2013-10-15
ATE487720T1 (en) 2010-11-15
CN101652365A (en) 2010-02-17
WO2008093075A3 (en) 2008-10-02
RU2009132605A (en) 2011-03-10
DE602008003404D1 (en) 2010-12-23
CA2675677A1 (en) 2008-08-07
AU2008211729A1 (en) 2008-08-07
EP2109612A2 (en) 2009-10-21
MX2009008084A (en) 2009-10-12
EP2109612B1 (en) 2010-11-10
US7799781B2 (en) 2010-09-21
KR20090104920A (en) 2009-10-06

Similar Documents

Publication Publication Date Title
EP2109612B1 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
US11548896B2 (en) Heterocyclic compounds as RET kinase inhibitors
US11680068B2 (en) Compounds useful as RET inhibitors
US9371319B2 (en) Pyrrolopyridineamino derivatives as MPS1 inhibitors
WO2018206539A1 (en) Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2015079251A1 (en) Quinazoline compounds
ES2739148T3 (en) N2-phenyl-pyrido [3,4-d] pyrimidin-2,8-diamine derivatives and their use as MPS1 inhibitors
ES2898423T3 (en) Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity
CA3056726A1 (en) Tricyclic compounds for use in treatment of proliferative disorders
CA3095371A1 (en) Bcl6 inhibitors
BR112016007329B1 (en) compound, pharmaceutical composition, and, use of a compound for the manufacture of a drug for the treatment of cancer, autoimmune diseases or viral diseases
WO2020104820A1 (en) Substituted benzimidazolones as anti-cancer agents
WO2022074379A1 (en) Mettl3 inhibitory compounds
WO2024094963A1 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
WO2022074391A1 (en) Compounds inhibitors of mettl3
WO2023156791A1 (en) Heterocyclic compounds useful for treating a erk5-mediated disease
WO2024094962A1 (en) Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
NZ786565A (en) Heterocyclic compounds as ret kinase inhibitors
NZ787350A (en) Heterocyclic compounds as ret kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010915.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701973

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008211729

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2675677

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008084

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008211729

Country of ref document: AU

Date of ref document: 20080131

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009547752

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008701973

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2829/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009132605

Country of ref document: RU

Ref document number: 1020097018333

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0807868

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090728

ENP Entry into the national phase

Ref document number: PI0807868

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090728